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ABSTRACT 
Abnormalities in CD4+CD25+CD127loFoxP3+ regulatory T cells (Tregs) have been implicated 
in susceptibility to autoimmune disease. To define migratory Treg subsets that may be 
implicated in the pathogenesis of diseases manifested in different tissues, we designed 11 and 
13 colour flow-cytometry panels to measure the expression of a range of chemokine 
receptors and integrins on Tregs in the peripheral blood (PB) of healthy individuals (n=44) 
and patients with rheumatoid arthritis (RA) (n=34) or psoriasis (n=44). 
 
We showed that CLA, CCR4, CCR5, CCR6, CCR10 and CD62L were expressed on a higher 
proportion of CD4+CD25+CD127lo Tregs than conventional CD4+ T cells (Tconvs) in healthy 
adults. A significantly lower proportion of Tregs expressed the gut homing α4 (CD49d) and 
β7 when compared to Tregs that expressed the skin homing CLA, CCR4 and CCR10. 
Furthermore, the skin homing receptors, CLA, CCR4 and CCR10, were expressed on a much 
higher proportion of Tregs than Tconvs.  
 
We used flow cytometry to analyse the levels of CXCR3+, CCR4+, CCR5+ and CCR6+ Tregs 
in the PB of RA patients. RA patients had significantly reduced levels of effector/memory 
Tregs in their PB. We also found a significantly reduced frequency of effector/memory Tregs 
expressing each of the chemokine receptors examined in the PB of RA patients. This could 
indicate a trafficking deficiency, resulting in less Tregs entering the joints and a consequent 
disruption of immune homeostasis at the site.  
 
We examined the levels of β7+, CD49d+, CLA+, CCR4+, CCR10+, CCR5+, CD62L+, CXCR3+ 
and CCR6+ Tregs in the PB of psoriasis patients. We found Treg frequency to be increased in 
the PB of untreated psoriasis patients. However, the frequency of effector/memory Tregs 
expressing CXCR3 and CCR6 was significantly reduced in the PB of these patients. CXCR3+ 
and CCR6+ Tregs are known to be crucial to regulating Th1 and Th17 type immune 
responses, which are both involved in the pathogenesis of psoriasis. Therefore a reduction in 
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CXCR3 and CCR6 expression on Tregs could indicate a trafficking deficiency resulting in 
less Treg entry into psoriatic lesions. 
 
We used bioinformatic tools to analyse all flow cytometry data obtained from patients and 
controls. We hope these methods of analysis will facilitate the uptake of flow cytometry in 
detecting preclinical disease or selecting patients for optimal treatment.  
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CHAPTER 1:  LITERATURE REVIEW 
 
1.1  Introduction 
 
In the early 1970s immunologists speculated that a subset of thymically derived T cells, then 
called ‘suppressor T cells,’ were involved in the peripheral regulation of immune responses. 
The widespread acceptance of these T cells, later termed regulatory T cells (Treg), as a 
significant subpopulation came after the identification in 1995 of CD25 as a marker of a 
subset of CD4+ T cells with suppressive activity in vivo [1]. CD4+CD25+ cells were later 
shown to express high levels of the transcription factor FoxP3 [2]. CD4+CD25+FoxP3+ Tregs 
are now widely regarded as primary mediators of peripheral tolerance and immune 
regulation. Due to their demonstrated importance in preventing allergy and autoimmunity, in 
contributing to immune evasion by tumours and in preventing transplant rejection, the study 
of mechanisms of Treg function and development is currently at the forefront of research in 
immunology.  
 
An understanding of how Tregs function to prevent autoimmunity could help us develop 
targeted treatment for autoimmune disease. Although the mechanisms whereby Tregs 
suppress immune responses are still controversial, it has become clear that Tregs are involved 
in regulation at multiple points of an immune response. Their presence in both lymphoid and 
non-lymphoid tissues suggests they are involved in regulating both the priming and effector 
phases of conventional CD4 T cell responses. This led us to hypothesise that the trafficking 
and localisation of Tregs is crucial to their function and that deficiencies in Treg subsets 
expressing particular trafficking receptors may play a role in immune disease pathogenesis.  
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1.2  The Immune Response 
 
The mammalian immune system consists of many cellular and molecular mechanisms that 
work together to protect the individual from invading microbes and abnormal host tissue. 
Immune defence can be viewed as two interrelated systems, termed innate and adaptive. 
Innate immunity is the first line of protection and consists of biochemical and cellular 
defences that are in place before a foreign substance is encountered, allowing a rapid 
response. The primary components of the innate immune system include selectively 
permeable barriers, commensal flora, acidic and mucous secretions and an array of cells and 
proteins that can eliminate microbes by recognising pathogen associated molecular patterns 
(PAMPs) characteristic of pathogenic organisms. Such recognition is mediated via pattern 
recognition receptors (PRRs), which are encoded by germline genes.  
 
In contrast to the innate immune response, the defining features of the adaptive response are 
its ability to respond specifically to distinct molecules and generate ‘memory’ so that it can 
respond more rapidly to repeated exposure. The key mediators of the adaptive response are 
the T and B-lymphocytes derived from pluripotent haemopoietic stem cells. Lymphocytes 
recognise antigen by means of cell surface receptors that are formed by genetic 
recombination within the lymphocyte. This process of gene recombination generates a 
diverse range of receptors capable of recognising and responding to almost any molecular 
shape, including those that are made by the individual.  
 
Both innate and adaptive immune responses can cause significant damage to host tissues and 
serious chronic disease states can ensue if they become deregulated. Hence the immune 
system has evolved multiple mechanisms designed to regulate its response and in particular 
to distinguish between self and non-self antigen (Ag). The maintenance of a balance between 
self-antigen-driven tolerance and pathogen-driven immunity is essential to human health. 
Despite constant exposure to self antigen, the immune system can maintain this balance 
whilst responding to microbes and remaining unresponsive to self. 
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The immune system represents a hierarchy of information transfer between different cell 
types. Information determining the type of immune response is passed from antigen 
presenting cells to T cells which finally activate B cells [3]. If T cell tolerance is incomplete, 
the self reactive T cells can provide help to self-reactive B cells and so the tissue damage 
becomes more severe and prolonged. When T lymphocyte processes are deregulated, 
inflammatory responses can develop against self-tissues. Such responses are termed 
autoimmune. As a group, autoimmune diseases have a significant health impact in terms of 
overall prevalence and mortality and are among the leading causes of death among young 
and middle aged women (reviewed in [4]).   
 
Since most autoimmune diseases are believed to be T cell dependent, whether the major 
pathogenic mediators are cells or T-dependent antibodies, the processes involved in 
developing and maintaining self tolerance within the T cell compartment will be reviewed 
here.  
 
1.3  T Cell Regulation 
 
1.3.1  T Cell Receptor Development and Clonal Selection 
 
The mammalian immune system has the potential to produce a vast array of receptors that 
can sense and react to virtually any chemical structure possible, hence giving it the capability 
to fight off any possible microorganism. The production of lymphocytes expressing such a 
large repertoire of different receptors raises the question of how certain cells are selected to 
survive and proliferate while others are not. This issue was first addressed by MacFarlane 
Burnet in 1959 in the ‘Clonal Selection Theory’ (CST), which hypothesised that once the 
immunological repertoire of receptors develops spontaneously in the host, selective 
interaction between antigen and receptor signals cell survival and proliferation (reviewed in 
[5]).  
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In respect to T lymphocytes, the diversity of T cell receptors (TCR) is generated in the 
thymus by a process of somatic genome modification that occurs selectively within 
lymphocytes (reviewed in [6]). This process is known as V(D)J recombination and involves 
the random splicing and recombination of the three separate segments of the TCR genes; the 
variable (V), the diversity (D) and the joining (J) genes [7].  A large diversity of receptors is 
formed in this process with a significant fraction, estimated to represent approximately 20-
50%, having the capacity to bind self antigen with a potentially dangerous affinity [8]. This 
random receptor generating process is deliberate and is believed to have evolved in 
vertebrates in order to increase the efficiency of detection of foreign antigen. However, with 
it emerged the issue of self-reactivity [3].  
 
1.3.2  Self Tolerance 
 
Immunological tolerance is defined as antigen specific unresponsiveness induced by prior 
exposure to the antigen (reviewed in [9]). It is not fully understood what regulatory 
mechanisms control whether an immune response will lead to tolerance or immunity [5]. It is 
however known that failure of tolerance mechanisms results in ‘forbidden’ clones of cells 
that can find opportunity, upon antigen encounter, to proliferate and inflict damage on the 
body in an autoimmune response. The regulation of self-tolerance within the T cell repertoire 
is maintained at two levels: centrally and peripherally.  
 
1.3.2.1   Central Tolerance 
 
Once developing T cells within the thymus have undergone V(D)J recombination of their 
TCR genes, they express and display the rearranged TCR on their cell surface. The process of 
V(D)J recombination in the thymus may be accompanied by receptor editing and cellular 
deletion in a process known as thymic selection [10].  It is estimated that approximately 
5x107 T cells are produced daily, but only 1- 2x106 of these exit the thymus to enter the 
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circulation (reviewed in [11]). This loss of ~95% of thymocytes reflects a strict selection 
process that determines the T cell repertoire in the periphery. 
 
Central tolerance refers to events in the thymus (usually in the thymic medulla) that trigger 
clonal deletion of thymocytes expressing TCRs with high affinity for self-Ag [12]. The 
molecule that determines whether a T cell will be deleted is the TCR itself. It seems that the 
receptor and its signalling pathway are able to discriminate between low affinity and high 
affinity binding to Ag [13]. The processes that eliminate high affinity self-reactive cells are 
referred to as mechanisms of negative selection [13].  
 
The microenvironment in the thymic medulla contains a significant measure of self-Ags. The 
large diversity of self-Ags available to T cells in the medulla determines the extent of central 
tolerance. These include Ags intrinsic to various cell types found within the thymus, such as 
epithelial cells, dentritic cells (DC), macrophages and thymic B cells. Self-Ags can also enter 
the thymus through the circulation or on immigrating cells [11]. In addition, analysis of 
thymic stromal cells by Derbinski and others in 2001 revealed the expression by medullary 
thymic epithelial cells (mTEC) of over 30 Ags previously believed to be synthesised only in 
non-thymic tissues [14]. 
 
The autoimmune regulator (AIRE) protein regulates the expression of these “tissue specific” 
Ags by thymic epithelial cells [15]. It has been shown that mutations in the gene encoding 
AIRE can result in a severe human autoimmune disease syndrome termed autoimmune 
polyendocrinopathy-candidiasis-ectodermal dystrophy or APECED [16]. The AIRE protein 
promotes the expression of tissue specific Ags and has several potential DNA-binding 
domains in order to regulate transcription of a wide range of genes [17]. The expression of 
tissue specific Ag in the thymus is of crucial importance; studies in mice in which medullary 
major histocompatibility complex (MHC) molecules are absent or blocked have shown that T 
cells with self-reactive TCRs can reach the periphery and cause systemic inflammatory 
conditions (reviewed in [6]).  
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Although the autoimmunity that develops in AIRE deficiency demonstrates the importance of 
central tolerance, central tolerance alone is not sufficient to prevent autoimmunity. T cells 
that recognise self-Ag at an affinity below the threshold required for deletion during central 
tolerance are released into the periphery.  If not regulated, these T cells can generate an 
autoimmune response.  
 
1.3.2.2   T Cell Maintenance, Growth and Differentiation 
 
After development in the thymus, the T cells that escaped negative selection enter the 
peripheral blood circulation as naive T cells. These T cells migrate to and enter secondary 
lymphoid tissues such as draining lymph nodes, spleen and Peyer’s patches, where they are 
ready to encounter their antigen and become activated. Functionally naive T cells may 
survive for long periods of time in the absence of exposure to specific foreign antigen [18].  
 
Antigen driven activation of functionally naive T lymphocytes changes them phenotypically 
into effector/ memory T cells. The formation of a complex between a TCR and a peptide-
major histocompatibility complex (pMHC) ligand represents the molecular solution to the 
recognition of Ag and the activation of the T cell [19]. The TCR is ‘MHC restricted’ and can 
only bind Ag that is itself bound to MHC on the surface of the antigen-presenting cell (APC) 
[20]. T cells can be divided into two classes: CD4+ and CD8+. CD8+ T cells are restricted to 
the MHC class 1 molecules expressed on the surface of most nucleated cells and are 
generally called cytotoxic T lymphocytes (CTL). CD4+ T cells are termed T helper cells and 
recognise MHC class II molecules on a more restricted set of APCs such as macrophages and 
DCs (reviewed in [20]). The differentiation of naive CD8+ T cells transforms them into 
CTLs, which are activated by recognition of pMHC on infected cells allowing them to 
subsequently directly kill the cell. When activated CD4+ T cells encounter pMHC they 
release cytokines capable of activating macrophages or stimulating antibody (Ab) production 
by B cells.  
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The engagement of the TCR with pMHC is not sufficient to generate an activation signal 
within the T cell. For complete activation a second signal is required. Second signals include 
costimulators and cytokines that promote clonal expansion of specific T cells as well as their 
differentiation into effector/ memory cells. Two members of the B7 family, B7-1 (CD80) and 
B7-2 (CD86) are well-defined costimulators. Expression of these molecules on APCs is 
increased once they are activated by microbes or cytokines produced during the initial 
immune response [21].  
 
Upon activation, T cells produce interleukin (IL)-2. IL-2 is the prototypical T cell growth 
factor and functions in an autocrine and paracrine way to cause clonal expansion of the T 
cells stimulated by Ag [22].  
 
1.3.2.3  Peripheral Tolerance 
 
Despite undergoing negative selection during central tolerance, a significant number of low-
affinity self-specific TCRs fail to be edited or to trigger deletion, and hence self-reactive 
specificities enter the periphery expressed by naive T cells. It has been shown that T cells can 
become tolerant to peripherally administered Ag, even in the absence of the thymus [9]. 
Injection of protein into adult mice that had been thymectomised produced specific 
unresponsiveness to the Ag and hence demonstrated that processes in the periphery could 
achieve Ag specific tolerance [9]. Below we will discuss these processes.  
 
Passive Tolerance 
 
Lymphocyte responses can be prevented or terminated in the periphery by deprivation of 
necessary growth and survival factors, leading to a failure to initiate responses and hence 
functional inactivation or death of the lymphocytes involved (reviewed in [22]). Furthermore, 
peripheral Ags may not provoke an immune response if they elude T cells. This may be 
because they are sequestered in an immunologically privileged site or are expressed by cells 
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that do not express MHC molecules and are hence unable to present Ags (reviewed in [9]). 
This ‘ignorance’ of extrathymic autoantigen by the immune system may be important in 
avoiding autoimmune responses. However, this mechanism is potentially dangerous, as 
molecules may be released from dying cells, particularly following tissue damage.  
 
Level of Costimulation 
 
Bretscher and Cohen were the first to propose that the distinction between immunity and 
tolerance depended on whether the lymphocyte received a sufficient costimulatory signal at 
the time of Ag recognition (reviewed in [9]). The activation state of APCs is an important 
factor in determining whether this required level of costimulatory signal is present. Activated 
APCs provide high levels of costimulatory molecules and favour T cell proliferation. On the 
other hand, APCs in steady state express low levels of costimulatory molecules and favour 
ignorance in the form of either apoptosis of the T cell or the induction of functional anergy 
[23].  
 
Because high affinity self-reactive T cells are removed in the thymus during central 
tolerance, the self-reactive T cells in the periphery have a comparatively weak affinity for 
self-Ag [12]. For this reason, these self-reactive T cells are more dependent on higher levels 
of costimulation for their activation. Steady-state APCs presenting self-Ag and expressing 
low levels of costimulatory molecules do not provide sufficient signals to these self-reactive 
T cells, therefore preventing them from undergoing activation, proliferation and 
differentiation to generate an autoimmune response [24]. 
 
Activation Induced Cell Death 
 
Activation induced cell death occurs as a result of antigenic stimulation of T cells which 
triggers mechanisms that prevents their proliferation and survival. Experiments done by 
Thompson and Allison have demonstrated that a second receptor for the B7 molecules, 
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termed the cytotoxic T lymphocyte Ag-4 (CTLA-4), functions to shut off T cell activation 
[25]. The expression of CTLA-4 on the surface of T cells is known to increase upon 
activation, but its mechanism of action remains controversial. Two widely accepted theories 
are that it competes with CD28 for binding to B7 ligands and hence reduces CD28-mediated 
signalling, or that its binding to B7 generates alternative signals that interfere with signals 
from the TCR/CD28 pathways (reviewed in [26]).  
 
Activation of T cells also induces the expression of the death receptor Fas and its ligand, 
FasL. Fas-FasL interactions trigger T cell death by inducing the caspase 8 proteolytic cascade 
and causing apoptosis; this pathway has been shown to be induced by repeated activation 
(reviewed in [6]). Expression of Fas and FasL is important for maintaining tolerance to self, 
as demonstrated by Nagata and Suda who showed that fatal autoimmune disease develops in 
mice with mutations in Fas or FasL [27]. Defects in Fas expression or function have also 
been shown to have similar effects in humans [28]. 
 
Tolerogenic APCs 
 
Another model of peripheral tolerance has been proposed by Barbara Fazekas. This model 
suggests that lymphocytes are not capable of distinguishing between foreign and self-Ag and 
must rely on discrimination made by two subsets of APCs with distinct ontogenic origins, the 
lymphoid- and myeloid-derived DCs, which induce tolerance and immunity, respectively [3]. 
This model suggests that the induction of tolerance rather than immunity is determined not 
only by the level of costimulation but also by the subset of DCs presenting the Ag. This is 
determined by several factors such as the structure of the Ag and the location of the APC. 
Fazekas argues that this model can thus explain how peripheral tolerance and immunity can 
be induced in naïve T cells by different protocols of Ag administration [3]. A study by 
Kearney et al. confirmed these influences of Ag administration on the T cell response. They 
showed that subcutaneous injection of Ag produced immunity. On the other hand, when Ag 
was administered into the blood, cells at first proliferated for a short time but then 
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disappeared, leaving behind a small population that were hypo-responsive to Ag stimulation 
[29].  
 
Regulatory T Cells 
 
The existence of a subpopulation of T cells that specialise in the suppression of the immune 
response is now well established. These regulatory T cells (Treg) are widely regarded as the 
primary mediators of tolerance in peripheral tissues, where they have been shown to prevent 
autoimmune disease and limit chronic inflammation. Tregs are the major focus of this study 
and will be reviewed in more detail in section 1.5.  
 
1.4  Autoimmune Disease 
 
The existence of autoimmune disease suggests that central and peripheral tolerance are far 
from absolute. Many factors make it difficult to reach precise conclusions regarding the 
mechanisms of autoimmunity. The modelling of self tolerance in in vitro culture has proven 
to be difficult and has required that studies are performed in vivo. However the in vivo 
experimental systems are complex, often with multiple changes occurring in response to a 
single stimulus, making effects difficult to dissect [26]. Although the target Ag has been 
identified in a very few number of autoimmune diseases, such as celiac disease [30] and 
some forms of glomerulonephritis [31], the initiating stimulus and target Ag of most human 
autoimmune diseases have not yet been identified, therefore making it impossible to choose 
appropriate self-Ags to study in mice. 
 
Although autoimmune diseases cause immense damage to self tissues, studies in transgenic 
mouse models suggest that this may be due more to the chronicity of the response rather than 
its initial magnitude. It is the persistence of self-Ag in the body that drives the chronicity of 
autoimmune responses. Often, auto-immune responses are initiated but never followed by 
any clinical manifestations unless additional events favour disease progression [32]. 
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Progression of an autoimmune disease from initial activation to a chronic state often involves 
an increase in the number of auto-antigens targeted by T cells and antibodies (reviewed in 
[33]). This process is known as “epitope spreading” and both B cells and T cells contribute. 
Activated, autoreactive B cells can act as APCs generating and presenting peptides from self-
Ags that have not yet been presented to naive T cells and thus are not tolerised against 
(reviewed in [33]). This cascade continues with T cells activating additional autoreactive B 
cells, leading to chronic inflammation.  
 
Several strategies have been proposed to account for how a breakdown in central tolerance 
can allow auto-specific T cells to escape negative selection in the thymus. Cibotti and others 
have demonstrated that presentation of self-Ag at too low a concentration within the thymus 
can allow peripheral auto-reactivity to develop for some self proteins [34]. Furthermore, 
Mamula and others have shown that difficulty in processing and presenting particular self-
Ags in the thymus can allow self reactive T cells specific for those Ags to escape central 
tolerance [35].  
 
It can be predicted that gross defects in the induction of self-tolerance will lead to 
overwhelming autoimmunity to the entire range of self-Ags. This situation is not seen in 
human autoimmune disease. Thus human autoimmune disease is more likely to result from a 
partial dysregulation of peripheral tolerance rather than a major defect in central tolerance 
[3]. A common belief is that self-Ags can induce tolerance in T cells due to the absence of 
second signals whereby lack of costimulation induces deletion or anergy [22]. It can 
therefore be said that the initiation of autoimmunity can be caused by a stimulus that 
activates APCs to upregulate expression of costimulatory molecules. The frequently noted 
association between autoimmunity and infection has been attributed to this upregulation of 
costimulatory molecules on APCs in response to the infection [22]. It has also been suggested 
that the role of infection in predisposing to autoimmunity is mediated not by upregulation of 
constimulatory molecules on APCs but rather by the release of self-Ag, due to inflammation, 
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which is then taken up by immunogenic APCs which relocate to the secondary lymphoid 
organs to activate T cells [3]. 
 
In contrast to T cell-intrinsic tolerance, the role of regulatory T cells in preventing 
autoimmunity has been shown to be highly significant. According to Sakaguchi, any genetic 
abnormality or environmental insult can cause or predispose to autoimmune disease if it 
would tip the balance between Tregs and self reactive T cells towards the dominance of the 
latter [36]. Sakaguchi was the first to define the importance of Tregs in autoimmunity by 
demonstrating that mice depleted of Tregs developed histologically and serologically evident 
autoimmune disease [1].  
 
Autoimmune diseases are heterogeneous, and hence it is possible that multiple areas of 
tolerance breakdown can exist, with different initiating triggers, genetic susceptibility loci 
and activity modifiers contributing to clinically recognised disease in different groups of 
patients [26]. One of the earliest classifications of autoimmune disease was to divide them 
into systemic versus organ-specific. The prototypical systemic disease is systemic lupus 
erythematosus (SLE). This disease is generalised and may involve multiple tissues including 
skin, muscle, kidney and virtually every other organ [26]. It is characterised by the presence 
of antibodies that can bind to double stranded DNA and other nuclear targets [37]. Organ-
specific autoimmune disease is characterised by auto-reactivity to self-Ags that are specific 
to an individual tissue. They are usually mediated by autoreactive T cells which are initially 
activated in lymphoid tissue by an APC and then migrate to peripheral non-lymphoid tissue 
to cause damage. Type 1 diabetes is an example of an organ specific disease. It is caused by 
an autoimmune attack on self-Ags expressed by the pancreatic islet beta cells that make 
insulin, leading to cell loss and a deficit in insulin production [26].  
 
1.4.1  Epidemiology of Autoimmune Disease 
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Autoimmune diseases are individually rare but together affect over 5% of the population in 
Western countries [33]. The incidence and prevalence of autoimmune disease is often 
dependent on genetic and environmental factors that also influence clinical manifestations 
and disease progression. Factors that initiate disease may not be identical to factors that 
influence severity or progression of the disease [38]. 
 
The incidence of human autoimmune diseases varies over a wide range: from less than one 
newly diagnosed systemic sclerosis to more than 20 cases of adult onset rheumatoid arthritis 
per 100,000 per year [4]. Autoimmune disorders can cause significant chronic morbidity and 
disability [39] and have become one of the leading causes of death among young and middle 
aged women in the US [4]. There is strong epidemiologic evidence of a rise in the incidence 
of autoimmune diseases in developed countries over past three decades [40]. The diseases 
that have shown the most profound increases are multiple sclerosis (MS), type I diabetes 
(T1D) and Crohn’s disease [40].  
 
Most autoimmune diseases more frequently affect women than men, with at least 65% of 
patients being female [4]. On the basis of population-based estimates of autoimmune disease 
incidence, Jacobson et al calculated that 2.7 times more women than men will develop an 
autoimmune disease during their lifetime [39]. Furthermore, there are notable differences in 
the age distribution among autoimmune diseases. Although disease can occur at almost any 
age, most autoimmune diseases have a characteristic age of onset. Juvenile rheumatoid 
arthritis and T1D have a mean age onset of 8-10 years [4]. MS and Graves’ disease generally 
occur in patients between ages 30 and 50 years whereas Hashimoto’s thyroiditis, and 
rheumatoid arthritis are diagnosed in patients with an older age group of 40-70 years [4]. 
 
The lifetime risk of specific autoimmune diseases varies considerably in different countries, 
with the highest prevalence of autoimmune disease evident in more developed countries [40]. 
One of the most profound geographical influences on prevalence is seen in MS with a 
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gradient of increasing prevalence with increasing latitude. This gradient is however currently 
seen only in Europe, the USA and Australasia [41].  
 
1.4.2  Genetic Susceptibility 
 
Epidemiological studies have demonstrated that genetic factors are important in determining 
susceptibility to autoimmune disease. The search for these genetic familial links was initiated 
by the observation of the evident clustering of autoimmune disease within families and the 
higher rate of concordance for autoimmune disease in monozygotic twins when compared to 
dizygotic twins [33]. 
 
Only a tiny fraction of autoimmune diseases arise from a mutation or defect in a single gene. 
As mentioned above, the rare APECED syndrome is caused by a mutation in the AIRE gene, 
which is essential for thymic negative selection [6]. More commonly, minor genetic defects 
in multiple genes responsible for central tolerance pathway may predispose an individual to 
autoimmunity rather than directly cause it. 
 
The defective development or organization of thymic medullary epithelial cells can 
predispose to disease. This is evident in gene-targeted mice in which autoimmunity correlates 
with perturbed integrity of the medullary microenvironment [11]. In a study conducted by 
Boehm and colleagues, it was shown that a reduced number of mTECs and disrupted 
medullary architecture can cause inefficient central tolerance induction [42]. 
 
Central tolerance can also be disrupted due to mutations that alter the medullary expression 
of tissue-specific Ags and hence predispose to autoimmunity. Variations in the expression of 
insulin, ocular Ags or myelin can correlate with susceptibility to diabetes, experimental 
autoimmune uveitis or experimental autoimmune encephalomyelitis, respectively, in mouse 
models (reviewed in [11]). 
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Mutations in genes that down-regulate or maintain immune responses in the periphery may 
also contribute to autoimmunity. Most autoimmune diseases are multigenic, with multiple 
susceptibility genes working together to cause the abnormality. The susceptibility 
polymorphisms occur in normal, healthy people where they are compatible with normal 
immune function [33]. However, it is the individual combination of these susceptibility genes 
that is believed to predispose an individual to developing an autoimmune disease. MHC 
molecules make by far the biggest contribution to disease susceptibility, with the majority of 
autoimmune diseases being linked to a particular class I or class II MHC gene [43]. However 
it is believed that in some cases this MHC association to autoimmune disease may require a 
link to a mutation in another gene within the MHC gene locus, such as tumour necrosis factor 
(TNF)-α or complement (reviewed in [33]). 
 
Mutations that can cause autoimmunity include those in genes encoding cytokines, co-
receptors, co-stimulatory molecules, and signalling pathways that induce apoptosis. This has 
been demonstrated in mouse models where at least 25 genes were found to contribute to 
autoimmune disease when they are deleted or over expressed (reviewed in [33]). In humans, 
allelic variations of the gene encoding CTLA-4 causes a decrease in the inhibition of T cells 
and are associated with Graves’ disease [33]. However, whether a mutation in a gene causes 
disease depends on the host’s genetic background, which may either promote disease or be 
protective. Often complex genetic loci rather than a single gene have been linked to disease 
predisposition, and many loci are becoming an important focus of research in many 
autoimmune diseases. 
 
1.4.3  Environmental Triggers 
 
Autoimmunity is generally assumed to involve complex interactions between genetic traits 
and environmental factors [32]. That is to say, even in a genetically predisposed person, an 
environmental trigger is believed to be required to cause disease [33]. The importance of 
environmental triggers in promoting disease is supported by evidence that shows altered 
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disease development in similar populations living in different conditions. This is evident in 
MS where the number of MS cases in a genetically similar population changes as they 
migrate to other regions [44]. These observations, along with the lower than expected rate of 
disease concordance in identical twins (almost always less than 50%), suggest that an 
environmental factor promotes disease development [33]. For most autoimmune diseases, 
however, this trigger is not known.  
 
It is generally believed that an infection can trigger autoimmune disease via two mechanisms. 
A popular theory is that infectious agents trigger autoimmunity in an Ag-specific way due to 
molecular mimicry. This is when antigenic epitopes of microbes have a similar structure to 
antigenic epitopes of the host proteins and thus the host immune system inadvertently 
responds to their own host Ags as well as those of the microbe [32, 33, 40]. Zhao and others 
described an example of molecular mimicry in mice following infection with herpes simplex 
virus Type 2. They showed that T cells that react to viral protein UL6 can also cross react 
with a peptide derived from corneal Ag [45]. Another example of molecular mimicry comes 
from an experimental model of MS in which hepatitis B virus was shown to cause signs of 
encephalomyelitis in rabbits (reviewed in [32]). However, in the case of autoimmune disease 
in humans, there is still no convincing evidence that these pathogenic cross-reactivites 
identified in animal studies are of significance to the human pathology. In a very few number 
of human autoimmune diseases, such as Guillain-Barre syndrome [46] and reactive arthritis 
[47], links to an infection have been established. 
  
Another mechanism whereby microbes can induce autoimmunity is termed ‘bystander 
activation’. This Ag non-specific mechanism involves the release of previously sequestered 
self-Ags or stimulation of the innate response by microbial infection, resulting in activation 
of APCs that present self-Ag [32]. Activation of APCs in turn causes them to express 
costimulatory molecules and migrate to secondary lymphoid organs where they can activate 
naïve self-specific T cells. In a study by Miller and others, it was demonstrated that infection 
of the central nervous system by Theiler’s virus results in autoimmunity to myelin Ags in the 
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mouse [48]. The study concluded that the autoimmune attack resulted from the release and 
processing of myelin Ag by CNS APCs that had been activated by the viral infection. The 
bystander activation theory argues that infection stimulates the innate response to induce 
activation of APC, hence providing naïve self-reactive T cells with the second signal required 
for their activation.  
 
Some of the mechanisms by which microbes can initiate autoimmune disease in animal 
models are also evident in humans. The challenge therefore is to ascertain why all infections 
do not induce autoimmunity. The general lack of autoimmune disease following infection 
demonstrates the importance of the fine-tuned regulatory mechanisms in the immune system, 
which are presumably the result of evolutionary pressure to protect the host from infection 
yet prevent extensive tissue damage.  
 
1.4.4  The Hygiene Hypothesis 
 
The incidence of autoimmune disease is on the rise in developed countries. Parallel with this 
is a decrease in the incidence of many infectious diseases due to improved hygiene and better 
socio-economic conditions [40]. Intestinal infections are the most notable of these, with their 
prevalence in developed countries significantly lower than that of less developed countries, 
particularly among children (reviewed in [40]). It is believed by many that the main factor 
contributing to increased levels of autoimmune disease in developed countries is the 
reduction in the incidence of infectious diseases and exposure to microbial agents due to 
higher levels of hygiene. As early as 1966, Leibowitz et al suggested that the risk of MS is 
increased amongst people who spent their childhood in a highly sanitized home [49]. 
 
There is also experimental evidence suggesting that exposure to infection is associated with a 
decreased incidence of autoimmune disease. It has been consistently observed that 
autoimmune diseases in a susceptible strain of mice develop earlier and are more severe in 
mice bred in a pathogen free environment [40]. Furthermore, Martins et al. demonstrated that 
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diabetes in non-obese diabetic (NOD) mice can be prevented by infecting the young mice 
with mycobacteria [50]. How infection protects against autoimmune disease is unknown. It 
was be suggested that infection stimulates the production of Tregs whose effects extend 
beyond the invading microbe.  
 
1.5  Regulatory T Cells 
 
With multiple mechanisms acting at different levels and in complementary fashions to 
maintain self-tolerance, it is important to determine at what level defects lead to autoimmune 
disease. Among the mechanisms of immunologic self-tolerance, there is increasing emphasis 
on the role of regulatory T cells (Tregs) as a key mechanism maintaining self-tolerance and 
immune regulation. The existence of a subpopulation of T cells that specialise in the 
suppression of immune responses was first proposed in the early 1970s [51]. The widespread 
acceptance of Tregs as a significant subpopulation came with the identification of CD25 as a 
reliable marker of CD4+ T cells with suppressive activity in vivo [1].  
 
Tregs are now widely regarded as the most important primary mediators of peripheral 
tolerance. There exists a spectrum of T cell populations to which regulatory functions have 
been attributed [52]. Several subtypes of Tregs have been defined, each with a distinct 
phenotype, cytokine production profile and mechanism of action. These Tregs are found 
within both the CD8+ and CD4+ T cell compartments. Within CD4+ T cells, three subsets of 
Tregs have been defined. The Tr1 cells emerge during induction of anergy or after repetitive 
stimulation, and are characterised by their ability to secrete high amounts of IL-10 [53]. Tr1 
cells have been shown to suppress the immune response of other T cells both in vivo and in 
vitro (reviewed in [52]). Another CD4+ Treg subset is termed Th3. Th3 cells are induced by 
oral Ag administration, produce high concentrations of transforming growth factor (TGF)-β 
and can inhibit development of immune pathology in mouse models [52].  
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‘Natural’ or “thymic” Tregs develop in the thymus after recognition of self-Ag. These Tregs 
are distinct from conventional T cells in that they do not require TCR-mediated signals to 
constitutively express CD25, the α chain of the IL-2 receptor [54].  
 
The natural Tregs that develop in the thymus are generated in a burst of activity during the 
early stages of foetal and neonatal T cell development [55]. Jordan et al. first demonstrated 
that expression of a self peptide in thymic stromal cells caused CD4+ T cells expressing 
TCRs specific for this peptide to differentiate into CD4+CD25+ cells [56]. Accumulating 
evidence indicates that thymic development of Tregs requires unique interactions between 
TCRs and self-pMHC complexes on thymic cells. These interactions must not be of such 
high affinity that they lead to deletion of the T cells, yet relatively high enough to promote 
Treg development. However, because the depletion of autoreactive T cells also involves high 
affinity interactions with self pMHC, other mechanisms, independent of TCR avidity, are 
suggested to be involved in Treg development [57]. These mechanisms may involve Ag-
independent interactions via accessory molecules such as CD28 or programmed death (PD)-
1, as well as cytokines including IL-2 and TNF-α [57]. The importance of the thymus in the 
development of Tregs has been demonstrated in mouse models in which athymic mice were 
shown to have impaired generation of Tregs leading to multi-organ autoimmunity [58]. 
 
1.5.1  Tregs in Autoimmune Disease 
 
Early studies in a number of experimental animal models of autoimmune and immuno-
inflammatory disease provided substantial evidence that Tregs are an essential part of the T 
cell repertoire and are required to prevent autoimmunity in normal individuals. In 1969 
Nishizuka and Sakakura showed that neonatal thymectomy of mice led to autoimmune 
destruction of the ovaries [59]. Later, in the 1980s, it was shown that the inoculation of NOD 
mice with CD4+ T cells from healthy animals prevented the spontaneous development of 
diabetes [36]. In 1995 Sakaguchi et al. demonstrated that the transfer of CD4+ T cell 
suspensions depleted of CD25-expressing cells into immunodeficient mice caused the 
Chapter 1: Literature review  20 
 
development of a number of organ-specific autoimmune diseases such as thyroiditis, gastritis 
and glomerulonephritis. Sakaguchi et al also showed that the co-transfer of CD4+CD25+ cells 
in this model prevented autoimmune disease in a dose-dependent fashion [1]. These results 
suggested that although self-reactive T cells exist in the periphery, their activation and 
expansion was regulated by CD4+CD25+ Tregs.  
 
Previously, the lack of a marker that could be used to identify Tregs in humans made it 
difficult to elucidate the role of Tregs in autoimmune disease. In mice, Tregs make up a 
phenotypically distinct CD25+ population, whereas in humans ~20-40% of peripheral blood 
CD4+ T cells express CD25 to some extent [54]. When human CD4+ cells are subfractionated 
according to CD25 expression, only the top 1-2% that express the highest levels of CD25 
were shown to have suppressive activity [60]. It was later shown that the lack of suppression 
by CD25+ cells as a whole resulted from interference in the assay by conventional (non Treg) 
CD25+ cells, rather than from the failure of Treg cells expressing lower levels of CD25 to 
suppress.  
 
Since the report of FoxP3 being expressed exclusively by Tregs and the demonstration that 
gene transfer of FoxP3 confers a regulatory phenotype on murine naive CD4+ CD25- T cells 
[2], FoxP3 was accepted as the first truly specific marker for CD4+ CD25+ Treg cells in mice 
and humans. However, FoxP3 is an intracellular molecule and hence its detection requires 
fixation and permeabilisation of the cells, making it impossible to isolate viable Treg 
populations for functional studies [61]. This, along with the difficulty in reproducibly 
defining a CD25 ‘high’ subset on the basis of flow cytometric analysis, prompted the search 
for another marker that could be used to reliably identify the entire population of human 
Tregs. 
 
The identification of one such marker was made in our lab, where it was demonstrated that 
low surface expression of CD127 (the α chain the IL-7 receptor) in combination with CD25 
can distinguish CD127loCD25+ Tregs from conventional T cells [61]. This study confirmed 
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that the surface CD127loCD25+ phenotype was highly correlated with intracellular FoxP3 
expression and hence provided a viable alternative for identifying human Tregs by surface 
markers alone.  
 
Evidence that Tregs are crucial in maintaining immune tolerance in humans is the syndrome 
of multi-organ autoimmunity, dermatitis and allergy that results from a dysfunctional FoxP3 
gene (immunodysregulation, polyendocrinopathy, enteropathy X-linked (IPEX) syndrome) 
[62]. However, most human autoimmune and immuno-inflammatory diseases are not caused 
by such an absolute dysfunction of Tregs, and it is thought that minor deficiencies in Treg 
frequency, function and development may predispose individuals for disease.  
 
CD25hi ‘Tregs’ isolated from patients with autoimmune diseases including MS, myasthenia 
gravis and rheumatoid arthritis have been shown to have reduced suppressive capacity when 
compared to ‘Tregs’ from healthy controls (reviewed in [57]). However, these in vitro assays 
could be influenced by contamination with activated non-regulatory T-cells, as has recently 
been shown in a study of MS patients [63]. In vitro assays are also influenced by the 
susceptibility of the responder CD4+CD25- cells to suppression, and there is evidence that 
responder cells from autoimmune disease patients may be resistant to Treg-mediated 
suppression. For example, T cells from the synovial fluid of rheumatoid arthritis patients 
have been shown to be more difficult to suppress than T cells from peripheral blood 
(reviewed in [57]). This may be due to factors such as cytokines at the inflamed site, which 
may enhance the resistance of CD4+CD25- T cells to suppression. 
 
The reported levels of circulating CD4+CD25hi T cells (the previous working definition of 
human Tregs) in healthy humans ranges from 0.6 to 7.9%. This indicates a lack of 
reproducible Treg phenotypic definitions between laboratories. Reduced levels of circulating 
CD4+CD25hi T cells have been described in individuals with juvenile arthritis [64], psoriatic 
arthritis [65], systemic lupus erythematosus [66] and Kawasaki disease [67]. In contrast to 
these findings, studies on other types of autoimmune disease such as spondyloarthritis and 
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multiple sclerosis have detected no significant difference in the number of CD4+CD25hi 
between healthy and diseased patients [65, 68]. Therefore it can be seen that a reduction in 
Treg numbers is not a general finding in patients with autoimmune disease.  
 
Furthermore, studies in patients with juvenile idiopathic arthritis, rheumatic disease, 
inflammatory bowel disease (IBD), and rheumatoid arthritis have demonstrated increased 
numbers of CD4+CD25hi T cells within inflamed tissues in comparison to peripheral blood 
[64, 65, 69, 70]. Tregs at sites of inflammation have generally been shown to have an 
activated phenotype, with high levels of CTLA-4 and increased suppressive potency [57]. 
 
1.5.2  Mechanisms of Treg mediated suppression 
 
Although it is clear that Tregs prevent autoimmune disease, the mechanisms by which they 
do this in vivo are still unclear. One of the difficulties in elucidating Treg mechanism of 
action is the current opinion that Treg cells depend on cell-to-cell contact in order to mediate 
their function. Experiments done in vitro support this claim; Treg cells have not been shown 
to suppress effector T cell proliferation when the two populations were separated by a 
permeable membrane [71]. There is however no evidence that contact between Treg cells and 
effector cells is required in vivo. In fact, experiments using intravital microscopy to study the 
interactions of T cells, Tregs and antigen-bearing DCs in lymph nodes have demonstrated 
that there is no direct contact between Tregs and T cells in vivo [72, 73].  
 
Although Treg-mediated suppression is consistently cytokine independent in vitro, there is 
evidence that Tregs utilise immunosuppressive cytokines in vivo. Inhibitory cytokines such 
as IL-10 and TGF-β have been the focus of attention as mediators of Treg cell induced 
suppression. In an animal model of inflammatory bowel disease (IBD), protection from 
colitis is dependent on production of TGF- β and IL-10 by a population of T cells enriched 
for Tregs [74]. Interestingly, IL-10 knockout mice do not develop spontaneous autoimmune 
disease but do show enhanced pathology in the colon, suggesting that IL-10 is important in 
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preventing or reducing inflammation at that site [75]. Mice deficient in TGF-β have a severe 
multi-organ autoimmune disease, similar to that seen in FoxP3-deficient mice [76]. These 
TGF-β-deficient mice have significantly reduced numbers of Tregs and reduced expression 
of FoxP3 on their peripheral Tregs. 
 
Tregs are also believed to be able to inhibit T cell proliferation in vivo. In Treg-sufficient 
non-obese diabetic (NOD) mice, fewer CFSE-labelled T cells proliferated; with 20-40% 
entering division compared 60-80% in Treg-deficient hosts [72]. In this study, Tregs were 
also shown to reduce the rate of T cell proliferation, thus preventing both activation and 
reducing the initial T cell proliferative burst.  Similarly, the rapid proliferative response that 
takes place in RAG-/- mice following T cell adoptive transfer has been shown to be inhibited 
by Tregs [77]. 
 
Tregs are able to mediate inhibition of T cell responses indirectly via dendritic cells. This 
provides insight into how a comparatively small Treg population can mediate control over a 
much larger conventional T cell population. In studies looking at the in vivo interactions of T 
cells, Tregs and antigen-bearing DCs in lymph nodes using microscopy, Tregs were shown to 
prevent the stable contact between T cells and DCs, therefore impairing T cell activation [72, 
73]. Neither of these studies demonstrated direct contact between Tregs and T cells, with 
only Treg-DC and T cell-DC contact observed.  
 
Several in vitro studies have shown that the co-culture of DCs with CD4+CD25+ Tregs can 
downregulate the amount of costimulatory molecules (CD80 and CD86) expressed by the 
DCs [78]. CTLA-4 is constitutively expressed on Treg cells and is upregulated by TCR 
ligation. In these in vitro assays, the addition of CTLA-4 blocking Abs has been shown to 
inhibit the Treg-mediated modulation of CD80/CD86 expression [79]. Furthermore, Tregs 
isolated from CTLA-4-deficient mice are unable to modulate the expression of CD80/CD86. 
Although these studies provide evidence for the in vitro influence of Tregs on the expression 
of CD80/CD86 by DCs, evidence for the in vivo relevance of these findings was only 
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recently established in our lab. In this study, Treg-reconstitution of RAG-/- mice led to a Treg-
specific, CTLA-4 dependent downregulation of CD80/CD86 on host DCs [80]. 
 
It is clear that Tregs are functionally heterogeneous and the mechanisms by which they 
mediate suppression may be tissue or context dependent. Tregs may have multiple 
mechanisms to limit autoimmunity and these may vary among Treg subsets that localise to 
distinct tissue environments [81]. The importance of Treg trafficking and entry into various 
tissues is central to this study and will be reviewed in detail below. 
 
1.6  Regulatory T Cell Trafficking 
 
1.6.1  Introduction on T cell trafficking  
 
T cells constantly recirculate between blood and tissue in order to carry out their immune 
function [82]. This trafficking of lymphocytes directs subsets to specialised 
microenvironments depending on their state of differentiation and activation. Naïve T cells 
leave the thymus and specifically ‘home’ to secondary lymphoid organs in order to encounter 
antigen presented by dendritic cells. Activated effector T cells express a range of molecules 
that direct them to non-lymphoid tissues and sites of inflammation. Specialised endothelial 
surfaces are required to control the migration of T cells from blood into tissues; these are 
either the high endothelial venules in secondary lymphoid tissue or the post-capillary venules 
in non-lymphoid tissue. A combination of molecules on the endothelium and the surface of T 
cells are involved in the interaction that results in the extravasation of T cells from the blood 
into the tissue. 
 
In order to leave the circulation, T cells must engage several adhesion pathways [83]. The 
first step involves the formation of ‘tethers’ or weak bonds between T cells and the 
endothelium. These tethers are mediated by the selectin family and their ligands that engage 
and disengage rapidly, allowing the cells to slow down and ‘roll’ along the endothelial lining 
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in order to sample the site for factors that can trigger firm adhesion [84]. The activation of 
firm adhesion is mediated by chemokines on the endothelium binding to chemokine receptors 
on T cells [85]. This interaction results in the activation of integrins on the T cell surface 
which then form high affinity bonds to their ligands on the endothelium, resulting in T cell 
arrest and transmigration through the endothelium into the tissue [86]. Chemokines then 
work as chemotactic factors directing the migration of T cells within the tissue.  
 
T cells, including Tregs, express various combinations of selectins, integrins and chemokine 
receptors required for entry into a range of peripheral tissues. This differential expression 
determines their migration to distinct tissues and sites of inflammation. The expression of 
these homing receptors by Tregs is discussed below. 
 
1.6.2  Tregs in lymphoid and non-lymphoid tissues 
 
Where Tregs travel in vivo and where they act has recently been intensely studied. Studies 
have shown that under steady state conditions there exists a distribution of 
FoxP3+CD25+CD4+ T cells in secondary lymphoid tissues [87]. In a mouse model of colitis it 
was demonstrated that CD25+ Tregs transferred into mice migrated into both the mesenteric 
lymph nodes (LN) and the colon, suggesting Tregs are active at both these sites [88]. 
Additionally, the presence of Tregs at sites of ongoing inflammation demonstrates their 
ability to migrate into peripheral tissues. Tregs have been shown to increase in inflamed 
peripheral tissues in both mouse and human immuno-inflammatory disease [89]. 
Furthermore, Tregs have been shown to express a vast array of integrins and chemokine 
receptors that would facilitate their entry into peripheral tissue. These include CCR4, CCR8, 
CCR6, CLA and CCR5 (summarised in Table 1.1) [90-92].  
 
Treg homing to secondary lymphoid organs such as LNs is important in several in vivo 
models. In a mouse model of graft versus host disease (GvHD), it has been shown that Tregs 
expressing higher levels of the lymph node homing molecule CD62L were superior in vivo 
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suppressors compared with Tregs expressing low levels of CD62L [93]. This study also 
showed that the CD62Llo and the CD62Lhi Tregs were similar in their suppressive capacity in 
vitro, indicating a crucial role for Treg localisation to LNs in the control of inflammation in 
vivo. Tregs also express the LN homing chemokine receptor CCR7. It has been shown that 
Tregs lacking expression of CCR7 are unable to prevent colitis due to their inability to home 
to lymph nodes and suppress primary T cell activation [94].  
 
The importance of Treg homing to non-lymphoid tissues has also been demonstrated in 
numerous studies. In a study by Sather et al., it was shown that Tregs were present in all 
peripheral tissues tested (skin, lung, liver, lamina propria) and were particularly prevalent in 
the skin [81]. Furthermore, they demonstrated that mice with a complete loss of the 
chemokine receptor CCR4 on their Tregs develop severe inflammatory disease in the skin 
and lungs. Tregs have also been shown to recirculate from peripheral tissue to draining 
lymph nodes in the absence of ongoing inflammation. Using transgenic mice that express 
Kaede protein, which allows cell labelling in response to UV light exposure, Tomura et al., 
were able to show that Tregs recirculate from the skin to draining lymph nodes in the steady 
state [95]. They also showed that in order to downregulate cutaneous immune responses, 
Tregs within the circulation infiltrate the skin, migrate to draining lymph nodes and then 
recirculate back to the skin. This further indicates that Treg migration into peripheral sites is 
crucial for Treg-mediated suppression. 
 
1.6.3  Treg Trafficking phenotype switch: from naïve to effector Tregs 
 
Upon activation, T cells in humans switch from expressing CD45RA, a naïve T cell marker, 
to expressing CD45RO, characteristic of effector/memory T cells. Most Tregs in the 
peripheral blood of adult humans express CD45RO, suggesting they have been previously 
activated [54]. On the other hand, CD45RA (naïve) Tregs are more prevalent in early life, 
with a high proportion of cord blood Tregs expressing this phenotype [96]. Naïve and 
effector memory Tregs have been shown to display phenotypic differences. Importantly, it 
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has been demonstrated that CD45RA (naïve) and CD45RO (effector/memory) Tregs 
preferentially localise to different tissues [97]. This is due to a switch in the expression of 
tissue specific homing receptors and integrins from lymphoid to non-lymphoid homing.  
 
Naïve Tregs are CD62L+CCR7+ and migrate to secondary lymphoid tissues where, following 
antigen priming in these tissues, they downregulate CD62L and CCR7 and upregulate 
homing receptors including CCR2, CCR4, CCR6 and CCR8 that allow entry into peripheral 
tissue [92]. It has been shown that FoxP3+ Tregs undergo this activation-dependent switch in 
homing receptors at a faster rate than FoxP3- T cells [92]. Expression of the integrin αE in 
mice has been shown to subdivide the CD25+ Treg compartment into two subpopulations that 
differ in their in vivo suppressive role and migratory pattern [98]. αE- CD25+ Tregs were 
shown to express CD62L and CCR7 and recirculate through secondary lymphoid tissues. 
These cells lacked suppressive capacity under acute inflammatory conditions but were potent 
at suppressing naïve T cell expansion in lymph nodes. The αE+ CD25+ Tregs on the other hand 
migrated to inflamed tissues and had high suppressive potential in these tissues.  
 
In humans, naïve FoxP3+ cells have also been shown to express lymphoid tissue homing 
receptors such as CCR7 and CD62L whereas effector/memory FoxP3+ cells express 
inflammatory chemokine receptors such as CCR5, CCR6 and CCR4 [99]. 
 
1.6.4  Tissue specific homing of conventional T cells and Tregs: Gut versus Skin 
 
The migration of conventional T cells to different peripheral tissues results, at least in part, 
from expression of particular combinations of integrins and chemokine receptors. Of these 
tissue homing phenotypes, the gut specific α4β7+ [100, 101] and CCR9+ [102] and the skin 
specific CLA+, CCR4+ and CCR10+ [103, 104] are the best defined. Such tissue-specific 
trafficking plays an important role in the inflammatory response within that tissue. In a 
mouse model of inflammatory skin disease, only CCR4 expressing donor T cells 
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accumulated in the skin whereas CCR4 knock out (KO) T cells failed to cause inflammation 
[105].  
 
Imprinting of tissue specificity on conventional CD4+ T cells is influenced by the tissue 
microenvironment and the presence of organ specific dendritic cells (DCs) during priming in 
secondary lymphoid tissue. Activated effector/memory T cells have often been shown to 
migrate preferentially to tissues within the lymphoid drainage site of their original primary 
lymphoid organ. For example, T cells activated by dendritic cells from mesenteric lymph 
nodes and Peyer’s Patches are induced to express high levels of α4β7 and CCR9 which then 
aid their future entry into gut tissue [106, 107].  
 
Recently, two studies have demonstrated mechanisms by which skin and gut resident 
dendritic cells can induce expression of tissue specific integrins and chemokine receptors by 
conventional T cells. Iwata et al. reported that DCs from the gut associated lymphoid organs 
could produce retinoic acid from vitamin A (retinol), which in turn induced T cell expression 
of α4β7 and CCR9 [107]. Similarly, Sigmundsdottir et al. showed that the active form of 
vitamin D3 induced the expression of CCR10 on T cells which then enabled them to migrate 
in response to the skin specific chemokine CCL27 [103]. In this study, it was also 
demonstrated that the upregulation of the skin homing phenotype was accompanied by a 
downregulation of gut homing receptors.  
 
Mechanisms responsible for a degree of tissue specificity in Ag-primed conventional T cells 
have also been shown to function during Treg differentiation. The priming of Tregs within 
skin draining LNs leads to the expression of P and E selectin ligands, which aid their 
migration into inflamed skin, whereas priming in mesenteric LNs results in the upregulation 
of integrin α4β7 and entry into the gut [108]. Furthermore, Sather et al. demonstrated that 
Treg expression of the skin homing receptor CCR4 is induced by activation in subcutaneous 
LNs [81].  
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Many studies of trafficking phenotypes of Tregs in adult mice and humans have 
demonstrated a skewed skin versus gut phenotype, with the majority of Tregs shown to 
express higher levels of skin homing CLA and CCR4 and less gut homing α4β7 [81, 91, 109-
111]. Interestingly, the reverse is true in early life, when the majority of Tregs express α4β7 
[110]. This indicates a possible role for the gut in Treg cell exposure to exogenous Ags in 
early life and could possibly shape the Treg compartment and influence homing receptor 
expression patterns and phenotype in later life.  
 
1.6.5  Treg regulation of different immune responses 
 
During their initial activation, conventional CD4+ T cells can assume one of several 
functional fates (Th1, Th2 or Th17).  These fates are largely determined by the cytokines that 
are present during activation and the transcription factors that are induced. Each of these 
defined immune responses can, if they are deregulated, cause harm to host tissue. In fact, 
known autoimmune, allergic and other immuno-inflammatory conditions are believed to be 
the result of uncontrolled Th1, Th2 and Th17 immune responses to harmless antigen. Defects 
in Treg function have been shown to result in Th1-, Th2- or Th17-mediated inflammatory 
disease and recently there has been increasing interest in mechanisms by which Tregs can 
regulate these specific types of inflammation. 
 
Several studies suggesting that different Treg subsets are specialized in regulating polarized 
Th1, Th2 or Th17 immune responses have recently been published. The functional 
specialisation of Th1, Th2 and Th17 effector CD4+ T cells is mainly dependent on 
differential expression of transcription factors that turn on programs of gene expression 
determining function and, importantly for this review, migration of the CD4+ T cell 
(reviewed in [89]). It has recently been demonstrated that subsets of Tregs also express these 
transcription factors, which aid them in their suppressive function. A study by Koch et al. 
demonstrated that in response to IFN-γ, FoxP3+ Tregs upregulated the Th1 associated 
transcription factor T-bet which subsequently induced the expression of CXCR3, a 
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chemokine receptor commonly associated with Th1 responses [112]. This upregulation of 
CXCR3 resulted in CXCR3+ T-bet+ Tregs accumulating at sites of Th1 mediated 
inflammation. Furthermore, it was shown that T-bet deficient Tregs failed to localise to 
inflamed tissue and could not control Th1 type inflammation [112].  
 
It has also been shown that Treg expression of IRF4, a transcription factor involved in Th2 
differentiation, is required for control of Th2 type inflammation. Mice with an IRF4 deletion 
in their FoxP3+ Tregs develop lymphoproliferative disease characterized by IL-4 producing 
CD4 T cells [113]. Additionally, Tregs with the IRF4 deletion displayed reduced levels of 
CCR8, a chemokine receptor that has been implicated in T cell homing to sites of Th2 type 
inflammation [114-116].  
 
It has been shown that CCR6 mediates entry into sites of Th17 inflammation [117] and is 
required for Treg suppression of Th17 responses. The deletion of a transcription factor 
associated with Th17 inflammation, STAT3, in Tregs resulted in the development of 
intestinal inflammation characterised by IL-17 production and deregulated Th17 responses 
[118]. In this study, CCR6 expression on STAT3 KO Tregs was impaired. Furthermore, in a 
study of experimental autoimmune encephalomyelitis (EAE), a Th17 mediated disease 
model, a lack of CCR6 expression on Tregs resulted in a failure of Treg entry into the 
inflamed tissue and hence failure of disease control [119]. These studies all provide evidence 
for the importance of the co-localisation of Tregs with effector T cells at sites of 
inflammation. 
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1.7  Project Aims 
 
The appropriate localisation of Tregs is crucial to their function. Despite this, very few 
studies have examined Treg trafficking phenotypes in patients with autoimmune disease. We 
hypothesise that deficiencies in Treg subsets expressing particular trafficking receptors may 
play a role in human autoimmunity.  
 
Since Tregs have been shown to recirculate via the blood and are generally increased at sites 
of inflammation, analysis of their expression of chemokine receptors and integrins in 
peripheral blood should provide insights into their regulatory role in different tissues. The 
majority of studies that have examined Treg trafficking in humans defined Tregs as 
CD4+CD25hi cells. This definition makes it difficult to distinguish Tregs from conventional 
CD25+ T cells and has been shown to exclude a large percentage of the total Treg 
compartment. 
 
We aimed to use the CD127loCD25+ phenotype, in association with a range of integrins and 
chemokine receptors, to define Treg subsets in healthy humans and in patients with 
rheumatoid arthritis and psoriasis, and to assess how these subsets may be implicated in 
disease severity and response to therapy in these diseases. 
 
It is believed that Tregs can be subdivided into populations that express migratory receptors 
that target them to certain tissues, such as skin and gut, and specific sites, such as Th1, Th2 
and Th17 mediated inflammation. Whether these phenotypes are specific and mutually 
exclusive has not been well defined. We aimed to take a novel approach by designing 
antibody panels that will allow for the analysis of up to 8 different chemokine receptors and 
integrins on Tregs, therefore allowing us to examine gut versus skin trafficking phenotypes 
and transcription factors and their associated homing phenotypes together in the same cell 
sample. 
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Flow cytometry involves the rapid quantification of multi-dimensional characteristics for 
millions of cells. The manual analysis of cell subset data derived from such high-throughput 
multidimensional experiments is extremely time consuming, particularly when determining 
correlations between multiple different cell subsets in multiple subject groups. For this 
reason, there is a need for more efficient data viewing and analysis methods. The final aim of 
this study was to develop bioinformatic methods to analyse multiparameter flow cytometric 
data and to perform automated comparisons between multiple conventional CD4+ T cell and 
Treg subsets in patients and controls. 
 
Future therapeutic strategies based on Tregs will need to take into consideration that 
appropriate trafficking properties are crucial to their success. A comprehensive study of the 
trafficking phenotypes of Tregs in humans has not been carried out. Here we hope to provide 
insight on the role of Tregs in peripheral tissue immune surveillance so that strategies can be 
developed to support Treg activity as a treatment option in autoimmune disease.
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Table 1.1: Summary of chemokine receptors and integrins and their homing association. 
Receptor/ 
Integrin 
Ligand Association Key reference 
CCR2 CCL2 
CCL7 
CCL18 
Migration to 
inflamed tissue 
• Upregulated on Tregs upon activation, allows 
entry into peripheral tissue [92] 
CXCR3 CXCL9 
CXCL10 
CXCL11 
Migration to 
Th1-mediated 
inflammation 
• Expression dependent on T-bet and allows 
entry to sites of Th1 inflammation [112] 
CX3CR1 CX3CL1 
(Fractalkin, 
FKN) 
Migration to 
inflamed gut 
• Increased expression of 
CX3CR1 ligand on gut mucosal epithelium and 
increased expression of CX3CR1 on T cells in 
patients with IBD [120]. 
CCR4 CCL17 Migration to 
skin and sites 
of Th2-
mediated 
inflammation 
• Expressed by high proportion of 
Tregs [91].  
• CCR4 expression increased on T 
cells taken from skin inflammatory site AND 
deletion of CCR4 on Tregs causes skin 
inflammatory disease [81]. 
• Deletion of CCR4 on Tregs 
causes lung inflammatory disease [81] 
• Directs homing and entry into 
sites of Th2 inflammation [114]. 
CCR5 CCL5 
CCL3 
CCL4 
Migration to 
inflamed tissue 
• Important for Treg homing to sites of infection 
[121] 
CCR6 CCL20 Migration to 
sites of Th17-
mediated 
inflammation 
• Deletion of STAT3 in Tregs results in 
inflammation characterised by IL-17 production 
and deregulated Th17 responses [118]. 
• Mediates entry into sites of Th17 inflammation 
and is required for Treg suppression of Th17 
responses [117]. 
CCR7 CCL19  
CCL21 
Migration to 
Lymph nodes 
• Required for prevention of T cell activation in a 
mouse model of colitis [94]. 
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CCR8 CCL8 Migration to 
lungs and sites 
of Th2-
mediated 
inflammation 
• Expressed by Th2 cells and Tregs [116] 
• Key regulator of Th2 cell recruitment into sites 
of allergic inflammation [115]. 
CCR9 CCL25 Migration to 
small intestine 
• Mediates T cell entry into small intestine [122]. 
• Increased expression of CCR9 by T cells taken 
from gut mucosa [123]. 
CCR10 CCL27 
CCL28 
Migration to 
skin 
• Allows migration to skin specific chemokine 
CCL27 [103]. 
CD62L L- selectin Migration to 
lymph nodes 
• Required for Treg migration to LN [124]. 
α4β7 MadCAM-1 Migration to 
gut 
• DCs from Peyer’s Patches induce expression of 
α4β7 which aid entry into gut tissue [106, 107]. 
CLA E-selectin Migration to 
skin 
• Highly expressed by Tregs [91] 
• Homes Tregs to skin [109]. 
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CHAPTER 2:  MATERIALS & METHODS 
 
In order to study the frequency of Tregs and Treg subsets in patients and healthy donors, 
peripheral blood was collected from individuals and peripheral blood mononuclear cells 
(PBMCs) were isolated using density gradient centrifugation and stored. PBMCs were then 
stained with combinations of monoclonal antibodies and data was acquired on a custom built 
LSRII 10-laser flow cytometer (BD) and analysed using FlowJo software (Tree Star). 
Descriptions of patient recruitment and materials and methods are outlined below. 
 
2.1  Patient and Control Cohorts 
 
Informed written consent was obtained from all patients and controls prior to the study. The 
studies were approved by the Sydney Local Health District ethics review committees at 
Royal Prince Alfred Hospital, Camperdown and Concord Repatriation General Hospital, 
Concord. All personal and medical information collected from the patients, including sex, 
date of birth, diagnosis, treatment, disease duration and past clinical details, was stored 
confidentially.  
 
2.1.1  Rheumatoid Arthritis Patients 
 
Peripheral blood specimens were collected from 34 patients with rheumatoid arthritis (RA) 
(65% female, average age 56.4 years) and 34 sex and age matched controls (65% female, 
average age 55.6 years). Patients with RA, diagnosed according to the European League 
Against Rheumatism (EULAR) 2010 criteria [125], were enrolled in the study over a period 
of one year by Dr Diana Chessman at Concord Repatriation General Hospital (Concord, 
NSW, Australia). Clinical information including disease duration, disease activity, as 
assessed by the disease activity score in 28 joints (DAS28), treatment, smoking status and 
seropositivity was recorded at the time the blood was collected. Patient characteristics are 
summarised in Table 4.1 in Chapter 4. 
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2.1.2  Psoriasis Patients  
 
Peripheral blood samples were obtained from patients treated by Professor Wolfgang 
Weninger and Dr Patricia Lowe at the Dermatology Centre of Royal Prince Alfred Hospital 
in Gloucester House (Camperdown, NSW, Australia). Specimens were collected from 44 
patients with chronic psoriasis (77% male, average age 47.6 years) and 44 sex and age 
matched controls (77% male, average age 49.1 years). Clinical information including disease 
duration, disease activity, as assessed by the psoriasis area severity index (PASI) and 
treatment was recorded at the time the blood was collected. Patient characteristics are 
summarised in Table 5.1 in Chapter 5. The 44 control subjects were also analysed as a 
separate cohort in Chapter 3.  
 
2.2  Reagents 
 
2.2.1  Phosphate Buffered Saline (PBS) 
 
Milli-Q filtered H2O containing 8g/L NaCl, 0.2g/L KCL, 1.15g/L Na2HPO4 and at pH 7.2 was 
prepared at the Centenary Institute, kept sterile and stored at room temperature. 
 
2.2.2  Ficoll-paque Plus  
 
Each 100ml of Ficoll-Paque plus (GE Healthcare, UK) contains 5.7g Ficoll 400, 9.0g 
Diatrizoate Sodium with Edetate Calcium Disodium in water. This reagent was stored at 
room temperature and protected from direct light. 
 
2.2.3  Tissue Culture Medium 
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RPMI Medium 1640 with L-glutamine and HEPES buffer (Invitrogen) supplemented with 
10% heat activated foetal calf serum (FCS) (Trace MultiSer Biosciences, Australia) and 
2mM L-Glutamine. 25mM 2-Mercapto-ethanol, and 1000units/L of Penicillin (Invitrogen) or 
1000 ug/L Streptomycin (Invitrogen) was added to prevent organism contamination. TCM 
was kept sterile and stored at 4oC. 
 
2.2.4  Freezing Medium 
 
2 x Freezing Medium consisted of RPMI 1640 and 20% Dimethyl sulfoxide (Sigma) filtered 
through a 0.22um sterile filter (Millipore) and then supplemented with 40% FCS. Reagent 
was kept sterile and stored at 4oC. 
 
2.2.5  Fluorescence Activating Cell Sort (FACS) Wash 
 
This reagent was used in wash and resuspension steps during antibody labelling for flow 
cytometry. FACS wash (F/W) contained 5% Foetal Calf Serum (FCS) and 0.05M sodium 
azide in PBS. 
 
2.2.6  Fluorescence Activating Cell Sort (FACS) Fix 
 
All samples analysed by flow cytometry were fixed with FACS Fix after staining. This 
reagent consists of 1% paraformaldehyde (BDH Laboratory Supplies) in PBS.  
 
2.2.7  BD Pharmingen Transcription Factor Buffer Set  
 
This set contains concentrated stock solutions of Fix/Perm buffer, Diluent buffer and 
Perm/Wash buffer (BD Pharmingen, 562574). Working solutions of the fix/perm buffer were 
made by mixing 1 part Fix/Perm concentrate with 3 parts Diluent buffer. Working solutions 
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of the perm/wash buffer were made by mixing 1 part Perm/Wash buffer concentrate with 4 
parts triple distilled water. Working solutions were prepared fresh and stored at 4oC.  
 
 
2.3  Isolation of mononuclear cells from peripheral blood 
 
This protocol is for a single venous blood sample collected in a 9 ml Lithium Heparin tube 
(Greiner bio-one). All blood samples were handled in a Class 2 biosafety hood and under 
sterile conditions.  
 
An automated cell count was first performed using a Sysmex KX-21 Haematology Analyser, 
to determine the concentration of leucocytes and lymphocytes in the venous blood. The blood 
was then diluted 1:2 with PBS in sterile 50ml tubes (BD Falcon). 12mls of Ficoll-Paque Plus 
solution (GE Healthcare) was next layered underneath the blood and the tube was centrifuged 
for 30 minutes at 600RCF at room temperature with the brake disengaged. The PBMCs were 
then collected from the interface between the Ficoll-Paque and the diluted plasma and 
transferred into sterile 15 ml tubes (BD Falcon) and washed twice with PBS (10 minutes, 
230RCF, 22oC). Cells were resuspended in PBS, an aliquot taken for counting, and then 
centrifuged and resuspended in equal parts cold TCM and freezing medium at a 
concentration of 2-4 x 106 cells per ml. 1ml aliquots were frozen at -1oC/minute using a 
Cryo-1oC/minute Freezing Container (Nalgene) and stored at -180oC in LNO2. 
 
2.4  Flow Cytometric Analysis  
 
2.4.1  Monoclonal antibodies 
 
Isolated mononuclear cells were stained for expression of a range of surface and intracellular 
markers using combinations of monoclonal antibodies (mAbs). The mAbs used in this study 
are listed in Table 2.1. 
Table 2.1: Summary of monoclonal antibodies used in this study 	  
Antibody Fluorochrome Clone Source Cat# 
Mouse anti-human  CD4 BD V500 RPA-T4 BD Biosciences 560768 
Mouse anti-human  CD4 BV786 SK3 BD Biosciences 563877 
Mouse anti-human  CD25 BV421 MA251 BD Biosciences 562442 
Mouse anti-human  CD25 APC MA251 BD Biosciences 555434 
Mouse anti-human  CD127 BUV737 HIL-7R-M21 BD Biosciences 624230 
Mouse anti-human  CD127 PE-CF594 HIL-7R-M21 BD Biosciences 562397 
Mouse anti-human  CD45RA PE-Cy7 HI100 BD Biosciences 560675 
Mouse anti-human  CD45RO BUV395 UCHL1 BD Biosciences 564291 
Mouse anti-human  CD45RO Biotin UCHL1 BioLegend 304220 
Rat anti-human  Beta7 Biotin FIB504 BioLegend 321209 
Mouse anti-human  CCR10 PE 1B5 BD Biosciences 563656 
Mouse anti-human  CCR4 APC L291H4 BioLegend 359408 
Mouse anti-human  CCR4 PE-Cy7 L291H4 BioLegend 359410 
Rat anti-human  CCR5 AF700 HEK/1/85a BioLegend 313714 
Mouse anti-human  CCR6 PE 11A9 BD Biosciences 559562 
Mouse anti-human  CD49d PerCP-Cy5.5 9F10 BioLegend 304312 
Mouse anti-human  CD62L APC-Cy7 DREG-56 BioLegend 304814 
Rat anti-human  CLA FITC HECA-452 BD Biosciences 555947 
Mouse anti-human  CXCR3 AF488 1C6 BD Biosciences 558047 
Mouse anti-human  FoxP3 PE-CF594 236A/E7 BD Biosciences 563955 
Mouse anti-human  FoxP3 AF488 259D BioLegend 320212 
Armenian hamster anti-human  
Helios 
APC 22F6 BioLegend 137216 
Mouse anti-human  RORγt AF647 Q21-559 BD Biosciences 563620 
Mouse anti-human  T-bet BV711 O4-46 BD Biosciences 563320 
Zombie Yellow Fixable Viability 
dye 
- - BioLegend 423104 
Live/Dead Fixable Near IR - - Invitrogen L10119 
Live/Dead Fixable Blue - - Invitrogen L23105 
Strepavidin AF594 - Invitrogen S32356 
Strepavidin DyLight-800 - Thermo Scientific 21851 	  
Abbreviations: APC- Allophycocyanin; PE- Phycoerytherin; PE/Cy7- 
Phycoerythrin-Cyanine 7; AF488- Alexa Fluor 488; AF647- Alexa Fluor 647; 
AF594- Alexa Fluor 594; PerCp/Cy5.5- Peridinin chlorophyll protein/ cyanine 5.5; 
BV- Brilliant Violet; BUV- Brilliant Ultraviolet;  	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2.4.2  Immuno-staining for cell surface markers 
 
Frozen mononuclear cells were thawed in a 37oC water bath and transferred to tubes 
containing 9mls of pre-warmed TCM (37oC). The tubes were inverted to mix and then 
centrifuged (1000rpm, 10 mins, 22oC), resuspended in 2mls of cold FACS wash (FW), and 
an aliquot removed for counting. 1x106 viable cells from each sample were next transferred 
to a 96-well U-bottomed plate and washed twice with 150ul of FW (1500rpm, 3 mins, 4oC).  
 
Following these wash steps, samples were incubated with a pre-diluted antibody and viability 
dye mix (containing antibodies and viability dye at optimal concentrations in a final volume 
of 100ul) for 45 mins at 4oC. If a biotinylated mAb was used and an avidin-fluorochrome 
conjugate was required, cells were washed three times with 150ul FW (1500rpm, 3 mins, 
4oC) and the second layer of pre-diluted mix (50ul) was added for a further 45 mins at 4oC. 
Cells were then washed twice with 150ul FW (1500rpm, 3 mins 4oC), fixed in 150ul FACS 
fix for 15 mins at 4oC and washed again with 150ul FW (1500rpm, 3 mins, 4oC). Cells were 
then either stained for intracellular markers or filtered into 2mL FACS tubes immediately 
before acquisition on a flow cytometer. 
 
2.4.3  Immuno-staining for intracellular markers 
 
After the completion of cell surface staining, cells were transferred to FACS tubes and fixed 
in 1 ml Fix/Perm buffer (1x) (BD Pharmingen, 562574) (50min, 4oC, in the dark). 1 ml 
Perm/Wash buffer (1x) was next added and cells were centrifuged (350g, 6mins, 4oC), 
supernatant was removed and cells then washed again with 2 ml Perm/Wash buffer (1x) 
(350g, 6mins, 4oC). Cells were then resuspended in 100ul of pre-diluted antibody mix 
(contains antibodies at optimal concentrations in Perm/Wash buffer) and incubated for 50 
minutes at 4oC in the dark. Cells were then washed twice in 2 ml Perm/Wash buffer (1x) 
(350g, 6mins, 4oC) and resuspended in 150ul FW for acquisition on a flow cytometer.  
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2.4.4  Compensation Controls 
 
Compensation controls were prepared using antibody capture beads (CompBeads, BD). 
Beads were incubated with a single fluorochrome-conjugated antibody for 10 minutes prior 
to data acquisition on a flow cytometer. Unconjugated beads were used as negative controls.  
 
2.4.5  Flow cytometric acquisition and analysis 
 
Data were acquired on a LSRII 10-laser Flow Cytometer (Becton Dickinson, San Jose, CA, 
USA). Instrument performance was verified prior to acquisition using standard fluorescent 
microparticles (Spherotech) to check laser delays. Uncompensated data in FCS3 file format 
was collected using the FACSDiva digital software (Becton Dickinson). Data was then 
compensated manually using compensation controls to generate a compensation matrix in 
FlowJo software (Tree Star Inc., San Carlos, CA, USA). FlowJo software was subsequently 
used to analyse cell populations.  
 
2.4.6  Gating strategy for the analysis of conventional T cells and Tregs 
 
A general gating strategy was employed for the analysis of all PBMC flow cytometric data 
(Figure 2.1 A-E). A time gate was first used to exclude artefacts due to fluidics instability at 
the start and end of samples. A fixable dead cell exclusion dye was next used to remove dead 
cells from analysis. Doublets were next excluded by first gating on Forward Scatter-Area 
(FSC-A) versus Forward Scatter-Height (FSC-H) followed by a Side Scatter-Area (SSC-A) 
versus Side Scatter-Height (SSC-H) gate. CD4+ cells were then selected for analysis. 
 
Tregs were identified within the CD4+ gate on the basis of expression of CD25, CD127 and 
FOXP3 (Figure 2.1 F&G). Tregs were defined as CD25+CD127lo and/or FOXP3+CD127lo 
cells. Conventional T cells (Tconvs) were defined as everything outside the indicated 
CD127loCD25+ Treg gate (Figure 2.1 G). CD45RO was used as a marker of post-thymic 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
	  	  
	  
	  
                 Figure 2.1: General gating strategy for the analysis of Treg and Tconv subpopulations. Peripheral blood mononuclear cells 
(PBMC) were isolated from human blood and examined for the expression of markers that allowed for the identification of Tregs 
(CD4, CD25, CD127 and FoxP3) and then the further examination of subsets (CD45RO and CR/integrins). This is an example of a 
stain with CXCR3 as the trafficking receptor examined. A FSC-H vs time gate was used to exclude artefacts due to fluidics instability 
at the start and end of the samples (A). A fixable dead cell exclusion dye was next used to remove dead cells from analysis (B). 
Doublets were excluded using sequential FSC-A vs FSC-H (C) and SSC-A vs SSC-H (D) gates. CD4+ cells were then gated (E) and 
CD4+ Tregs were identified as CD127loCD25+ (G) or CD127loFOXP3+ (F). Conventional T cells (Tconvs) were defined as everything 
outside the indicated CD127loCD25+ Treg gate (G). Tregs and Tconvs were next subdivided on the basis of CD45RO expression in 
order to differentiate between CD45RO+ (effector/memory) and CD45RO- (naïve) subsets, and analysed for the various CRs and 
integrins examined. CXCR3 is used as an example here (H&I). CXCR3+CD45RO+ cells in the upper right gate and 
CXCR3+CD45RO- cells in the upper left gate were identified on both Tregs (H) and Tconvs (I). Numbers indicate cells within the 
gate as a percentage of the parent population. 
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activation and differentiation. Tregs and Tconvs were next subdivided on the basis of 
CD45RO expression in order to differentiate between CD45RO+ (effector/memory) and 
CD45RO- (naïve) subsets, and analysed for the various CRs and integrins examined. CXCR3 
is used as an example in Figure 2.1 (H&I). CR+CD45RO+ cells in the upper right gate and 
CR+CD45RO- cells in the upper left gate were identified on both Tregs (Figure 2.1 H) and 
Tconvs (Figure 2.1 I).  
 
2.5  Statistical Analysis 
 
Statistical analysis was performed using Prism 6 software (GraphPad Software, Inc., La Jolla, 
CA, USA). The Mann-Whitney t-test was used to compare differences between two groups. 
The Kruskal –Wallis test followed by Dunn’s multiple comparison was used to analyse 
differences between three or more groups. The non-parametric Spearman method was used to 
calculate correlation coefficients. P-values <0.05 were considered significant. 
 
Statistical analysis was also performed using MultiExperiment Viewer (MeV) (TM4–
Microarray Software Suite). Data was loaded into MeV in .txt format and heatmaps were 
generated. Differences between groups were evaluated using an automated Mann-Whitney t-
test. A Kruskal-Wallis test was used for identification of differences between three or more 
groups. P values less than 0.05 were considered significant. Unsupervised cluster analysis 
was performed using the hierarchical clustering (HCL) algorithm.  
 
2.6  Flow Cytometric Panel Design for Accurate Measurement of T Cell 
Subsets   
 
Polychromatic flow cytometry allows for the identification of specialised cell subsets within 
populations that were once considered to be homogeneous, allowing us to monitor changes in 
these subsets during autoimmune disease. 
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It is believed that Tregs can be subdivided into distinct populations that express migratory 
receptors that target them to certain tissues, such as skin and gut [81, 108], and specific sites, 
such as Th1, Th2 and Th17 mediated inflammation [112-116, 118, 119]. Despite this, no one 
has looked at these markers on conventional T cells (Tconvs) and Tregs in conjunction with 
each other using flow cytometry. This is probably due to the fact that developing a multi-
colour flow cytometric panel is time consuming and requires a number of validation trials. 
We took a novel approach and designed two 10-13 colour antibody panels that will allow for 
the analysis of up to 8 different chemokine receptors (CR) and integrins on Tregs at a time, 
therefore allowing us to examine gut versus skin trafficking phenotypes and transcription 
factors and their associated homing phenotypes together in the one stain. 
 
2.6.1  The LSRII-10-Laser Flow Cytometer 
 
An LSRII-10-laser (BD) flow cytometer was used in this study. The standard bandpass and 
dichroic filter configuration of this instrument is summarised in Figure 2.2. An important 
step in developing a flow cytometric panel is to understand the optical configuration of the 
flow cytometer and to choose filters based on maximum emission spectra of the 
fluorochromes, while simultaneously avoiding unwanted spectral overlaps. This was 
particularly important for our study because we aimed to use a large number of 
fluorochromes to measure co-ordinately expressed cell markers. In order to provide ourselves 
with a guide in predicting optimal detection while minimising spillover, we calculated the 
%efficiency of fluorochromes on each of the filters available on the LSRII-10-laser flow 
cytometer (Figure 2.3).  
 
However, despite the fact that we can predict relative dye brightness and spectral overlap, 
these factors are also influenced by the level of expression of the markers of interest, thus 
making it crucial to test antibody-fluorochrome combinations and perform trials on panels 
with the relevant controls.  
 
	  	  	  	  	  	  	  	  	  	   	  
	  	  
	  
Figure 2.2: Standard optical configuration of the 10-Laser BD FACS LSRII. The instrument is equipped with 10 lasers: UV 
(355nm), Infrared (786nm), Violet (405nm), Blue-Violet (445nm), Blue (488nm), Green (514nm), Green_2 (532nm), Yellow-Green 
(561nm), Orange (592nm) and Red (628nm). The optics are set up in octagon - (violet, blue-violet, green_2 and yellow/green 
lasers) and trigon – (UV, infrared, blue, green, orange and red lasers) shaped arrays, with a series of photomultiplier tubes (PMT) 
and filters (dichroic and band pass) that enable for the analysis of up to 30 parameters. The set of laser and detector combinations 
in the bottom panel represent the basic standard configuration of the machine for which cytometer setup and tracking (CST) is 
carried out daily by the flow cytometry facility. Any variations from this standard configuration will require the user to test and 
optimise settings.  
	  	  
Figure 2.3: %Efficiency of fluorochromes when excited by the lasers on the LSRII-10 Laser. 
The % Efficiency for each fluorochrome was calculated by multiplying the %Excitation by each 
given laser with the % total emission detected by the standard machine filters.  
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2.6.2  Fluorochromes and Optimal Detectors 
 
In the current study, PBMCs are stained for the basic human Treg identification panel (CD4, 
CD25, CD127, FoxP3, CD45RO) plus combinations of CR/integrins and transcription 
factors. Due to the commercial unavailability of a wide range of fluorochrome conjugated 
antibodies directed at human chemokine receptors and integrins, we decided to move our 
standard Treg markers off the more popular lasers (blue, yellow-green and red), giving us 
room to make various combinations of CRs and integrins.  
 
PE-CF594 on the Orange Laser 
 
One of the main advantages of the LSRII-10-laser cytometer is the availability of an orange 
592nm laser. However despite this, human antibodies directly conjugated to fluorochromes 
designed for this laser, such as the Alexa Fluor 594 (AF594), are not available commercially. 
This is probably due to the fact that flow cytometers installed with an orange laser are 
extremely rare, resulting in little demand for antibodies designed for this laser. 
 
The PE-CF594 fluorochrome is designed for the yellow-green 561nm laser. However the 
orange 592nm laser can also significantly excite this fluorochrome. Because spectral 
spillover makes PE and PE-CF594 incompatible together when both are detected off the 
yellow-green laser, we decided to trial PE-CF594 detection in the 610/20 filter off the orange 
laser (Figure 2.4). In order to do this, PBMCs were either stained with biotinylated CD127 
followed by streptavidin-AF594 (the fluorochrome designed for the 610/20 channel on the 
orange laser) (Figure 2.4, A) or CD127 conjugated to PE-CF594 (Figure 2.4, B&C).  
 
Although PE-CF594 is designed for the 615/10 channel on the yellow-green laser, it is 
evident that it is comparable on the 610/20 channel on the orange laser (Figure 2.4, B&C), 
hence allowing us to utilise the PE-CF594 fluorochrome while eliminating the issue of 
emission spillover from other fluorochromes excited by the yellow/green laser, particularly 
	  	  	  	  
	  
	  
Figure 2.4: Detecting PE-CF594 on the 610/20 filter off the 592nm orange laser. 
PBMCs were examined for the expression of markers that allowed for the identification of 
Tregs (CD4, CD25, CD127, FoxP3). CD4+ cells were gated and examined for the 
expression of CD127 and CD25 or FoxP3 and Tregs were gated as CD127loCD25+ or 
CD127loFoxP3+. (A) Treg staining using CD25 BV421 and CD127 conjugated to biotin 
followed by streptavidin-AF594. The AF594 fluorochrome is designed for the O_610 
channel on the orange laser. (B&C) Treg staining using CD25 BV421 and CD127 PE-
CF594. PE-CF594 is designed for the YG_615 channel on the yellow/green laser (C) 
however it is comparable on the O_610 channel on the orange laser (B). Detecting PE-
CF594 on the orange laser minimises emission spillover from fluorochromes excited by the 
yellow/green laser, particularly PE. (D) Treg staining using CD127 BUV737 and FoxP3 
PE-CF594 detected on the O_610 channel on the orange laser. Numbers indicate cells 
within the gate as a percentage of the parent population. 
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PE. PE-CF594 detected on the orange laser also proved to work well with intracellular FoxP3 
(Figure 2.4, D). Because we were later presented with an alternative fluorochrome for 
CD127 (Figure 2.8, B), we decided to make FoxP3 PE-CF594 a standard in our intracellular 
panel. 
 
Brilliant Violet 
 
Because CD25 discrimination is relatively poor, it is necessary for it to be conjugated to a 
dye that is both bright and has minimal spillover from other channels. In our initial Treg 
panel, prior to our attempts to create a 10-13-colour panel, CD25 was conjugated to APC. In 
these initial stains, because the CD25 signal in APC was both crucial and low, no other 
antibody conjugates were detected on the red laser. In order to have more flexibility with 
antibody combinations, we decided to trial CD25 on a range of dyes. Preferably, we wanted 
to move CD25 off APC, making the three channels on the red laser available for other 
commercially available antibodies.  
 
The recent introduction of the brilliant violet-421 (BV421) fluorochrome presented us with 
an alternative dye that was both bright and in a channel where not many of the markers we 
are interested in are available. Figure 2.5 looks at Treg differentiation, using the 
CD127loCD25+ gate, with CD25 conjugated to a range of fluorochromes (APC, FITC, PE, 
Brilliant Violet 421 and Brilliant Violet 605). We tested CD25 on both BV421 and BV605 
(Figure 2.5, bottom panel). Although CD25-BV605 was found to be as bright and 
discriminating as CD25-PE and CD25-APC, CD25-BV421 offered a much brighter, more 
distinguished Treg population. For this reason, it was decided to use CD25-BV421 as our 
standard CD25 conjugate in all our panels. 
 
When testing BV421 conjugated antibodies, we noticed a remarkable difference in Treg 
differentiation and signal when comparing the Canto II and the LSRII-10-laser flow 
cytometers (Figure 2.6, A). The Canto II provides a more suitable filter for the detection of 
	  	  	  	  	  	  	  
	  	  
Figure 2.5: Comparing fluorochrome conjugates of CD25 on the CANTO II. PBMCs 
were examined for the expression of markers that allowed for the identification of Tregs 
(CD4, CD25, CD127) with a different CD25 fluorochrome conjugate tested in each stain. 
CD4+ cells were gated and examined for the expression of CD127 and CD25 and Tregs 
were gated as CD127loCD25+. Numbers indicate cells within the gate as a percentage of 
the parent population.  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  
	  
	  
	  
	  
	  
	  
	  
Figure 2.6: Comparing Brilliant Violet 421 conjugated CD25 and CD127 on the Canto II 
(filter 450/40) and LSRII-10 Laser (filter 470/20). (A) PBMCs were examined for the 
expression of markers that allowed for the identification of Tregs (CD4, CD25, CD127). CD4+ 
cells were gated and examined for the expression of CD127 and CD25 and Tregs were gated 
as CD127loCD25+. Top panel shows Treg discrimination with CD25 conjugated to brilliant violet 
421 on the Canto II (left) and LSRII-10 (right). Bottom panel shows Treg discrimination with 
CD127 conjugated to brilliant violet 421 on the Canto II (left) and LSRII-10 (right). Numbers 
indicate cells within the gate as a percentage of the parent population. (B) The brighter BV421 
signal seen on the Canto II was due to a more suitable filter for detection of BV421 emission 
(450/40 compared to 470/20). A more suitable filter (447/60) was available to use on the LSRII-
10 however this filter was found to be incompatible with the two violet lasers on the machine. 
The 447/60 filter permits the 445nm violet laser through to the detector, resulting in a strong 
positive signal in the BV421 channel.	   	  
	  	  
	  
	  
	  
	  
	  
Figure 2.7: Optimal lasers and filters for detection of Brilliant Violet 421 (BV421) and 
Brilliant Violet 711 (BV711). (A) A more suitable filter (447/60) was added in place of the 
standard 470/20 filter for optimal detection of BV421 emission. The 445nm violet laser was 
also switched off to eliminate interference with signal in the 447/60 filter. The standard 
780/60 filter and 755LP band-pass in the A position were also removed and replaced with 
a 710/50 filter and 685LP band-pass for optimal detection of BV711 emission. These filters 
were then used for detection of CD25 BV421 (B) and T-bet BV711 (C).  
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BV421 emission (450/40 on the Canto II vs 470/20 on the LSRII-10-laser), resulting in a 
brighter BV421 signal. A more suitable filter (447/60) was available to use on the LSRII-10-
laser, however this filter was found to be incompatible with the two violet lasers on the 
machine (Figure 2.6, B). The 447/60 filter permits the 445nm violet laser through to the 
detector, causing everything to be positive in the BV421 channel. 
 
In order to fix this, it was necessary to switch off the 445nm laser and use only the 405nm 
violet laser in combination with the 447/60 filter for optimal BV421 detection (Figure 2.7 
A&B). The standard 780/60 filter and 755LP band-pass in the A position on the violet laser 
were also removed and replaced with a 710/50 filter and 685LP band-pass for optimal 
detection of BV711. This channel was used for detection of T-bet conjugated to BV711 in 
our transcription factor panel (Figure 2.7 A&C). 
 
Brilliant Ultraviolet  
 
Brilliant ultraviolet (BUV) dyes are UV-excitable fluorochromes that provide great 
population resolution and hence expanded the capabilities of the 355nm UV laser on flow 
cytometers. We used BUV dyes for two of our standard Treg panel markers, CD127 on 
BUV737 and CD45RO on BUV395 (Figure 2.8). A more suitable filter (740/35) and long-
pass (690LP) was added in place of the standard 825/40 filter for optimal detection of 
BUV737 emission (Figure 2.8, A). The standard 450/50 filter in the C position on the UV 
laser was also removed and replaced with a 379/28 filter for optimal detection of BUV395 
emission. These filters were then used for detection of CD127 BUV737 (Figure 2.8, B) and 
CD45RO BUV395 (Figure 2.8, C).  
 
Detecting Th1, Th2 and Th17 associated transcription factors 
 
Our aim was to take a novel approach and design an antibody panel that will allow for the 
analysis of transcription factors and their associated homing phenotypes together in the one 
	  	  
	  
	  
	  
	  
	  
Figure 2.8: Optimal filters and band-passes for detection of Brilliant Ultraviolet 737 
(BUV737) and Brilliant Ultraviolet 395 (BUV395). (A) A more suitable filter (740/35) and 
band-pass (690LP) was added in place of the standard 825/40 filter for optimal detection 
of BUV737 emission. The standard 450/50 filter in the C position was also removed and 
replaced with a 379/28 filter for optimal detection of BUV395 emission. These filters were 
then used for detection of CD127 BUV737 (B) and CD45RO BUV395 (C).  
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stain. Due to the lack of flow cytometric data on the expression of these transcription factors 
by CD4 T cells in peripheral blood, we tested each antibody using fluorescence minus one 
(FMO) controls  (Figure 2.9). PBMCs were surface stained for CD4 followed by 
intracellular staining for RORγt, T-bet and GATA-3. Lymphocytes were examined for the 
expression of CD4 and RORγt (Figure 2.9, top panel), CD4 and T-bet (Figure 2.9, middle 
panel) and CD4 and GATA-3 (Figure 2.9, bottom panel). Small populations of CD4+ cells 
are seen to express RORγt and T-bet while almost the entire CD4+ population (~99%) 
expresses GATA-3. For this reason, it was decided to eliminate GATA-3 from the stain and 
replace it with FoxP3.  
  
2.6.3  Two optimised 11 and 13 – colour panels 
 
The two final 11 and 13 colour panels are summarised in Table 2.2. Figures 2.10 & 2.11 
represent a basic overview of the gating strategy and subsets of Tconvs and Tregs examined. 
A general gating strategy was first employed for the analysis of all PBMC flow cytometric 
data (Figure 2.1 A-E). Tregs were then identified within the CD4+ gate on the basis of 
expression of CD25, CD127 and FOXP3 (Figure 2.10 and 2.11, B). Tregs were defined as 
CD25+CD127lo and/or FOXP3+CD127lo cells. Conventional T cells (Tconvs) were defined as 
everything outside the indicated CD127loCD25+ Treg gate. CD45RO was used as a marker of 
post-thymic activation and differentiation. Tregs and Tconvs were next subdivided on the 
basis of CD45RO expression in order to differentiate between CD45RO+ (effector/memory) 
and CD45RO- (naïve) subsets, and analysed for the various CRs, integrins, and transcription 
factors examined (Figures 2.10 & 2.11, C&D).  
 
Further analysis of the subset data derived from these two flow cytometric panels will be 
presented and discussed in Chapters 3 and 5. The experiments in Chapter 4 were performed 
before these two panels were finalised, however, an optimised 9-colour panel, that formed 
the basis for the two final panels, was used.  
	  	  
Figure 2.9: Flow cytometric analysis of the transcription factors RORγt, T-bet and 
GATA-3. PBMCs were surface stained for CD4 followed by intracellular staining for 
RORγt, T-bet and GATA-3. Lymphocytes were gated based on FSC and SSC and 
examined for the expression of CD4 and RORγt (top panel), CD4 and T-bet (middle panel) 
and CD4 and GATA-3 (bottom panel). A fluorescence minus one (FMO) control was 
included for each transcription factor to verify populations. Numbers indicate cells within 
the gate as a percentage of the parent population.   
 
 
Table 2.2: Two flow cytometric panels for the analysis of conventional T cell and Treg subsets 
 
 UV 355nm Violet 405nm Blue 488nm Yellow/green 
561nm 
Orange 
592nm 
Red 628nm 
PANEL BUV395 BUV737 BV421 Zombie 
Yellow 
V500 BV711 BV786 FITC/ 
AF488 
PerCp-
CY5.5 
PE PE-Cy7 AF594/ 
PE-CF594 
APC/ 
AF647 
AF700 APC-Cy7/ 
Near IR 
13-colour CD45RO CD127 CD25 Dead cell 
exclusion 
- - CD4 CLA CD49d CCR10 CD45RA β7 CCR4 CCR5 CD62L 
11-colour CD45RO CD127 CD25 - CD4 T-bet - CXCR3 - CCR6 CCR4 FoxP3 RORγt  Dead cell 
exclusion 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  
	  
	  
Figure 2.10: 11-colour flow cytometric panel for the analysis of Treg and Tconv subpopulations. Peripheral blood 
mononuclear cells (PBMC) were isolated from human blood and examined for the expression of markers that allowed for the 
identification of Tregs (CD4, CD25, CD127 and FoxP3) and then the further examination of subsets (CD45RO, CR/integrins and 
transcription factors T-bet and RORγt). A FSC-H vs time gate was used to exclude artefacts due to fluidics instability at the start and 
end of the samples and a fixable dead cell exclusion dye was used to remove dead cells from analysis. Doublets were excluded 
using sequential FSC-A vs FSC-H and SSC-A vs SSC-H gates (refer to figure 2.1). CD4+ cells were then gated (A) and CD4+ Tregs 
were identified as CD127loCD25+ or CD127loFOXP3+ (B). Conventional T cells (Tconvs) were defined as everything outside the 
indicated CD127loCD25+ Treg gate (B). Tregs and Tconvs were next subdivided on the basis of CD45RO expression in order to 
differentiate between CD45RO+ (effector/memory) and CD45RO- (naïve) subsets, and analysed for the various CRs and integrins 
and transcription factors examined (C&D). Numbers indicate cells within the gate as a percentage of the parent population. 
	  
	  	  
	  
	  
Figure 2.11: 13-colour flow cytometric panel for the analysis of Treg and Tconv subpopulations. Peripheral blood 
mononuclear cells (PBMC) were isolated from human blood and examined for the expression of markers that allowed for the 
identification of Tregs (CD4, CD25, CD127) and then the further examination of subsets (CD45RO and CR/integrins). A FSC-H vs 
time gate was used to exclude artefacts due to fluidics instability at the start and end of the samples and a fixable dead cell 
exclusion dye was used to remove dead cells from analysis. Doublets were excluded using sequential FSC-A vs FSC-H and SSC-A 
vs SSC-H gates (refer to figure 2.1). CD4+ cells were then gated (A) and CD4+ Tregs were identified as CD127loCD25+ (B). 
Conventional T cells (Tconvs) were defined as everything outside the indicated CD127loCD25+ Treg gate (B). Tregs and Tconvs 
were next subdivided on the basis of CD45RO expression in order to differentiate between CD45RO+ (effector/memory) and 
CD45RO- (naïve) subsets, and analysed for the various CRs and integrins examined (C&D). Numbers indicate cells within the gate 
as a percentage of the parent population. 
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CHAPTER 3:  EXPRESSION OF TRAFFICKING RECEPTORS 
BY REGULATORY T CELLS IN HEALTHY HUMANS  
 
3.1  Introduction 
 
Naturally occurring CD4+CD25+CD127loFoxP3+ regulatory T cells (Tregs) are crucial for the 
maintenance of immune tolerance. For this reason, Treg based therapeutic strategies may 
offer therapeutic benefit in many immune disorders and early clinical trials in humans appear 
promising [126-128]. However, an understanding of Treg trafficking could optimise Treg-
selection and contribute to the development of more targeted Treg-therapy. 
 
The appropriate localisation of Tregs is crucial to their function. Despite this, very few 
studies have examined the migratory potential of Tregs in humans. In mice, Treg homing to 
lymphoid organs has been shown to be crucial to their role in suppressing T cell responses 
and limiting inflammation [88, 93, 94, 98]. Furthermore, naïve Tregs have been shown to 
undergo priming in murine secondary lymphoid tissues, where they upregulate homing 
receptors required for entry into peripheral non-lymphoid tissues [92]. The expression of 
these homing receptors by Tregs has been demonstrated to be critical to their suppressive 
ability, allowing them to co-localise with effector T cells at sites of inflammation [81, 112-
116, 118, 129] (reviewed in Chapter 1, section 1.6). 
 
The majority of studies that have examined the expression of Treg trafficking molecules in 
humans defined Tregs as CD4+CD25hi cells. This definition makes it difficult to distinguish 
Tregs from conventional CD25+ T cells and has been shown to exclude a large percentage of 
the total Treg compartment [61]. Here, we used the CD127loCD25+ phenotype, in 
combination with a range of integrins and chemokine receptors, to define Treg migratory 
subsets and compare them to conventional T cells (Tconvs) in the peripheral blood of 44 
healthy humans. We hypothesised that the migratory behaviour of Tregs in humans 
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influences their suppressive capacity in vivo and postulate that an understanding of these 
trafficking phenotypes will provide insights into their regulatory role in different tissues. 
 
3.2  Summary of methods 
 
The study was approved by the Sydney Local Health District ethics review committee at 
Royal Prince Alfred Hospital, Camperdown. Informed written consent was obtained from all 
individuals prior to the study. Peripheral blood mononuclear cells (PBMCs) were isolated 
from heparinised venous blood by density gradient centrifugation and stored in 1 ml aliquots 
at -180oC in LNO2 (outlined in Chapter 2, section 2.3).  
 
Cells were later thawed in batches and immuno-stained with two optimised 11 and 13- colour 
flow cytometric panels (Table 2.2, Figures 2.10 & 2.11). Details of the monoclonal 
antibodies used are listed in Table 2.1 and staining procedure is described in Chapter 2, 
section 2.4. Data was acquired on a LSRII 10-laser flow cytometer (BD) and analysed using 
FlowJo software (Tree Star). A general gating strategy was employed for the analysis of all 
flow data (Figure 2.1, described in Chapter 2, section 2.4.6).  
 
Statistical analysis was performed using Prism 6 software (GraphPad Software, Inc., La Jolla, 
CA, USA). The Mann-Whitney t-test was used to compare differences between two groups. 
The non-parametric Spearman method was used to calculate correlation coefficients. P-
values <0.05 were considered significant. 
 
Statistical analysis was also performed using MultiExperiment Viewer (MeV) (TM4–
Microarray Software Suite). Data was loaded into MeV in .txt format and heatmaps were 
generated. Unsupervised cluster analysis was performed using the hierarchical clustering 
(HCL) algorithm.  
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3.3  Results and Discussion 
 
3.3.1  Identifying regulatory T cells in human peripheral blood 
 
Using the surface expression of CD4 and CD25 to isolate human Treg cells, it was originally 
demonstrated that only CD4+ cells that express the highest levels of CD25 had suppressive 
activity in vitro [60]. This CD25hi population constitutes 1-2% of human peripheral blood 
CD4+ T cells. This percentage is considerably smaller than that found in mice (6-7% of 
circulating CD4+ T cells), suggesting that the CD25hi gate may have excluded some human 
Tregs from analysis.  
 
The production of monoclonal antibodies reactive with human FoxP3 in 2005 improved the 
specificity of Treg cell detection over that provided by the combination of anti-CD4 and anti-
CD25 antibodies. However, FoxP3 is an intracellular molecule and its detection requires 
fixation and permeabilisation to disrupt the cell surface membrane. It has previously been 
shown in our lab that the fixation and permeabilisation steps involved in FoxP3 detection 
affect many of the fluorochromes used in multiparameter flow cytometry, especially APC 
and tandem dyes such as PerCp-Cy5.5 and PE-Cy7 (Figure 3.1 A, taken from a methods 
paper published in our lab, [130]). In addition to this, on days where experiments are 
prolonged and the cells are subjected to many steps, FoxP3 staining may have unanticipated 
consequences, including a remarkable increase in autofluorescence, seen particularly in the 
detectors on the violet laser (Figure 3.1 B). This degree of autofluorescence makes 
differentiation between signal and background impossible.  
 
We previously showed in our laboratory that the surface expression of CD127, the α-chain of 
the interleukin-7 receptor, allows distinction between CD127lo Treg cells and CD127hi 
conventional T cells in human peripheral blood and lymph node [61]. With the demonstrated 
problems with FoxP3 staining, we tested whether FoxP3 was absolutely required to identify 
Treg cells, by comparing Treg numbers calculated as CD127loCD25+ with those calculated as 
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CD127loFoxP3+. PBMCs were stained with CD127, CD25, CD4 and FoxP3 and gated as 
indicated in Figure 2.1, F&G. Figure 3.1 C shows the correlation between the percentage of 
cells within CD127loCD25+ and CD127loFoxP3+ gates in the 44 healthy individuals analysed 
in this study. The percentages of Tregs within the two gates in each individual were very 
highly correlated. It was therefore decided that it was not necessary to include FoxP3 in all 
subsequent stains, allowing a more sensitive and stable detection of multiple surface 
molecules. 
 
In instances where it was necessary to stain for intracellular transcription factors, as was the 
case in one of our panels (Table 2.2), cells were split pre the fixation and permeabilisation 
steps. This ensured that only half of the PBMCs from each sample underwent 
fixation/permeabilisation therefore allowing us to monitor effects on tandem dyes and 
autofluorescence.  
  
3.3.1.1  Frequency of CD4+CD127loCD25+ Tregs in the peripheral blood of healthy 
volunteers 
 
Peripheral blood samples from our cohort of 44 healthy volunteers were examined for the 
number of total, effector/memory (CD45RO+) and naïve (CD45RO-) CD127loCD25+ Tregs 
(Figure 3.2). While conventional CD4+ T cells are almost equally divided into CD45RO+ and 
CD45RO- cells, the majority of Tregs fall within the CD45RO+ compartment. The mean 
number (± SEM) of effector/memory Tregs (CD4+CD127loCD25+CD45RO+) as a percentage 
of total CD4+ T cells was 6.2 ± 0.24, while the percentage of naïve Tregs 
(CD4+CD127loCD25+CD45RO-) was 2.1 ± 0.19, giving a total of 8.3 ± 0.25% of CD4+ T cells 
(Figure 3.2 B). It has previously been shown that the frequency of naïve Tregs in peripheral 
blood declines with age, possibly due to thymic involution [54, 61, 131]. We have shown this 
to be true in our cohort (Figure 3.2 C). In contrast, the frequency of effector/memory Tregs 
is stable.  
 
	  
Figure 3.1: Effect of FoxP3 fix/perm treatment on detection of Tregs. (A) Effect 
of FoxP3 fix/perm treatment on fluorescence of conjugated antibodies. (i) 
Expression of CD25 and CD127 on CD4+ cells and (ii) the same sample, with 
additional staining for FoxP3 according to the manufacturer’s instructions. (iii) Effect 
on fluorescence of various dyes. Samples were stained with a single colour and half 
of each sample was then treated with the FoxP3 fix/perm buffers as per the 
manufacturer’s instructions. The treatment was found to reduce the signal and 
increase the background/noise for each fluorochrome tested. Signal:noise ratios 
were calculated for all fluorochromes and the reduction in signal:noise after FoxP3 
treatment was expressed as a percentage of signal:noise without FoxP3 treatment. 
(B) Prolonged staining procedures and mistreatment of cells sometimes results in 
significantly increased background autofluorescence, particularly on the violet laser. 
This makes it impossible to differentiate signal from background (B, left panels – 
normal autofluorescence/background, right panels – increased 
autofluorescence/background. Gated on CD4+ cells). (C) Correlation between the 
frequencies of CD4+ Tregs identified by gating for CD127loCD25+ versus 
CD127loFOXP3+ cells. PBMCs from healthy individuals (n=44) were stained and 
Tregs gated as in Figure 2.1 F&G. The correlation was statistically evaluated using 
a non-parametric Spearman test and was found to be significant (p<0.0001 ****).  
Part (A) is taken from a methods paper published in our lab: Fazekas de St Groth, 
B., et al., Flow cytometric detection of human regulatory T cells. Methods Mol Biol, 
2011. 707: p. 263-79.  
  
 
 
Figure 3.2: Levels of CD4+CD127loCD25+ cells in the peripheral blood of 
44 healthy donors. (A) CD4+ Tregs were identified as CD127loCD25+ and 
then subdivided into CD45RO+ and CD45RO- subpopulations. Numbers 
indicate cells within the gate as a percentage of total CD4+ cells. (B) CD45RO+ 
(effector/memory), CD45RO-  (naïve) and total Tregs expressed as a 
percentage of total CD4+ T cells. Each point represents an individual subject 
(n=44) and horizontal bars represent the group means. (C) Relationship 
between CD45RO+ and CD45RO- Treg subpopulations and age. The 
correlation was evaluated using a non-parametric Spearman test.  
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3.3.2  Expression of trafficking receptors by Tconvs and Tregs 
 
It has long been known that lymphocytes not only leave the blood to enter peripheral tissue, 
but also continuously recirculate back to the blood, therefore maintaining immunological 
surveillance [82]. Difficulty in acquiring tissue from healthy individuals makes the peripheral 
blood the most accessible tissue for the analysis of lymphocytes that recirculate. Using 
transgenic mice that express Kaede protein, which allows for T cell labeling in the periphery 
under physiological conditions, it has been shown that Tregs and Tconvs within the 
circulation infiltrate the skin, migrate to draining lymph nodes and then recirculate back to 
the skin in both the steady state and in response to inflammation [95]. This establishes that 
Tregs recirculate between the blood and peripheral tissues to both maintain homeostasis and 
control ongoing immune responses. Furthermore, it has been demonstrated that at steady 
state in mice, the vast majority of skin CD4+ T cells equilibrate with the circulation rather 
than remaining fixed in the tissue [132]. 
 
We hypothesised that the analysis of surface molecules required for migration to peripheral 
tissues would provide an indication of Treg activity within those tissues. The trafficking 
receptor profile of conventional CD4+ T cells (Tconvs) has been well characterised. We 
defined this phenotype in Tregs and compared the expression of these molecules on Tregs 
and Tconvs. To do this, mononuclear cells from the peripheral blood of 44 healthy 
individuals were stained using a range of monoclonal antibodies to various chemokine 
receptors (CRs) and integrins (Table 2.1 & 2.2) and then subjected to 11 or 13 colour flow 
cytometry. The integrins chosen for comparison were β7, α4 (CD49d), CLA and CD62L. 
The CRs examined were CCR4, CCR5, CCR6, CCR10 and CXCR3.  
 
Studies in mice have shown that, upon activation, Tregs undergo a trafficking receptor switch 
from molecules that enable recirculation through lymphoid tissues to molecules that enable 
migration and entry to non-lymphoid peripheral tissues [92, 98]. In order to study the 
trafficking phenotypes of effector and naïve Tregs in humans, we subfractionated cells on the 
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basis of CD45RO expression. In humans, T cells exit the thymus expressing CD45RA and 
switch to CD45RO upon antigen recognition [133]. Hence, CD45RO is a marker of post 
thymic differentiation and effector/memory cells. By including CD45RO in our stains, we 
were able to examine the trafficking receptor phenotype on both CD45RO+ effector/memory 
and CD45RO- naïve human Tregs. 
 
3.3.2.1  Expression of trafficking receptors on CD45RO+ Tconvs and Tregs 
 
Representative dot plots showing the expression of β7, α4 (CD49d), CLA, CCR4, CCR10, 
CCR5, CD62L, CXCR3 and CCR6 on CD45RO+ Tconvs and Tregs can be seen in Figure 
3.3 with numbers for the entire cohort in Figure 3.4.  
 
Among CD45RO+ Tconvs, integrin α4 (CD49d), CCR4, CD62L, CXCR3 and CCR6 are the 
most highly expressed trafficking receptors (Figure 3.4A). Within CD45RO+ Tregs, CLA, 
CCR4, CD62L and CCR6 are expressed on the highest proportion of cells (Figure 3.4B). 
CLA is expressed on a higher proportion of CD45RO+ Tregs than Tconvs (mean 36% vs 9% 
respectively), as is CCR4 (70% vs 32%), CCR10 (30% vs 6%), CCR5 (21% vs 8%), CD62L 
(45% vs 21%) and CCR6 (49% vs 23%). No differences were found between Tconvs and 
Tregs in terms of α4 (CD49d), β7 and CXCR3 expression.  
 
While no differences were found between effector/memory Tconvs and Tregs in terms of 
expression of the gut-associated β7, a significantly smaller proportion of Tregs express β7 
(mean 8%) when compared to Tregs that express CLA (mean 36%), CCR4 (mean 70%) and 
CCR10 (mean 30%). Furthermore, these skin homing receptors, CLA, CCR4 and CCR10, are 
expressed on a much higher proportion of Tregs than Tconvs (36% vs 9%, 70% vs 32% and 
30% vs 6% respectively). For this reason, adult human Tregs can be considered to showing a 
bias towards migration to the skin, indicating an important role for Treg immune regulation 
at this site. 
 
	  
 
 
 
 
Figure 3.3: Expression of chemokine receptors and integrins by CD45RO+ Tconvs 
and Tregs. (A) CD4+ Tregs were identified as CD127loCD25+ and conventional T cells 
(Tconvs) were defined as everything outside the indicated CD127loCD25+ Treg gate. (B) 
Tregs and Tconvs were next subdivided on the basis of CD45RO expression in order to 
identify CD45RO+ (effector/memory) subsets, and analysed for the various chemokine 
receptors and integrins examined (β7, CD49d, CLA, CCR4, CCR10, CCR5, CD62L, 
CXCR3 and CCR6). Numbers indicate cells within the gate as a percentage of the parent 
population.	  	  
	  	  
 
Figure 3.4: Expression of chemokine receptors and integrins by Tconvs 
and Tregs in healthy individuals (n=44). Expression of chemokine 
receptors and integrins (CR/I) by CD45RO+ Tconvs (A) and Tregs (B), gated 
as in Figure 3.3. Each point represents an individual donor and horizontal 
bars represent the group means. The Mann-Whitney t-test was used to 
compare differences between Tconvs and Tregs, **** = p<0.0001, ns= not 
significant. 
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L-selectin (CD62L) has been shown to be required for the homing of naïve and central 
memory cells to secondary lymphoid tissue [134]. Based on CD62L expression, CD45RO+ 
cells can be subdivided into CD62L- memory cells that migrate to non-lymphoid peripheral 
tissues and CD62L+ central memory cells that migrate to lymphoid tissues. We have shown 
that Tregs contain a significantly higher proportion of these CD62L+ central memory cells 
when compared to Tconvs (45% vs 21%), suggesting an enhanced role for Tregs in 
regulating systemic immunity within lymphoid tissues. 
 
All the trafficking receptors examined, except for α4 (CD49d), β7 and CXCR3, are 
expressed on a higher proportion of effector/memory Tregs than Tconvs. For this reason, it 
appears that Tregs in healthy humans are a highly migratory subset with roles in both 
lymphoid and non-lymphoid tissues. Tregs are diverse in terms of trafficking receptor 
expression and this heterogeneity is different to that seen in Tconvs. Figure 3.5 is a heat map 
representing the level of each CR and integrin examined (rows) on CD45RO+ Tconvs (left) 
and Tregs (right) in our cohort of 44 healthy individuals. Unsupervised hierarchical 
clustering resulted in Tconvs and Tregs clustering in two separate groups, highlighting that 
effector/memory Tregs have a unique trafficking receptor signature that differentiates them 
from effector/memory Tconvs. 
 
 
Trafficking phenotypes on Tregs gated as CD25hi versus CD127loCD25+ 
 
A study using FoxP3 to identify Tregs showed that the proportion of Tregs expressing CLA, 
CCR4, CCR6, and α4β7 was similar to the proportions we determined using CD127loCD25+ 
to identify Tregs [99]. Although studies that used CD25hi to define Tregs also demonstrated 
that the highest proportions of Tregs expressed CLA, CCR4, CCR6 and CD62L and the 
lowest expressed α4β7 [90, 91, 109, 110, 135], the size of these proportions differed 
significantly to ours. For example, one of these studies reported that ~80% of Tregs 
expressed CLA and ~73% expressed CCR6 [91] whereas we found ~36% of CD127loCD25+ 
	  	  	  
 
 
 
Figure 3.5. Tregs and Tconvs have distinct trafficking phenotypes. Data obtained from flow cytometric experiments is visualised 
colorimetrically in a heat map. Each row represents the subsets of chemokine receptors and integrins examined and each column 
represents the levels on either Tconvs (left) or Tregs (right) in each individual (n=44). Frequencies that are increased relative to the row’s 
mean are indicated in yellow, decreased in blue and frequencies that show no difference are indicated in black. Unsupervised 
hierarchical clustering resulted in Tconvs (green) and Tregs (red) clustering in two separate groups.  
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cells expressed CLA and ~49% expressed CCR6. Furthermore, published studies have shown 
that 80-95% of CD25hi Tregs in adults express CCR4 [91, 109, 110, 135] while ~7% express 
α4β7 [91, 110], whereas we found ~70% of Tregs to express CCR4, ~25% to express α4 
(CD49d) and ~8% to express β7. Additionally, studies that measured the levels of CD62L+ 
cells on CD25hi Tregs reported that ~80-90% of Tregs express CD62L [91, 135] while we 
found that only ~45% of Tregs express CD62L. 
 
These data suggested that the expression of trafficking receptors may correlate with that of 
CD25; with cells that express the highest levels of CD25 also expressing the highest levels of 
CLA, CCR4, CCR6 and CD62L. In order to test this, we examined the trafficking receptor 
phenotype of Tregs gated as CD4+CD25hi (top 3% of CD25 expression) and compared them 
to Tregs gated as CD4+CD127loCD25+ (Figure 3.6). In doing this, we demonstrated that the 
proportions of cells expressing almost all of the trafficking receptors examined were 
significantly increased within the CD25hi “Treg” gate. The three receptors whose expression 
was unchanged between CD25hi and CD127loCD25+ Tregs were α4 (CD49d), β7 and CXCR3, 
the three receptors we found to be equally expressed by Tregs and Tconvs (Figure 3.4 & 
3.5).  
 
We wanted to test whether this correlation between expression of trafficking receptors and 
CD25 is also evident in conventional CD4 T cell populations. In order to do this, we selected 
the CD45RO+ trafficking receptor-expressing Tconvs (Figure 3.7, A) and calculated the MFI 
of CD25 expression within this population (Figure 3.7, B). Interestingly, CD25 expression 
was highest on CLA, CCR4, CCR10, CD62L and CCR6 expressing cells and lowest on α4 
(CD49d) and β7 expressing cells. This indicates that the trafficking phenotypes commonly 
associated with Tregs may in fact be a function of CD25 expression rather than the Treg 
phenotype itself. 
 
3.3.2.2  Expression of trafficking receptors on CD45RO- Tconvs and Tregs 
 
  
 
Figure 3.6: Expression of chemokine receptors and integrins by Tregs gated as 
either CD127loCD25+ or CD25hi. Expression of chemokine receptors and integrins (CR/I) 
by CD45RO+ Tregs gated as either CD127loCD25+ (black) or CD25hi (red). Flow plots of the 
gates are displayed on the right hand side. Each point represents an individual donor 
(n=44) and horizontal bars represent the group means. 
  
Figure 3.7: Differing levels of CD25 expression on the various CR/Integrin+ Tconv 
subsets. (A) Tconvs were gated as cells that fall outside the CD127loCD25+ Treg gate and 
then examined for CR/Integrin+ effector/memory cells (red gate). (B) CR/Integrin+ 
CD45RO+ Tconvs were selected and examined for their mean fluorescence intensity (MFI) 
of CD25. Each point represents an individual donor (n=44) and horizontal bars represent 
the group means. 
 
Chapter 3: Tregs in healthy humans  55 
 
Two of the trafficking receptors examined, β7 and CD62L, were found to be expressed on a 
significant proportion of CD45RO- naïve Tconvs and Tregs.  Representative dot plots 
showing the expression of β7 and CD62L on CD45RO- naïve Tconvs and Tregs can be seen 
in Figure 3.8 B with numbers for each individual within the entire cohort of subjects in 
Figure 3.8 C.  
 
Among Tconvs, CD45RO- β7+ and CD45RO- CD62L+ cells make up equal proportions of 
total Tconvs (mean 48%). Among Tregs, CD45RO- CD62L+ cells are found at slightly higher 
levels than CD45RO- β7+ cells (21% vs 14%). Both β7 and CD62L are expressed on a higher 
proportion of CD45RO- Tconvs than Tregs. Interestingly, CD62L is expressed on a higher 
proportion of CD45RO+ Tregs than CD45RO- Tregs, whereas the opposite is true for Tconvs, 
suggesting a possible important role of circulating central memory Tregs in lymphoid tissue.  
 
It has been described that a lower proportion of circulating Tregs in adults express the gut 
homing integrin β7 when compared to Tconvs [91, 110]. However these studies did not 
divide Tregs into effector/memory and naïve subsets. By dividing Tregs this way, we have 
shown that the decrease in expression of gut homing β7 commonly associated with adult 
Tregs is due to less β7+ cells in the CD45RO- naïve Treg compartment.  
 
3.3.2.3  Concluding remarks on section 3.3.2 
 
In this part of the study, we set out to analyse the expression of migratory receptors on Tregs 
in the peripheral blood of healthy individuals. In doing so, we have shown that Tregs express 
receptors that enable entry into lymphoid and non-lymphoid tissues and that this migratory 
phenotype is distinct to that seen in Tconvs. This demonstrates that Tregs exert their 
regulatory function at various sites and are involved in both regulating the priming of cells in 
lymphoid tissue and limiting inflammation in non-lymphoid tissue, even in the absence of 
any ongoing inflammation. While it is crucial for Tregs to be able to co-localise with Tconvs 
in order to suppress responses at sites of ongoing inflammation, it is important to emphasise 
	  	  
Figure 3.8: Expression of chemokine receptors and integrins by CD45RO- Tconvs 
and Tregs. (A) CD4+ Tregs were identified as CD127loCD25+ and conventional T cells 
(Tconvs) were defined as everything outside the indicated CD127loCD25+ Treg gate. (B) 
Tregs and Tconvs were next subdivided on the basis of CD45RO expression in order to 
identify CD45RO- (naive) subsets, and analysed for the expression of β7 and CD62L, two 
markers found to be significantly expressed by naïve T cells. (C) Levels of expression of 
β7 and CD62L on naïve Tconvs (black) and Tregs (red). Each point represents an 
individual donor (n=44) and horizontal bars represent the group means. The Mann-
Whitney t-test was used to compare differences between Tconvs and Tregs, **** = 
p<0.0001 
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their role in immunosurveillance and maintaining homeostasis in the absence of 
inflammation. Tregs migrate in a coordinated fashion in order to carry out optimal 
immunosurveillance and function to prevent both the initiation of aberrant immune responses 
and limit the progression of these responses. We also demonstrated that the use of CD25 
alone to study Tregs results in an inaccurate interpretation of their migratory phenotype. 	  
 
The use of drugs targeting T cell trafficking has recently been trialled as a strategy to combat 
immune-mediated disease. However these drugs haven’t been as effective as anticipated 
[136-138] or have had unpredicted adverse events [139]. It is likely that this is partly due to 
the overlooked effects these drugs have on the trafficking of Tregs. A study that examined 
the binding specificity of Vedolizumab, an anti-α4β7 therapeutic antibody, on various cell 
subsets, examined total CD4 and CD8 T cells, B cells, natural killer cells, basophils, 
monocytes, eosinophils and neutrophils but not Tregs [140]. We have shown that Tregs are 
highly migratory and express trafficking receptors that target them to peripheral tissues, 
therefore emphasising that future therapeutic interventions targeting cell migration need to 
take into account the effects on Tregs. 
 
3.3.3  Tissue specific homing on Tconvs and Tregs 
 
It has long been known that a proportion of circulating CD4+ T cells display some degree of 
tropism for certain tissues, particularly the gut and skin.  This selective entry of lymphocytes 
is due to their expression of specific chemokine receptors and adhesion molecules that allow 
them to traffic through and engage in immunosurveillance of various tissues. Of these tissue-
associated homing phenotypes, the gut specific α4β7 [100, 101] and the skin specific CLA, 
CCR4 and CCR10 [103, 104, 141] are the most well known (reviewed in Chapter 1, section 
1.6.3).  
 
The integrin α4β7 allows lymphocytes to bind to the mucosal vascular addressin cell 
adhesion molecule-1 (MAdCAM-1) [142] resulting in the efficient trafficking of 
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lymphocytes into gut tissue [100, 101]. On the other hand, CD4+ T cells that express the 
cutaneous lymphocyte antigen (CLA), an adhesion molecule that binds E-selectin, have a 
tropism for cutaneous tissue [141]. CCR4 is expressed by most CLA+ skin homing T cells 
[143, 144] and is found at high levels on skin infiltrating lymphocytes [104] . Furthermore, 
the CCR4 ligand CCL17 (TARC) is associated with cutaneous endothelial cells [145]. More 
recently, another cutaneous T cell attracting chemokine, CCL27, was found to be expressed 
by cutaneous tissue and to bind the receptor CCR10 on T cells [146, 147]. 
 
While a few studies have examined the co-expression of these adhesion molecules and 
receptors on total CD4+ T cells in humans [143, 144, 147, 148], none have focused on Tregs. 
We designed a flow cytometric panel that allowed us to analyse combinations of these 
chemokine receptors and integrins on both Tconvs and Tregs (Table 2.2, Figure 2.11). 
Because CLA, CCR4 and CCR10 are mainly expressed on CD45RO+ CD4 T cells, for this 
next section we will focus only on this subset. 
 
3.3.3.1  Gut and skin–associated trafficking receptors on Tconvs and Tregs  
 
In order to analyse α4β7+ cells, we co-stained PBMCs with antibodies to α4 (CD49d) and β7 
integrins and analysed them in combination (Figure 3.9). A higher proportion of CD45RO+ 
Tconvs expressed α4β7 when compared to Tregs (mean 18.1 vs 8.9%) (Figure 3.9 B). In 
Figure 3.9A it is clear that within peripheral blood CD45RO+ T cells, all β7+ cells fall within 
the α4β7+ gate whereas a large proportion of α4+ (CD49d) cells do not. This means that 
expression of β7 alone is sufficient for identifying α4β7+ CD4 T cells in blood circulation. In 
order to confirm this, we gated total β7+ cells on CD45RO+ Tconvs and Tregs and overlayed 
them onto the α4 versus β7 cytometry plot, verifying that these β7+ cells made up all the cells 
in the α4β7+ gate (Figure 3.10).  
 
In order to explore the differences between the expression of CCR4 and CCR10 on CLA+ 
skin homing Tconvs and Tregs, we co-stained samples for CLA, CCR4 and CCR10 and 
	  	  
 
Figure 3.9: Expression of gut homing α4β7 by CD45RO+ Tconvs and Tregs. (A) 
Representative cytometry plots from three individual donors.  CD45RO+ (effector/memory) 
Tregs and Tconvs were gated and examined for the expression of α4 (CD49d) and β7. 
Co-expressing α4β7+ cells are in the indicated gates on both Tconvs (left panel) and Tregs 
(right panel). (B) Levels of co-expressing α4β7+ cells as a percent of total CD45RO+ 
Tconvs and Tregs. Each point represents an individual donor (n=44) and horizontal bars 
represent the group means. The Mann-Whitney t-test was used to compare differences 
between Tconvs and Tregs. **** = p<0.0001 
 
	  
 
Figure 3.10: β7 alone is enough to gate α4β7+ cells on CD45RO+ Tconvs and Tregs. 
(A) CD45RO+ (effector/memory) Tconvs and Tregs were selected and examined for the 
expression of β7. β7+ cells are within the indicated gate (red). (B) β7+ cells, as gated in A, 
were selected and overlayed onto the α4 vs β7 cytometry profile (red). β7+ cells fall within 
the α4β7+ gate on both Tconvs and Tregs. Representative cytometry plots from three 
individual donors. 
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examined co-expression amongst these molecules (Figure 3.11). In doing so, we were able to 
show that CCR4 is expressed on ~90% of CLA+ Tconvs but also on a significant proportion 
of CLA- Tconvs (only ~30% of CCR4+ Tconvs express CLA). Furthermore, almost all (99%) 
CLA+ Tregs expressed CCR4 where as only 58% of CCR4+ Tregs express CLA (Figure 
3.11, C i & ii). This demonstrates that CLA-CCR4+ cells exist in both the Tconv and Treg 
compartments, indicating a role for CCR4 in homing to other non-cutaneous peripheral 
tissues.  
 
In contrast, CCR10 is expressed on significantly fewer CLA+ skin homing T cells. Only 50% 
of CLA+ skin-homing Tconvs and 73% of CLA+ skin-homing Tregs express CCR10 (Figure 
3.11, C, i). Interestingly, 73% of CCR10+ Tconvs express CLA, therefore demonstrating that 
CLA-CCR10+ Tconvs also exist and suggesting that not all CCR10+ cells can be assumed to 
be skin-homing. The minor population of CCR10+ CD4 T cells that do not express CLA has 
been previously described [148]. Here we show that a larger proportion of CCR10+ Tregs 
express CLA when compared to Tconvs (mean 90% vs 73%) (Figure 3.11, C, iii).  
 
Interestingly, we found that virtually all CCR10+ Tconvs and Tregs expressed CCR4 (Figure 
3.11, C, iii), indicating that almost all of the CCR10+ Tconvs and Tregs are 
CLA+CCR4+CCR10+. Since both CCL17 and CCL27 (the ligands for CCR4 and CCR10) are 
upregulated on inflamed cutaneous endothelium, CCR4 and CCR10 may offer redundant 
mechanisms to allow CLA+CCR4+CCR10+ cells to enter inflamed skin. However, under non-
inflammatory homeostatic conditions, entry to the skin may be controlled differently. For 
example, CCR10 has been shown to be required for the entry of T cells into murine skin 
under homeostatic conditions but was dispensable for the infiltration of T cells into skin 
under inflammatory conditions [149]. In addition, CCR10 knockout mice displayed over-
reactive immune responses in the skin, likely due to the significantly reduced frequency of 
Tregs in the skin of these mice [149].  
 
	  
Figure 3.11: Co-expression of skin associated receptors by CD45RO+ Tconvs and 
Tregs. (A) CD45RO+ (effector/memory) Tconvs and Tregs are examined for the 
expression of CLA, CCR4 and CCR10. Co-expressing cells are in the indicated gates on 
both Tconvs (left panel) and Tregs (right panel). (B) Levels of co-expression of CLA, 
CCR4 and CCR10 as a percent of total CD45RO+ Tconvs and Tregs. (C) Percent CLA+ (i), 
CCR4+ (ii) and CCR10+ (iii) cells co-expressing other skin associated receptors on both 
Tconvs (black) and Tregs (red). Each point represents an individual donor (n=44) and 
horizontal bars represent the group means. The Mann-Whitney t-test was used to compare 
differences between Tconvs and Tregs, **** = p<0.0001 
Chapter 3: Tregs in healthy humans  59 
 
In this study, we showed that CCR10 is expressed more highly on Tregs than Tconvs (Figure 
3.4) and on a higher proportion of both CLA+ and CCR4+ Tregs than Tconvs (Figure 3.11). 
This suggests a potential role for Tregs to maintain homeostasis in the skin under steady-state 
non-inflammatory conditions. Therefore, developing strategies that can increase the number 
of CCR10+ Tregs might help restore immune homeostasis in skin related immune disease. 
 
In conclusion, we have shown that the skin homing compartment of CD4+ Tconvs and Tregs 
can be divided into subpopulations based on trafficking receptor expression, and that the 
proportions of these subpopulations differ amongst Tconvs and Tregs. Although both CCR4 
and CCR10 are associated with skin-homing CLA+ T cells, the association is incomplete in 
both cases. CCR4 is expressed on almost all skin-homing CLA+ T cells, but also on a subset 
of other cells. In contrast, CCR10 is almost exclusively found within a subset of CLA+ skin 
homing cells. 
 
3.3.3.2  Co-expression of gut and skin–associated trafficking receptors on Tconvs and 
Tregs  
 
Since we showed that β7 alone is sufficient for identifying α4β7+ cells (Figure 3.10), we 
used only β7 when examining the co-expression of gut and skin associated trafficking 
receptors. Expression of CLA and β7 is generally believed to be mutually exclusive [150], 
but we have shown here that a small proportion of cells co-express these markers (Figure 
3.12). On total CD45RO+ Tconvs, ~1.3% of cells are CLA+β7+ (Figure 3.12, B). On the other 
hand, ~3.8% of total CD45RO+ Tregs are CLA+β7+. Interestingly, 37% of β7+ 
effector/memory Tregs express CLA while only 8% of β7+ effector/memory Tconvs express 
CLA (Figure 3.12, C).  
 
CCR4+β7+ cells make up equal proportions of total CD45RO+ Tconvs and Tregs (~11-13%). 
Additionally, 67% of β7+ effector/memory Tconvs also express CCR4 while almost all (93%) 
β7+ effector/memory Tregs also express CCR4. This indicates that the expression of CCR4 is 
	  
 
 
 
Figure 3.12: Co-expression of skin and gut associated receptors by CD45RO+ 
Tconvs and Tregs. (A) CD45RO+ (effector/memory) Tconvs and Tregs are examined for 
the co-expression of gut associated β7 with skin associated CLA, CCR4 and CCR10. Co-
expressing cells are in the indicated gates on both Tconvs (left panel) and Tregs (right 
panel). (B) Levels of co-expression of β7 with CLA, CCR4 and CCR10 as a percent of total 
CD45RO+ Tconvs and Tregs. (C) Percent β7+ cells co-expressing skin associated CLA, 
CCR4 and CCR10 on both Tconvs (black) and Tregs (red). Each point represents an 
individual donor (n=44) and horizontal bars represent the group means. The Mann-
Whitney t-test was used to compare differences between Tconvs and Tregs, **** = 
p<0.0001 
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distributed within both gut and skin homing cells. ~90% of CLA+ Tconvs and 67% of β7+ 
Tconvs express CCR4 while almost all CLA+ and β7+ Tregs express CCR4. This again 
indicates a role for CCR4 in trafficking cells to non-cutaneous peripheral tissues, the gut 
included. On the other hand, CCR10 and β7 are generally mutually exclusive on Tconvs, with 
only 4% of β7+ Tconvs expressing CCR10. In a study that examined the co-expression of 
CCR10 and β7 on memory CD4+ T cells, it was concluded that “practically no” CCR10+ cells 
express detectable β7 [148]. However this study did not examine the expression of these 
molecules on Tregs. We have shown that 30% of β7+ Tregs express CCR10 (Figure 3.12, C). 
 
3.3.3.3  Concluding remarks on section 3.3.3 
 
The co-expression of adhesion molecules and CRs on a subset level suggests a wide variety 
of combinations that can target cells into diverse microenvironmental niches. The in vivo 
significance of the proportions of cells expressing these various combinations is currently 
unknown. Nevertheless, studying these subsets on both Tconvs and Tregs can provide clues 
for the design of future therapy. 
 
The optimal subpopulation of Tregs for immuno-therapy may be defined by trafficking 
receptors that favour certain tissues. Certainly, studies in an animal model of graft versus 
host disease (GvHD) have shown that CLA expressing Tregs are more efficient at preventing 
skin destruction [151]. More importantly, increased frequencies of CLA+ Tregs at the time of 
neutrophil engraftment in allogeneic stem cell transplant (ASCT) patients has been shown to 
be associated with the prevention of acute GvHD involving the skin [152]. It has also been 
shown that increased frequencies of CLA+ or β7+ Tregs are associated with reduced incidence 
[153] or severity [152] of skin or gut aGvHD, respectively. This confers that Tregs are not a 
single uniform subset, but that various migratory subsets within Tregs can represent a target 
that is potentially modifiable by cellular therapy.  
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3.3.4  Trafficking of CD4+ T cells to sites of Th1, Th2 and Th17 type inflammation  
 
During their initial activation, conventional CD4+ T cells can assume one of several 
functional fates (Th1, Th2 or Th17). Each of these subsets is believed to be defined by master 
regulator transcription factors and distinct patterns of cytokine production. Th1 cells express 
the transcription factor T-bet and secrete IFN-γ [154], Th2 cells express the transcription 
factor GATA-3 and secrete IL-4, IL-5 and IL-13 [155] and Th17 cells express the 
transcription factor RORγt and secrete IL-17 [156, 157].  
 
Once naïve CD4+ T cells are primed and develop into Th1, Th2, and Th17 type cells, they 
migrate from lymphoid organs to target peripheral tissues. It is thought that different CRs are 
preferentially expressed on Th1, Th2 and Th17 type cells, resulting in the selective migration 
of these subsets to particular tissues [158]. Generally, Th1 cells are believed to be CXCR3+ 
[159-162] while Th2 cells are CCR4+ [159-164] and Th17 cells CCR6+ [165, 166]. However, 
more recently these definitions have been modified, with Th1 cells being described as 
consisting of both CXCR3+CCR6- and CXCR3+CCR6+ subsets, while Th2 cells are CXCR3-
CCR6-CCR4+ and Th17 cells CXCR3-CCR6+CCR4+ [167, 168].  
 
It is important to note that these studies examined the CR expression of Th1, Th2 and Th17 
type cells on cells artificially polarised in vitro [159, 160, 163] or by isolating circulating CR 
expressing CD4+ T cells from human blood and examining their cytokine profiles following 
in vitro stimulation [161, 162, 167, 168]. For example, in two of these studies, a small 
proportion of isolated CD4+ memory T cells expressing CCR4 were shown to produce IL-4 
following in vitro stimulation whereas a proportion of CXCR3 cells produce IFN-γ [161, 
162]. It is worth mentioning that even following artificial stimulation, only a minority of the 
CR expressing subsets express the relevant cytokines, thus casting doubt on the use of CR 
expression patterns to study and measure all Th1, Th2 and Th17 type cells. 
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3.3.4.1  Chemokine receptor expression on circulating T-bet+ and RORγ t+ cells 
 
In order to study the CR expression patterns of Th1 and Th17 type T cells, we took a novel 
approach and designed an 11 colour antibody panel that allowed us to combine detection of 
the transcription factors T-bet and RORγt with their commonly associated CRs (Table 2.2, 
Figure 2.10). In doing so, we were able to identify circulating CD4+ T cells that express T-
bet and RORγt without the need for prior in vitro stimulation (Figure 2.9).  
 
When T-bet+ CD4+ cells were examined for the expression of CXCR3, CCR4 and CCR6, they 
were found to express only CXCR3, the CR commonly associated with Th1 T-bet+ cells 
(Figure 3.13). Numerous studies have described circulating CXCR3+ CD4 T cells as Th1 
type cells [159-162, 167-169]. However, it is evident in our study that in human PB not all 
CXCR3+ cells express T-bet. In fact, in the 44 healthy donors examined, 89% (mean) of 
CXCR3+CD4+ T cells did not express T-bet (Figure 3.15, B, subset 3). It should be noted, 
however, that T-bet expression is also seen in a proportion of cells that fall within the 
CXCR3 negative gate (Figure 3.13).  
 
When RORγt+CD4+ cells were examined for the expression of CXCR3, CCR4 and CCR6, 
they were all found to express CCR6, the CR commonly associated with Th17 RORγt + cells 
(Figure 3.14). In fact, the combination of RORγt and high CCR6 identifies a distinct 
population of RORγt+CCR6+ CD4 T cells in adult human blood. It is important to note 
however, that although all RORγt+ cells express CCR6, not all CCR6+ cells express RORγt. 
Interestingly, we also show that subsets of RORγt + cells express the CRs CCR4 and CXCR3. 
This trafficking receptor profile is consistent with their inflammatory role in an array of 
peripheral tissues [170-172]. 
 
In a few highly regarded studies, Th1, Th2 and Th17 cells in human PB were identified as 
CXCR3+, CXCR3-CCR6-CCR4+ and CXCR3-CCR6+CCR4+ memory CD4 T cells, 
respectively [167-169]. Although these studies found that “Th1” and “Th17” cells isolated 
	  
 
Figure 3.13: Not all CXCR3+ T cells express T-bet. Peripheral blood mononuclear cells 
(PBMC) were isolated from human blood and surface stained for CD4, CD25, CD127, 
CD45RO and the CRs CXCR3, CCR4 and CCR6 followed by intracellular staining for T-
bet, RORγt and FoxP3. CD4+ T cells here are examined for the co-expression of the 
transcription factor T-bet with Th1, Th2 and Th17 associated chemokine receptors 
(CXCR3, CCR4 and CCR6 respectively). Representative cytometry plots from four 
individual donors.  
	  
 
Figure 3.14: All ROR-γt+ cells express CCR6 but not all CCR6+ T cells express ROR-
γt. Peripheral blood mononuclear cells (PBMC) were isolated from human blood and 
surface stained for CD4, CD25, CD127, CD45RO and the CRs CXCR3, CCR4 and CCR6 
followed by intracellular staining for T-bet, RORγt and FoxP3. CD4+ T cells here are 
examined for the co-expression of the transcription factor ROR-γt with Th1, Th2 and Th17 
associated chemokine receptors (CXCR3, CCR4 and CCR6 respectively). Representative 
cytometry plots from four individual donors.  
Chapter 3: Tregs in healthy humans  63 
 
this way were enriched for IFN-γ and IL-17 producing cells respectively, they did not find 
them all to produce these cytokines. In order to examine “Th1” and “Th17” cells, identified 
as described in the literature [167-169], for the expression of T-bet and RORγt, we gated 
CXCR3+ (“Th1”) and CXCR3-CCR6+CCR4+ (“Th17”) cells within CD45RO+CD4+ cells 
(Figure 3.15, A, subsets 1&4). We next examined these subsets for T-bet and RORγt 
expression (Figure 3.15, A, subsets 3&6) and compared them to the percentages of total T-
bet+ and RORγt+ CD4 T cells (Figure 3.15, A, subsets 2&5).  
 
Figure 3.15B shows the quantification of these subsets in the PB of the 44 healthy 
individuals examined. “Th1” cells, defined as CXCR3+ effector/memory T cells, make up a 
mean of 23% of PB CD4+ T cells whereas T-bet+ cells makeup only a mean of 5.3%. 
Importantly, 89% of CXCR3+ effector/memory T cells do not express T-bet in human PB. 
“Th17” cells, defined as CXCR3-CCR6+CCR4+ effector/memory T cells, make up a mean of 
10.8% of PB CD4+ T cells whereas RORγt + cells makeup only 7% of PB CD4+ T cells. 
Significantly, 71.5% of CXCR3-CCR6+CCR4+ effector/memory T cells do not express RORγt 
in human PB.  
 
Based on our findings, CRs alone cannot be used to isolate pure Th1 and Th17 type cells, 
defined as expressing T-bet and RORγt respectively. The use of these surface markers to 
isolate Th1 and Th17 cells markedly overestimates their frequency in comparison to defining 
Th1 and Th17 cells based on intracellular staining for T-bet and RORγt.  
 
3.3.4.2  Th1 and Th17 associated Tregs 
 
If Th1, Th2 and Th17 type cells are deregulated, they can cause harm to host tissue. 
Recently, there has been increasing interest in mechanisms by which Tregs can regulate these 
specific types of inflammation, with several studies suggesting that Treg subsets are 
specialized in regulating polarized Th1, Th2 or Th17 immune responses [112-116, 118, 119] 
(reviewed in Chapter 1, section 1.6.4). 
  
 
Figure 3.15: The surface expression of chemokine receptors cannot be used to 
identify Th1 (T-bet+) and Th17 (RORγt+) CD4 cells in peripheral blood. (A) 
“Th1”(CXCR3+CD45RO+) and “Th17” (CXCR3-CCR6+CCR4+CD45RO+) cells were gated 
as described in the literature (1&4) and then examined for the expression of T-bet and 
RORγt, respectively (3&6). Total T-bet+ and RORγt+ CD4 cells were also gated (2&5). (B) 
Percentages of all the cell subpopulations identified in A in the peripheral blood of 44 
healthy individuals. Each point represents an individual donor and horizontal bars 
represent the group means. 
Chapter 3: Tregs in healthy humans  64 
 
 
In mice, it has recently been demonstrated that subsets of Tregs co-express the transcription 
factors T-bet or RORγt together with FoxP3 [112, 173, 174].  These studies demonstrated 
that the expression of T-bet and RORγt by Tregs in turn induces the expression of CXCR3 
and CCR6 respectively, thus allowing Tregs to co-localise with inflammatory effector cells at 
sites of Th1 and Th17 mediated inflammation.  
 
The co-expression of T-bet and RORγt with FoxP3 on unstimulated CD4 T cells in human 
PB has not been examined. We could not identify any CD4+ T cells that co-expressed T-bet 
and FoxP3 within human PB (Figure 3.16A). However interestingly, a study in ovarian 
cancer patients has shown that FoxP3+ Tregs that co-express T-bet and CXCR3 can be found 
in tumour tissue [175]. Despite the fact that FoxP3+ Tregs in our study do not express T-bet, 
they do express CXCR3 at levels equal to Tconvs (Figure 3.16B). 
 
When we examined CD4+ T cells for the co-expression of RORγt and FoxP3, we identified a 
clear population of RORγt+FoxP3+ cells (Figure 3.17A). Despite the fact that only a small 
proportion of FoxP3+ cells express RORγt, Tregs express CCR6 at levels higher than Tconvs 
(Figure 3.17B). 
 
In order to study the RORγt+FoxP3+ population more closely and compare it to RORγt+ and 
FoxP3+ cells, we divided CD4 T cells into 3 populations based on the expression of FoxP3 
and RORγt (Figure 3.18A). RORγt-FoxP3+, RORγt+FoxP3- and RORγt+FoxP3+ cells were 
identified and their levels in the PB of the 44 healthy individuals were quantified (Figure 
3.18B). RORγt-FoxP3+ cells made up a mean of 7.4% of total CD4+ T cells, RORγt+FoxP3- 
cells made up a mean of 6.1% and RORγt+FoxP3+ co-expressing cells made up only a mean 
of 1.1% of circulating CD4 T cells. Interestingly, when we examined whether the circulating 
levels of these subsets correlate with each other, we found that the RORγt+FoxP3+ co-
expressing cells in each individual highly correlated with total RORγt+ cells (Figure 3.18C).  
 
	  
 
Figure 3.16: Peripheral blood FoxP3+ CD4+ T cells do not co-express T-bet. (A) CD4+ 
T cells are examined for the co-expression of the transcription factors T-bet and FoxP3. 
Representative cytometry plots from four individual donors. (B) Percentage of cells that 
express the T-bet associated chemokine receptor CXCR3 on both Tconvs and Tregs. 
Each point represents an individual donor (n=44) and horizontal bars represent the group 
means.  
	  
 
Figure 3.17: A small percentage of CD4+ T cells in peripheral blood co-express the 
transcription factors RORγt and FoxP3. (A) CD4+ T cells are examined for the co-
expression of the transcription factors RORγt and FoxP3. Representative cytometry plots 
from four individual donors. (B) Percentage of cells that express the RORγt associated 
chemokine receptor CCR6 on both Tconvs and Tregs. Each point represents an individual 
donor (n=44) and horizontal bars represent the group means.  
  
Figure 3.18: Percentage of RORγt+FoxP3+ CD4 T cells in peripheral blood of 44 
healthy subjects. (A) CD4+ T cells are examined for the expression of the transcription 
factors RORγt and FoxP3. Three cell populations were identified; RORγt-FoxP3+ (1), 
RORγt+FoxP3- (2) and RORγt+FoxP3+ (3). (B) Percentages of RORγt-FoxP3+, 
RORγt+FoxP3- and RORγt+FoxP3+ within CD4+ cells. Each point represents an individual 
donor (n=44) and horizontal bars represent the group means. (C) Correlations between 
the three identified subpopulations. The correlation was evaluated using a non-parametric 
Spearman test.  
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We also examined the expression of CD45RO and CRs CXCR3, CCR4 and CCR6 on the 
RORγt-FoxP3+, RORγt+FoxP3- and RORγt+FoxP3+ cells identified above (Figure 3.19, 
B&C). We found that almost all of the cells in the RORγt+FoxP3- and RORγt+FoxP3+ subsets 
were of the effector/memory phenotype (CD45RO+) (mean 94%). When examined for the 
expression of CXCR3, the two FoxP3 expressing subsets (RORγt-FoxP3+ and RORγt+FoxP3+) 
expressed significantly less CXCR3 then the FoxP3- subset. However when CCR6 was 
examined, it was the two RORγt expressing subsets (RORγt+FoxP3- and RORγt+FoxP3+) that 
displayed the highest levels of CCR6 expression. It is important to note however that the 
RORγt+FoxP3+ cells expressed significantly less CCR6 than the RORγt+FoxP3- cells. When 
examined for expression of CCR4, the FoxP3 expressing subsets (RORγt-FoxP3+ and 
RORγt+FoxP3+) displayed the highest percentage of CCR4+ cells. Interestingly, the 
RORγt+FoxP3+ co-expressing cells contained the highest percentage of CCR4+ cells. 
 
It has previously been reported that a small proportion (3-4%) of human memory Tregs, 
purified as CD4+CD25hi, secrete IL-17 following in vitro stimulation [176, 177]. In one of 
these studies, a large proportion (34%) of “Tregs”, isolated as CD25hi, were found to express 
RORγt following stimulation [176]. This indicates that in vitro stimulation leads to a change 
in RORγt expression, leading to an overestimation of the frequency of IL-17 producing 
RORγt+ Tregs in human PB, and highlighting the importance of our work in identifying 
RORγt+ cells within PB CD4 T cells. 
 
When we compared the CR profile of FoxP3+ Tregs and RORγt+ cells, we found a high level 
of similarity. Both subsets contained higher proportions of CCR4+ and CCR6+ cells when 
compared to Tconvs (% for Tconvs in Figure 3.4). Interestingly, RORγt+ cells contained the 
highest proportion of CCR6+ cells while FoxP3+ cells contained the highest proportion of 
CCR4+ cells with RORγt+FoxP3+ co-expressing cells taking on both these features, expressing 
CCR6 at levels similar to RORγt+ cells and CCR4 at levels similar to FoxP3+ cells. The CR 
expression profile of IL-17 producing stimulated CD4 T cells and FoxP3+ Tregs has been 
  
 
 
 
  
Figure 3.19: Expression of CD45RO, CXCR3, CCR4 and CCR6 by RORγt-FoxP3+, 
RORγt+FoxP3- and RORγt+FoxP3+ CD4 T cells in peripheral blood. (A) CD4+ T cells 
were examined for the expression of the transcription factors RORγt and FoxP3 and three 
cell populations were identified; RORγt-FoxP3+ (1), RORγt+FoxP3- (2) and RORγt+FoxP3+ 
(3). (B&C) Representative cytometry plots (B) and percentages (C) of total CD45RO+, 
CD45RO+CXCR3+, CD45RO+CCR4+ and CD45RO+CCR6+ cells on RORγt-FoxP3+, 
RORγt+FoxP3- and RORγt+FoxP3+ CD4 T cells in the peripheral blood of 44 healthy 
individuals. Each point represents an individual donor and horizontal bars represent the 
group means. Differences were analysed using a Kruskal Wallis test, p values <0.05 were 
considered significant. 
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previously compared. This study, like us, found Tregs to be higher for CCR4 while IL-17 
producing cells were higher for CCR6 and CXCR3 [117]. 
 
3.3.4.3  Using combinations of CRs to define Th1, Th2 and Th17 –like Tregs 
 
With the discovery in mice of Treg subsets that co-express the transcription factors T-bet and 
RORγt with FoxP3 [112, 173, 174], there has been increasing interest in methods for 
isolating these Tregs for functional studies. In order to do this, one study has claimed to 
identify, using CRs, functionally distinct subsets of Tregs that resemble polarised Th1, Th2 
and Th17 type cells [169].  
 
These Th1, Th2 and Th17 – “LIKE” Tregs were defined as CXCR3+, CXCR3-CCR6-CCR4+ 
and CXCR3-CCR6+CCR4+ cells respectively. In doing this, the study claimed that Th17 cells 
were present at a substantially higher frequency within the Treg compartment when 
compared to Tconvs [169]. Only ~8% of the cells in the Th17 – “LIKE” Treg compartment 
were found to produce IL-17. Interestingly, Th17 – “LIKE” Tregs in this study were defined 
as CXCR3-CCR6+CCR4+, that is positive for two CRs known to be highly expressed by 
Tregs. This prompted us to examine the relationship between the co-expression of the CRs 
CXCR3, CCR4 and CCR6 in order to determine whether the increased expression of CCR4 
and CCR6 within the Treg compartment resulted in the increased co-expression of these CRs.  
 
In order to do this, we gated CXCR3+CCR4+, CXCR3+CCR6+ and CCR4+CCR6+ co-
expressing cells on Tconvs and Tregs and graphed their percentages against predicted 
frequencies of co-expressing cells (calculated by multiplying the percent of cells that express 
CR1 with the percent of cells that express CR2) (Figure 3.20A). In doing this, we showed 
that the co-expression of any two CRs examined was random and can be predicted (with high 
accuracy, r = 0.9+) based on the frequencies of cells that express each CR individually 
(Figure 3.20B). We also found this relationship to be true for Th2 and Th17 – “LIKE” Tregs 
identified as CXCR3-CCR6-CCR4+ and CXCR3-CCR6+CCR4+ (Figure 3.20C).  
	  
	  	  
Figure 3.20: Examining the co-expression of the chemokine receptors CXCR3, CCR4 and CCR6 on Tconvs and Tregs in the 
peripheral blood of 44 healthy individuals. (A) CD45RO+ Tconvs and Tregs were examined for the co-expression of CCR4 and 
CXCR3 (i), CCR6 and CXCR3 (ii) and CCR6 and CCR4 (iii). Co-expressing cells are in the indicated gates. Numbers indicate cells 
within the gate as a percentage of the parent population. (B) Examining the relationship between the frequency of cells that express each 
chemokine receptor individually ((i), CR1+ (green box) and CR2+ (blue box)) and co-expressing cells ((i), CR1+CR2+ (red box)). In order to 
do this, we calculated predicted frequencies of co-expressing cells (CR1+CR2+) by multiplying the percent of cells that express CR1 with 
the percent of cells that express CR2 and graphing them against the co-expressing cells gated by flow cytometry (ii). This was done on 
both Tconvs (blue) and Tregs (red). (C) “Th2” (CXCR3-CCR6-CCR4+) and “Th17” (CXCR3-CCR6+CCR4+) cells were gated as described 
in the literature on both Tconvs (blue) and Tregs (red) and graphed against predicted frequencies of CXCR3-CCR6-CCR4+ and CXCR3-
CCR6+CCR4+ cells. Correlations were evaluated using a non-parametric Spearman test.  	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3.3.4.4  Concluding remarks on section 3.3.4 
 
Many studies on inflammatory disease in humans have used various combinations of CRs to 
measure Th1, Th2 and Th17 type cells in human PB and/or organs [178-180]. For example, 
one study that used CCR6 to measure Th17 cells in children with asthma concluded that 
Th17 cells were increased in the PB of patients [178]. In the current study, we were able to 
identify circulating CD4+ T cells that express T-bet and RORγt without the need for in vitro 
stimulation. In doing so, we were able to study the CR expression profile of these T-bet+ and 
RORγt+ cells. None of the CRs examined was found to be exclusively expressed by T-bet+ 
Th1 cells or RORγt+ Th17 cells. In fact, RORγt+ Th17 cells were found to express all the CRs 
examined, not just CCR6 or CCR6 and CCR4 in combination. We also showed that most of 
the CXCR3, CCR4 and CCR6 expressing CD4 T cells express neither T-bet or RORγt in 
human PB. 
 
IL-17 has been shown to be necessary for the induction of maximal autoimmune 
inflammation in models of experimental autoimmune encephalomyelitis (EAE) [181], 
collagen induced arthritis [182, 183] and colitis [184]. Th17 type inflammation has also 
recently been implicated in a number of immune-mediated diseases in humans [185]. Indeed, 
the levels of IL-17 producing cells have been shown to be increased in inflamed tissues of 
patients with inflammatory bowel disease [170], multiple sclerosis [171] and rheumatoid 
arthritis [172]. These studies highlight the importance of being able to detect Th17 type cells 
in the PB and tissue of patients. Therefore, our method for identifying RORγt+ cells by flow 
cytometry is of great importance. An important challenge in this field of research is to find 
ways to isolate viable Th17 cells with high purity so that they can be used in functional 
studies. Now that we have shown that RORγt expression can be detected in unstimulated PB, 
this should aid the search for markers that correlate better with RORγt expression than the 
CRs currently used for that purpose. 
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CHAPTER 4:  EXPRESSION OF TRAFFICKING RECEPTORS 
BY REGULATORY T CELLS IN RHEUMATOID ARTHRITIS  
 
4.1  Introduction 
 
CD4+ regulatory T cells (Tregs) expressing the IL-2Rα chain (CD25) and the master 
regulator Foxp3 transcription factor play an important role in controlling autoimmune 
responses [36]. The strongest evidence for the importance of Tregs in maintaining immune 
tolerance in humans is the syndrome of multi-organ autoimmunity, dermatitis and allergy that 
results from a dysfunctional FoxP3 gene (immunodysregulation, polyendocrinopathy, 
enteropathy X-linked (IPEX) syndrome) [62]. However, most human autoimmune diseases 
are not caused by such a complete dysfunction of Tregs, and it is believed that more subtle 
imbalances in Treg frequency, function and development may serve as predisposing factors 
for disease.  
 
Rheumatoid arthritis (RA) is an inflammatory autoimmune disease characterised by the 
accumulation of inflammatory cells in the joints, resulting in tissue destruction and severe 
disability [186, 187]. The first evidence of self-reactivity in RA was the identification of 
rheumatoid factor, an autoantibody, in the blood of affected patients [188]. It became 
apparent that T cells played a crucial role in the pathogenesis of RA in the early 1980s, when 
the synovial tissue and fluid from patients was shown to be enriched with T cells, 
predominantly CD4+ T cells [189, 190]. The processes that initiate and cause the progression 
of a dysregulated T-cell dependent response in RA are still unknown. 
 
Tregs have been shown to play a critical role in the control of autoimmune arthritis in 
experimental models [191-193]. However, the involvement of Tregs in human RA is still not 
well understood. Some studies have shown that Treg numbers in the peripheral blood (PB) of 
RA patients are reduced compared with controls [65, 194] whereas others have found them to 
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be increased [195, 196] or unchanged [197-199]. Reduced suppressive function of Tregs 
derived from the PB of RA patients has been reported in some studies [197, 198, 200], 
whereas others have reported normal suppressive capacity of Tregs from RA patients [194, 
195, 201].  
 
It is clear there is conflicting evidence on the frequency and function of Tregs in RA. This is 
partly due to the fact that human Tregs were originally identified as CD25high [60] making it 
hard to distinguish Tregs from CD25+ conventional T cells, particularly in human blood 
where up to 20-40% of PB CD4+ T cells express CD25 to some extent [54]. There is a lack of 
consensus on the precise demarcation between CD25high and CD25+ expression. For this 
reason, studies in RA patients have defined Tregs as CD4+CD25+ [195, 199], CD4+CD25“high” 
[194, 196, 197, 200] and CD4+CD25“bright” [65, 201]. This has made it difficult to compare 
results from individual studies and to reach conclusions on the role of Tregs in RA.  
 
Nevertheless, Tregs have consistently been shown to be enriched in the synovial fluid of RA 
patients when compared to PB [65, 194, 195, 199, 201, 202]. To facilitate their entry into 
peripheral tissues, Tregs express a vast array of integrins and chemokine receptors (CR) that 
have been shown to be crucial to their role in regulating immune responses [81, 90-92]. 
Emerging evidence also suggests that distinct CR expression patterns may contribute to 
selective trafficking and compartmentalization of Tregs at sites where regulation is required 
[112, 113, 118].  Despite this, chemokine receptor expression by Tregs in the PB or joints of 
RA patients has not been examined.  
 
We have previously shown that low surface expression of CD127, the α chain of the IL-7 
receptor, in combination with CD25 can distinguish CD25+CD127lo Tregs from conventional 
CD4+ T cells (Tconvs) in human PB [61]. In the current study, we used nine-colour flow 
cytometry to analyse the levels of CXCR3+, CCR4+, CCR5+ and CCR6+ conventional T cells 
and CD25+CD127lo Tregs in the PB of RA patients. We hypothesised that the correct 
localisation of Tregs is vital to their role in preventing and regulating joint inflammation and 
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that deficiencies in Treg migratory subsets may play a role in disease pathogenesis. We also 
applied a novel method of using bioinformatic analysis software to analyse flow cytometric 
data, allowing us to simultaneously draw unsupervised, automated comparisons between 
Tconv and Treg subsets in RA patients and controls.  
 
4.2  Summary of methods 
 
4.2.1  Patients 
 
Peripheral blood specimens were collected from 34 patients with rheumatoid arthritis (RA) 
(65% female, average age 56.4 years) and 34 sex and age matched controls (65% female, 
average age 55.6 years). Patients with RA, diagnosed according to the European League 
Against Rheumatism (EULAR) 2010 criteria, were enrolled in the study over a period of one 
year by Dr Diana Chessman at Concord Repatriation General Hospital (Concord, NSW, 
Australia). All patients and controls gave written, informed consent and the study was 
approved by the Sydney Local Health District ethics review committee at Concord 
Repatriation General Hospital. 
 
Clinical information including disease duration, disease activity, as assessed by the disease 
activity score in 28 joints (DAS28), treatment, smoking status and seropositivity was 
recorded at the time the blood was collected from RA patients.  
 
4.2.2  Cell isolation  
 
Peripheral blood mononuclear cells (PBMC) were isolated from heparinised venous blood by 
density gradient centrifugation using Ficoll-Paque Plus (GE Healthcare). The isolated 
mononuclear cells were stored in 1 ml aliquots at -180oC in LNO2 (details in Chapter 2, 
section 2.3) 
 
Chapter 4: Tregs in Rheumatoid Arthritis  71 
 
4.2.3  Flow cytometric analysis 
 
Cells were thawed in batches and surface stained at 4oC for 45 minutes (details in Chapter 2, 
section 2.4) using the following antibodies: V500-conjugated CD4 (RPA-T4, BD Horizon), 
Brilliant violet 421-conjugated CD25 (M-A251, BD Horizon), phycoerythrin (PE)-CF594-
conjugated CD127 (HIL-7R-M21, BD Horizon), biotin-conjugated CD45RO (UCHL1, 
BioLegend), streptavidin-DyLight-800 (Thermo Scientific), Alexa Fluor 488-conjugated 
CXCR3 (1C6, BD Pharmingen), PE-conjugated CCR6 (11A9, BD Pharmingen), 
allophycocyanin (APC)-conjugated CCR4 (L291H4, BioLegend) and Alexa Fluor 700-
conjugated CCR5 (HEK/1/85a, BioLegend). A LIVE/DEAD Fixable Blue stain (Invitrogen) 
was used to exclude dead cells from analysis (antibodies listed in Table 2.1).  
 
Data was acquired on a LSRII 10-laser flow cytometer (BD) and analysed using FlowJo 
software (Tree Star). A general gating strategy was employed for the analysis of all flow data 
(Figure 2.1, description in Chapter 2, section 2.4.6).  
 
A batch of samples from RA patients and their matched controls were thawed on each day to 
avoid variability in comparing patients and controls due to flow cytometer instability. 
PBMCs from a single control not included in the study were included in each run to allow us 
to monitor flow cytometer stability and standardize performance.  
 
4.2.4  Statistical analysis 
 
Statistical analysis was performed using MultiExperiment Viewer (MeV) (TM4–Microarray 
Software Suite). Data was loaded into MeV in .txt format and heatmaps were generated. 
Differences between RA patients and controls were evaluated using an automated Mann-
Whitney t-test. A Kruskal-Wallis test was used for identification of differences between RA 
patients treated with TNF inhibitors, RA patients not treated with TNF inhibitors and 
controls. P values less than 0.05 were considered significant. Unsupervised cluster analysis 
was performed using the hierarchical clustering (HCL) algorithm.  
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We also used Graph Pad Prism 6 for analysis. Group means were compared using the Mann-
Whitney t-test or the Kruskal-Wallis test. Correlations were determined using the Spearman 
correlation test. P values less than 0.05 were considered significant. 
 
4.3  Results 
 
4.3.1  Chemokine receptor expression by conventional and regulatory T cells in the 
peripheral blood of patients with RA and healthy controls. 
 
We analysed the chemokine receptor (CR) expression by conventional T cells (Tconvs) and 
regulatory T cells (Treg) in the peripheral blood (PB) of 34 RA patients and 34 age and sex 
matched controls. Demographic and clinical information for the RA patients are presented in 
Table 4.1.  
 
We have previously shown that the expression of CD127, the α-chain of the interleukin-7 
receptor, along with CD25 allows for the accurate identification of CD25+CD127lo Tregs in 
human PB [61]. In this study, we developed a nine-colour flow cytometry panel that allowed 
us to use this definition of Tregs to investigate the expression of the chemokine receptors 
CXCR3, CCR4, CCR6 and CCR5 on Tregs and Tconvs in hope that an analysis of 
circulating Treg/Tconv subsets could provide a more accurate indication of their activity 
within tissues. 
 
Representative histograms showing expression of these chemokine receptors on Tregs and 
Tconvs can be seen in Figure 4.1. Tregs were defined as CD25+CD127lo (Figure 4.1A) and 
Tconvs as everything outside this gate. Figure 4.1C shows the correlation between the 
percentage of Tregs identified as CD25+CD127lo and FOXP3+CD127lo in 15 of the RA 
patients. The frequency of Tregs within the two gates in each individual was very highly 
correlated. 
Table 4.1 Clinical characteristics of RA patients included in study 
 
Characteristic Patients (n=34) 
Age, median (range), years 59 (29-82) 
% Female 65 
Disease duration, median (range), years 8 (0.5-30) 
% Ever smoked 47 
% Seropositive (RF and/or CCP) (n=29) 69 
Disease activity (DAS28), mean ± SD 3.07 ± 1.5 
% Methotrexate users 71 
% Corticosteroid users 62 
% TNFi users 29 
RA = rheumatoid arthritis; RF = rheumatoid factor; CCP = Cyclic 
citrullinated peptide; TNFi = Tumour necrosis factor inhibitor 	  	  	  
	  
Figure 4.1. Representative histograms of the expression of chemokine receptors (CRs) CXCR3, CCR4, CCR6 and CCR5 by 
conventional T cells (Tconvs) and regulatory T cells (Tregs) in the peripheral blood of patients and controls. Mononuclear cells 
were isolated as described and examined by flow cytometry for the expression of markers that allowed for the identification of Tregs, 
defined as CD4+CD127loCD25+ (A), and Tconvs, defined as everything outside the indicated Treg gate. Tregs and Tconvs were 
subdivided on the basis of CD45RO expression in order to differentiate between CD45RO+ (effector/memory) and CD45RO- (naïve) 
subsets, and analysed for the indicated CRs. Expression of the CRs by Tconvs and Tregs was analysed using two gates (B). 
CR+CD45RO+ cells in the upper right gate and CR+CD45RO- cells in the upper left gate. Numbers indicate cells within the gate as a 
percentage of total CD45RO+ or CD45RO- Tconvs and Tregs. (C) Correlation between the frequencies of CD4+ Tregs identified by gating 
for CD127loCD25+ versus CD127loFOXP3+ in 15 RA patients. The correlation was statistically evaluated using a non-parametric 
Spearman test (****). 
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Because the ability to enter non-lymphoid tissues is closely correlated with post-thymic 
differentiation in response to antigen, expression of chemokine receptors was examined 
along with CD45RO, an effector/memory marker, on both Tconvs (Figure 4.1B, upper 
panel) and Tregs (Figure 4.1B, lower panel). Effector/memory (CD45RO+) Tconvs and 
Tregs expressing the chemokine receptor of interest, calculated as a percent total CD45RO+ 
Tconvs/Tregs, appear in the upper right gate and naïve (CD45RO-) Tconvs and Tregs 
expressing the chemokine receptor of interest, calculated as a percent total CD45RO- 
Tconvs/Tregs, in the upper left gate. These subsets were quantified for all 68 patients and 
controls and used for further analysis.  
 
4.3.2  Decreased frequency of CXCR3+, CCR4+, CCR5+ and CCR6+ effector/memory 
Tregs in the PB of RA patients when compared with healthy controls. 
 
We used a bioinformatic analysis software, MeV, to draw simultaneous, automated 
comparisons between multiple Tconv and Treg subset data obtained from flow cytometry. 
Data was uploaded into the software and a heat map was generated (Figure 4.2A), providing 
a simple way to visualize all the data simultaneously. Each column represents an RA patient 
(left) or control (right) and each row the percent of cells within each Tconv or Treg subset, 
gated as indicated in Figure 4.1.  
 
Once data is loaded into MeV and a heatmap is generated, various statistical and clustering 
tools can be applied to allow for the identification of significant similarities and differences 
between subject groups. We next performed an automated t-test to identify the significant 
differences in Tconv and Treg subset frequencies between RA patients and controls. This 
identified nine subsets that were shown to be significantly different between patients and 
controls, seven of which were decreased in RA and two of which were increased, shown in a 
heat map in Figure 4.2B. Three of these subsets were in the Tconv compartment and six 
were within Tregs.  
 
	  	  
	  	  
Figure 4.2. Decreased expression of CXCR3, CCR4, CCR5 and CCR6 on effector/memory Tregs in the peripheral blood of 
rheumatoid arthritis (RA) patients (n=34) when compared with healthy controls (n=34). Peripheral blood mononuclear cells from 
patients and controls were examined by flow cytometry for the expression of CXCR3, CCR4, CCR5 and CCR6 within their Tconv and 
Treg (CD4+CD127loCD25+) compartment. (A) Data obtained from flow cytometric experiments is visualised colorimetrically in a heat 
map. Each row represents a Tconv or Treg subset; each column a patient or control. Frequencies that are increased relative to the 
row’s mean are indicated in yellow, decreased in blue and frequencies that show no difference are indicated in black. (B) An 
automated Mann-Whitney t-test indicated that nine subsets displayed significantly different frequencies between patients and controls 
(p<0.05), shown here in a heat map. Seven of these subsets were found to be significantly decreased in RA patients. (C) The nine 
Treg and Tconv subsets selected by statistical analysis to be significantly different between patients and controls were next used for an 
unsupervised hierarchical clustering where subjects are organized based on the overall similarity in expression patterns. Subjects 
clustered in two groups; one consisting mainly of RA patients (red) and the other controls (green). The nine Tconv (D) and Treg (E, F) 
subsets displayed as bar graphs. Each point represents an individual subject and horizontal lines represent means. The Mann-Whitney 
t-test was used to compare differences between patients and controls. * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. 	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Having indentified nine subsets that were significantly different between RA patients and 
controls, we next asked whether these subsets in combination could be used to differentiate 
between patients and controls. We performed an unsupervised hierarchical clustering of the 
68 patients and controls based on the frequencies of the nine subsets that differed 
significantly between patients and controls (Figure 4.2C). 30 out of the 34 RA patients 
clustered together, with 4 patients clustering in the control group. Furthermore, 30 out of the 
34 controls clustered together with 4 controls clustering with patients.  
 
Figure 4.2 D-F illustrates the nine subsets identified by MeV to be significantly between 
patients and controls in traditional graphs. CXCR3+ and CCR5+ effector/memory Tconvs 
were found to be decreased in the PB of RA patients when compared to controls (mean 
29.7% vs 49%, and 13.2% vs 20.8%) whereas CCR4+ effector/memory Tconvs were 
increased in RA (mean 70.4% vs 66.4%) (Figure 4.2D). Total effector/memory (CD45RO+) 
Tregs were found to be significantly decreased in RA patients (mean 54.4% vs 63.9%), 
subsequently, naïve (CD45RO-) Tregs were increased in RA patients (mean 45.6% vs 36.2%) 
(Figure 4.2E). Within the effector/memory Treg compartment, frequencies of all the 
chemokine receptors examined were shown to be decreased in patients with RA (Figure 
4.2F) (CXCR3+; mean 16.2% vs 37.2%, CCR4+; mean 90.6% vs 94.2%, CCR5+; mean 19.5% 
vs 31.1%, CCR6+; mean 48.6% vs 60.4%).  
 
Having found significant differences between patients and controls in the proportions of 
Tconv and Treg subsets, we next examined whether the percent of cells within subsets 
correlate with disease activity as measured by DAS28 (Figure 4.3). The frequency of both 
total effector/memory (CD45RO+) Tconvs and CXCR3+ effector/memory (CD45RO+) Tconvs 
correlated negatively with DAS28 (p < 0.01). Thus we showed that CXCR3+ 
effector/memory Tconvs were greatly reduced in RA (p < 0.0001) (Figure 4.2D) and that 
this decrease was more pronounced in patients with more active disease. No significant 
correlations were found with seropositivity and smoking status. 
 
	  	  
	  
 
 
 
Figure 4.3. Total effector/memory conventional T cells (Tconvs) and CXCR3+ effector/memory Tconvs negatively correlate with DAS28 
in RA patients (n=32). Peripheral blood mononuclear cells from RA patients were examined by flow cytometry for the expression of the 
indicated chemokine receptors by their Tconv and Treg (CD4+CD127loCD25+) compartment. The disease activity score based on 28 
joints (DAS28) was calculated for each patient at the time the peripheral blood specimen was collected. The Spearman correlation test 
was used to test for significance. ** = p < 0.01. Dashed lines represent the mean in the control group.  
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4.3.3  TNF inhibitor therapy may alter the frequency of total effector/memory Tregs, 
CCR4+ effector/memory Tregs and CCR6+ effector/memory Tregs.  
 
We next wished to determine whether incorporating clinical parameters into the analysis of 
data from RA patients would give us insights into whether any of these clinical parameters 
significantly affect the frequency of Tconv and Treg subsets (Figure 4.4). We performed an 
unsupervised hierarchical clustering of the 34 RA patients based on the frequencies of their 
Tconv and Treg subsets and four clinical parameters; DAS28, seropositivity, smoking status 
and TNF inhibitor (TNFi) use. This analysis clustered patients into three groups, one of 
which consisted 7 out of the 10 RA patients on TNFi therapy (boxed in red). 
 
To explore the effect of TNFi use on the frequencies of the Tconv and Treg subsets 
examined, we categorized patients into two groups, TNFi treated (n=10) and non-TNFi 
treated (n=24). There were no significant differences between TNFi treated and non-TNFi 
treated in age (mean 58 vs 57), DAS28 (mean 3.1 vs 3.0) and methotrexate (MTX) use (70% 
vs 70.8% MTX users). The TNFi treated patients had slightly longer disease duration (mean 
13.3 vs 7.5 years). We performed an automated Kruskal-Wallis test in order to identify the 
significant differences in Tconv and Treg subset frequencies between RA TNFi treated, RA 
non-TNFi treated and controls. This identified eleven subsets that were significantly different 
between these three groups. An unsupervised hierarchical clustering was generated on these 
eleven subsets, again resulting in 7 out of the 10 TNFi treated patients falling into one cluster 
(Figure 4.5A).  
 
Graphs of the eleven subsets identified by the automated Kruskal-Wallis test are presented in 
Figure 4.5, B&C. Effector/memory Tconvs were elevated in the PB of RA patients on TNFi 
therapy when compared to RA patients not on TNFi therapy (mean 45.0% vs 28.6%). In 
Figure 4.2 we showed that the frequency of effector/memory Tregs were decreased in the PB 
of RA patients. This decrease is not evident when comparing TNFi treated with controls 
(mean 62.1% vs 63.9%), suggesting TNFi use normalises effector/memory Treg frequency. 
	  	  
 
Figure 4.4. Unsupervised hierarchical cluster analysis of RA patients based on 
frequencies of Tconv/Treg subsets and clinical parameters results in patients on TNF 
inhibitor therapy to fall closely together. Peripheral blood mononuclear cells from RA 
patients were examined by flow cytometry for the expression of CXCR3, CCR4, CCR5 and 
CCR6 within their Tconv and Treg (CD4+CD127loCD25+) compartment. Data obtained 
from flow cytometric experiments and clinical information recorded at the time the 
peripheral blood specimen was taken is visualised colorimetrically in a heat map. Each row 
represents a Tconv or Treg subset or a clinical parameter; each column represents a 
patient (n=34). Frequencies that are increased relative to the row’s mean are indicated in 
yellow, decreased in blue and frequencies that show no difference are indicated in black. 
Unsupervised hierarchical clustering caused patients to fall into three groups; one 
consisting of 7 out of the 10 RA patients on TNF inhibitor therapy (boxed in red).  
	  
 
 
 
 
Figure 4.5. Frequencies of eleven Tconv and Treg subsets were significantly different between RA patients on TNF inhibitors 
(RA+TNFi), RA patients not on TNF inhibitors (RA) and controls. Peripheral blood mononuclear cells from patients and controls 
were examined by flow cytometry for the expression of CXCR3, CCR4, CCR5 and CCR6 within their Tconv and Treg 
(CD4+CD127loCD25+) compartment. (A) An automated Kruskal-Wallis test indicated that eleven subsets displayed significantly 
different frequencies between RA+TNFi (n=10), RA (n=24) and controls (n=34) (p<0.05). These eleven subsets were used for an 
unsupervised hierarchical clustering where subjects are organized based on the overall similarity in expression patterns. One cluster 
consists of 7 out of the 10 RA patients on TNF inhibitor therapy (boxed in red). Data is visualised here in a heat map where each 
row represents a Tconv or Treg subset; each column a patient or control. Frequencies that are increased relative to the row’s mean 
are indicated in yellow, decreased in blue and frequencies that show no difference are indicated in black. The eleven Tconv (B) and 
Treg (C) subsets selected by statistical analysis to be significantly different between the three groups displayed as bar graphs. Each 
point represents an individual subject and horizontal lines represent means. The Kruskal-Wallis test was used to compare 
differences between RA+TNFi, RA and controls. * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. 
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This trend was also true for CCR4+ and CCR6+ effector/memory Tregs, where no significant 
differences between TNFi treated patients and controls were evident, whereas non-TNFi 
treated patients had significantly reduced frequency of these subsets when compared to 
controls (Figure 4.5C). This trend was not evident for CXCR3 and CCR5 expressing 
effector/memory Tregs, where both TNFi treated and non- TNFi treated patients showed 
significantly decreased frequency when compared to controls. Interestingly, we found a 
significantly reduced frequency of CXCR3+ naïve Tregs in the PB of RA patients on TNFi 
therapy when compared to controls (mean 4.8% vs 8.6%). This trend was not seen in RA 
patients not on TNFi therapy. 
 
4.4  Discussion 
 
There has been a degree of confusion regarding the level of Tregs in the PB of RA patients 
[65, 194-199]. This is in part due to the fact that Tregs were originally identified as CD25high 
[60], making it difficult to determine the precise demarcation between CD25high and 
CD25+/intermediate. We have previously shown that human Tregs can be accurately identified as 
CD4+CD25+CD127lo [61]. We set out to use this definition to analyse the total frequency of 
Tregs, as well as that of various subsets of effector/memory and naïve Tregs that express the 
chemokine receptors CXCR3, CCR4, CCR5 and CCR6, in the peripheral blood of patients 
with RA (Figure 4.1).  
 
We report that the total frequency of CD4+CD25+CD127lo Tregs in RA PB is unchanged 
when compared to controls. However RA patients display significantly reduced frequency of 
effector/memory Tregs in their PB (Figure 4.2). Two other studies have used the low 
expression of CD127 in combination with CD25 to examine Treg levels in RA [203, 204]. 
One of these studies also reported no difference in the CD25+CD127- Treg frequency when 
comparing patients and controls, but demonstrated that RA Tregs displayed impaired 
suppressive function [203]. The other study reported that CD25hiCD127low/- Tregs were 
decreased in RA PB, particularly in active RA [204]. However on close examination of the 
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flow cytometric gating strategy used in that study, it is clear that CD25hi cells were first 
selected and then examined for low CD127 expression, therefore excluding a significant 
proportion of CD25+CD127lo Tregs from analysis. Interestingly, the CD25hiCD127low/- Tregs 
this study described may be representative of effector/memory Tregs, as it is known that 
activated Tregs display higher expression of CD25 [54, 131]. Then this study is consistent 
with our finding that effector/memory Tregs are reduced in RA PB. 
 
A number of studies have used FoxP3 expression to identify Tregs in RA. Our results are 
consistent with one group that found CD45RA-FoxP3hi activated/effector Tregs to be reduced 
in the PB of RA [205]. Total CD25highFoxP3+ cells have also been reported to be reduced in 
RA PB, but in this report CD25high cells were first selected and then examined for Foxp3 
expression, again eliminating a large proportion of Tregs [206]. Levels of CD4+FoxP3+ cells 
have been reported by one group to be unchanged in the PB of RA, although the average 
frequency of these CD4+FoxP3+ cells was 1.7% in controls and 1.9% in RA, indicating that 
the majority of Tregs were again missing from analysis [207]. It is clear that there is a critical 
need to standardize methods for Treg identification in the study of RA, allowing for 
comparisons across studies and for broader conclusions to be made. 
 
CD4+ conventional T cells (Tconvs) make up a large proportion of the inflammatory cells 
within the RA joint and contribute significantly to the inflammation [188]. CD25+CD127lo 
Tregs have also been shown to be enriched in the synovial fluid (SF) of RA patients [202], 
although difficulty in accessing control SF makes it hard to draw conclusions on whether the 
Tconv to Treg ratio is altered in RA. PB, on the other hand, is accessible to analysis and the 
detection of CR expression by blood Tconv and Treg subsets in RA patients may provide 
insights into the number of Tconvs and Tregs that migrate into joints. The co-localisation of 
Tregs with Tconvs in tissues has been shown to be crucial to their role in regulating immune 
responses [112, 113, 118]. It has been demonstrated that CXCR3+ Tregs migrate to sites of 
Th1 mediated inflammation whereas CXCR3 deficient Tregs fail to localise and control this 
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type of inflammation [112]. Furthermore, CCR6 deficient Tregs fail to enter sites of Th17 
mediated inflammation resulting in dysregulated Th17 responses [118].  
 
Despite the known importance of Treg homing, the chemokine receptor expression by Tregs 
in the PB or joints of RA patients has not been examined. We hypothesised that a reduced 
frequency of Tregs expressing certain chemokine receptors may result in less Treg entry into 
the joint prior to ongoing inflammation, consequently leading to the initiation and 
progression of a chronically dysregulated immune response. We found a significantly 
reduced frequency of effector/memory Tregs expressing all the chemokine receptors 
examined (CXCR3, CCR4, CCR5 and CCR6) in the PB of RA patients. We also found that a 
smaller proportion of effector/memory Tconvs in RA PB expressed CXCR3 and CCR5 
(Figure 4.2). This could indicate an initial, primary trafficking deficiency resulting in fewer 
total CD4+ cells entering the joints, with the consequence of disrupted homeostasis. It has 
been shown that co-culturing synovial tissue cultures from RA patients with CD4+ cells 
(containing Tregs) results in reduced IFN-γ production [208]. This regulatory effect was 
more pronounced when CD4+ cells were enriched for CD4+CD25+ Tregs were used. It is 
therefore possible that, under normal conditions, mixtures of Tconvs and Tregs enter the joint 
to prevent uncontrolled inflammation and that a homing deficiency on these cells could result 
in disrupted homeostasis and inflammation.  
 
T cells infiltrating the joint have been shown to predominantly express the chemokine 
receptors CXCR3 and CCR5 whereas CCR4 and CCR6 are largely absent [209-214]. 
Interestingly, CXCR3 and CCR5 are the receptors that showed the most marked decrease in 
the PB of RA patients. Thus it could be argued that a reduction in CD4+ cells expressing 
these receptors in the blood could be due to the accumulation of these cells in the joint. This 
hypothesis would indicate a strong negative correlation between PB CXCR3+ and CCR5+ 
Tregs and disease activity. However, in our analysis, none of the frequencies of 
effector/memory Treg subsets that express CXCR3, CCR4, CCR5 and CCR6 correlated with 
disease activity scores calculated based on 28 joints (Figure 4.3). If the reduction of these 
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Tregs in the blood was due to an accumulation in the joint, higher joint inflammation scores 
should correspond to fewer effector/memory cells within these subsets in the blood. 
 
Furthermore, studies in mice have shown that during the later stage of an immune response, 
disease specific CD4+ T cells equilibrate with the circulation [215, 216], thus suggesting that 
the measurement of CD4+ T cell subsets in the blood can provide a relevant correlate of 
chronic immune responses in the joint. In a murine melanoma model developed in our lab to 
study the effects of tumour-specific CD4+ T cells on tumour control, it was demonstrated that 
CD4+ T cells in the blood, lymph nodes, spleen and within the tumours were in equilibrium 
by day 40 of the response [215]. Additionally, another study in mice investigating the 
dynamics associated with T-cell localisation following infection of the skin by herpes 
simplex virus has shown that as the response enters the memory phase, virus specific 
memory CD4+ T cells within the dermis are largely in equilibrium with the circulation [216].  
 
The importance of chemokine receptor driven cell recruitment in inflammatory disease has 
led to the development of drugs targeting these receptors. However clinical trials have not 
yielded promising results [217, 218]. This could be due to a large gap in our understanding of 
the importance of Treg homing to these sites and the finely tuned Tconv to Treg balance 
required to maintain immune homeostasis.  
 
TNF-α is a key cytokine involved in RA joint inflammation and its blockade has proven to 
be an effective treatment [219]. Although TNF-α-inhibitors have a moderate to high (60%) 
rate of drug continuance due to sustained low disease activity and improved quality of life, 
inefficacy remains the main cause of discontinuation [220, 221]. The mechanism underlying 
the effectiveness of TNF-α blockade is not completely understood, consequently hindering 
our ability to select patients who will effectively respond to treatment. 
 
TNF-α-inhibitors have been shown to reduce inflammatory cell migration into the RA joint 
[222]. It has been suggested that an increase in CD4 T cells expressing CXCR3 in the PB of 
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RA patients following TNF-α-inhibitor therapy is a result of reduced infiltration of CXCR3+ 
cells into the joint [223, 224]. We showed a significant increase of total effector/memory T 
cells in the PB of patients on TNF-α-inhibitors when compared to patients not on TNF-α-
inhibitors (Figure 4.5). We also saw a trend towards increased CXCR3+ CD4 T cells, but this 
did not reach statistical significance. It is possible that this is due to altered lymphocyte 
trafficking as a result of therapy, causing cells to accumulate in the blood.  
 
Recent evidence suggests that TNF-α-inhibitors are able to normalise Treg cell function and 
induce an increase in distinct populations of Tregs in patients with RA [197, 206, 225-227]. 
The first of these studies demonstrated that CD4+CD25+ “Treg” cells isolated from patients 
with RA were unable to suppress pro-inflammatory cytokine secretion and that this effect 
could be reversed with anti-TNF-α treatment [197]. It has also been reported that Tregs from 
patients responding to adalimumab, a TNF-α-inhibitor, were able to inhibit IL-17 production 
in vitro whereas Tregs from non-TNF-α-inhibitor treated patients could not [226]. One study 
attributed impaired Treg cell function in RA to TNF-α in the inflamed joint inducing FoxP3 
dephosphorylation. In this study, Treg function was again shown to be restored by treatment 
of patients with TNF-α -inhibitors [227].  
 
The levels of total CD4+FoxP3+ Tregs in the PB of patients have been shown to be unaffected 
by TNF-α-inhibitor therapy [228, 229]. However, subsets of CD4+FoxP3+CD62L- Tregs have 
been shown to be increased in the PB of patients on anti-TNF-α therapy [225]. We also 
showed the levels of total Tregs to be unaffected, but we showed that treatment with TNF-α-
inhibitors was associated with normalisation of the numbers of effector/memory Tregs and 
effector/memory Tregs expressing the chemokine receptors CCR4 and CCR6 (Figure 4.5). 
Ours is the first study to look at the effect of TNF-α-inhibitor therapy on the chemokine 
receptor expression of Tregs in RA.  
 
A high degree of heterogeneity has been recognised in RA, making it a suitable condition for 
the application of personalised medicine. The identification of biomarkers that can guide 
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diagnosis, prognosis and treatment selection will have many benefits at the individual and 
societal level. High throughput genomic and transcriptomic technologies are increasingly 
being applied to clinical samples in RA in hope of identifying signatures that can predict and 
improve outcome. However, no one has yet applied bioinformatic analysis tools to flow 
cytometric data. Flow cytometry involves the rapid quantification of multiple parameters for 
millions of cells. The manual analysis of cell subset data derived from such high-throughput 
experiments is extremely time consuming, particularly when determining correlations 
between multiple cell subsets in multiple subject groups. For this reason, there is a need for 
more efficient data viewing and analysis methods. We used bioinformatic tools to analyse 
flow cytometry data obtained in our study. Automated clustering allowed us to identify nine 
cell subsets that in combination were able to differentially cluster RA patients and controls 
(Figure 4.2).  
 
In order to find a signature that can predict clinical outcome, it is important to be able to 
combine experimental data with clinical measures, again highlighting the significant role 
bioinformatic analysis can play in the identification of relevant clinical correlations. When 
we combined clinical measures into our analysis, we found that patients on anti-TNF-α 
therapy clustered together (Figure 4.4).  
 
Although anti-TNF-α therapies are among the most effective, they have serious potential 
adverse effects and not all patients respond [230]. Despite this, we still do not have ways to 
select patients for anti-TNF-α treatment. It is important to ask whether the patients on anti-
TNF-α therapy in our study clustered together due to the effects of treatment or because they 
had different subset frequencies to begin with, highlighting the possibility of identifying 
patients suited to anti-TNF-α therapy before they are trialled on other non-effective 
treatment. This highlights the power of bioinformatic tools for identifying predictive 
signatures in data obtained from flow cytometry. This type of information will be obtained in 
future experiments with longitudinal studies in which pre and post anti-TNF-α treatment 
samples are compared.  
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In RA, selecting the most effective treatment is currently a case of trial and error. Therefore, 
finding factors that can identify preclinical RA or select patients for treatment are crucial. We 
hope our methods of analysis will help the many groups that use flow cytometry to monitor 
cell subsets in RA patients, allowing them to retrieve the most out of their data. It is also 
crucial to study the effects other therapies, such as methotrexate and corticosteroids, have on 
Treg subsets in RA patients. Future studies need to take this into account and recruit larger 
well-defined patient cohorts including patients that are treatment naïve.  
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CHAPTER 5:  EXPRESSION OF TRAFFICKING RECEPTORS 
BY REGULATORY T CELLS IN PSORIASIS 
 
5.1  Introduction 
 
CD4+CD25+FoxP3+ regulatory T cells (Tregs) are crucial in preventing autoimmune 
responses. This role was first demonstrated in mice when it was shown that the transfer of 
CD4+ T cells depleted of CD25-expressing cells into immuno-deficient mice caused the 
development of a number of organ-specific autoimmune diseases [1]. In this model, the co-
transfer of CD4+CD25+ cells prevented autoimmune disease in a dose-dependent fashion. In 
humans, a dysfunctional FoxP3 gene causes multi-organ autoimmunity 
(immunodysregulation, polyendocrinopathy, enteropathy X-linked (IPEX) syndrome) [62], 
signalling that Tregs are essential for suppressing autoimmune responses. However, a 
complete dysfunction of Tregs is not evident in most human autoimmune diseases and it is 
thought that minor deficiencies in Treg frequency, function and development may predispose 
individuals for disease. 
 
Psoriasis is a chronic autoimmune skin disease of unknown etiology characterised by the 
formation of well demarcated raised skin lesions containing hyperproliferative keratinocytes 
and a dense lymphocytic infiltrate [231]. The disease affects ~2% of the world’s population 
[232] and leads to a significant impairment in the quality of life in patients due to social 
stigmatisation, pain, physical disability and psychological distress [233]. In the past, psoriasis 
was believed to be caused by an accelerated turnover of keratinocytes, but various studies 
have since established an immunological basis for the disease. As early as 1979, histological 
studies showed that the earliest events in the pathogenesis involved the dilation of blood 
vessels in the dermis followed by the appearance of a mononuclear cell infiltrate [234]. This 
mononuclear cell infiltrate was later shown to consist mainly of T cells [235, 236], 
predominantly CD4+ T cells [237].  
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Given the presence of a dense T cell infiltrate, it is plausible to hypothesise that impaired 
development and function of Tregs might be involved in the pathogenesis of the disease, 
resulting in deregulated T-cell mediated immune responses and disrupted skin homeostasis. 
We have shown that a large proportion of Tregs in healthy humans express CLA (Figure 
3.4), an adhesion molecule that allows migration into the skin. This suggests that Tregs may 
be involved in maintaining skin homeostasis, even in the absence of ongoing inflammation.   
 
There is conflicting evidence on the frequency and function of Tregs in psoriasis. Because 
human Tregs were originally identified as CD25high [60], it was difficult to distinguish Tregs 
from CD25+ conventional T cells. For this reason, some studies have shown that Tregs 
comprise similar proportions of CD4+ T cells in psoriatic and normal blood [238-240], while 
others have reported Tregs to be reduced [65, 241] and others increased [242]. In one study, 
it was found that psoriatic patients had dysfunctional blood and target tissue CD4+CD25hi cell 
activity [238].  CD4+CD25hi cells taken from these patients were functionally deficient in 
suppressing effector T cell responses in vitro, although this deficiency was not found to be 
absolute, with higher numbers of these CD4+CD25hi “Treg” cells providing similar 
suppression to normal cells.  
 
Nevertheless, numerous studies have consistently shown Tregs to be enriched in psoriatic 
skin lesions [242-250]. In order to enter peripheral tissues, Tregs express a range of integrins 
and chemokine receptors (CR) that have been shown to be essential to their role in regulating 
inflammation [81, 90-92]. Recent evidence also suggests that distinct CR expression patterns 
may contribute to selective trafficking and compartmentalisation of Tregs at sites where 
regulation is required [112, 113, 118].  Despite these findings, the expression of adhesion 
molecules and CRs by Tregs in the PB or skin of psoriasis patients has not been examined.  
 
We have previously shown that low surface expression of CD127, the α chain of the IL-7 
receptor, in combination with CD25 can distinguish CD25+CD127lo Tregs from conventional 
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CD4+ T cells (Tconvs) in human PB [61]. In the current study, we used 11 and 13-colour 
flow cytometry to analyse the levels of nine chemokine receptors and integrins (β7, CD49d, 
CLA, CCR4, CCR10, CCR5, CD62L, CXCR3 and CCR6) on conventional T cells and 
CD25+CD127lo Tregs in the PB of psoriasis patients. Since psoriasis has been shown to 
involve both Th1 and Th17 type immune processes [251, 252], we also examined the levels 
of T-bet+ Th1 and RORγt+ Th17 type cells in the PB of patients and controls.  
 
We hypothesised that the trafficking and localisation of Tregs is crucial to their function in 
regulating inflammation in human skin and postulate that an understanding of Treg 
trafficking in psoriasis could contribute to the characterisation of disease subsets and the 
development of more targeted Treg-therapy.  
 
5.2  Summary of methods 
 
5.2.1  Patients 
 
Peripheral blood samples were obtained from patients treated by Professor Wolfgang 
Weninger and Dr Patricia Lowe at the Dermatology Centre of Royal Prince Alfred Hospital 
in Gloucester House (Camperdown, NSW, Australia). Psoriasis was diagnosed based on 
clinical presentation. Psoriatic arthritis was diagnosed using the Classification Criteria for 
Psoriatic Arthritis (CASPAR) [253]. Specimens were collected from 44 patients with chronic 
psoriasis (77% male, average age 47.6 years) and 44 sex and age matched controls (77% 
male, average age 49.1 years). Clinical information including disease duration, disease 
activity as assessed by the psoriasis area severity index (PASI), and treatment were recorded 
at the time of blood collection.  
 
All patients and controls gave written, informed consent and the study was approved by the 
Sydney Local Health District ethics review committee at Royal Prince Alfred Hospital, 
Camperdown.  
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5.2.2  Cell isolation  
 
Peripheral blood mononuclear cells (PBMC) were isolated from heparinised venous blood by 
density gradient centrifugation using Ficoll-Paque Plus (GE Healthcare). The isolated 
mononuclear cells were stored in 1 ml aliquots at -180oC in LNO2 (detailed in Chapter 2, 
section 2.3). 
 
5.2.3  Flow cytometric analysis 
 
Cells were thawed in batches and immuno-stained with two optimised 11 and 13- colour flow 
cytometric panels (Table 2.2, Figures 2.10 & 2.11). Details of the monoclonal antibodies 
used are listed in Table 2.1 and staining procedure is described in Chapter 2, section 2.4. 
Data were acquired on a LSRII 10-laser flow cytometer (BD) and analysed using FlowJo 
software (Tree Star). A general gating strategy was employed for the analysis of all flow data 
(Figure 2.1, described in Chapter 2, section 2.4.6).  
 
A batch of blood samples from psoriasis patients and their matched controls were thawed on 
each day to avoid any possible discrepancy in comparing patients and controls due to flow 
cytometer instability. PBMCs from a single control, not included in the study, were included 
in each run to allow monitoring of flow cytometer stability and to standardise cytometer 
performance.  
 
5.2.4  Statistical analysis 
 
Statistical analysis was performed using MultiExperiment Viewer (MeV) (TM4–Microarray 
Software Suite). Data was loaded into MeV in .txt format and heatmaps were generated. 
Differences between patients and controls were evaluated using an automated Mann-Whitney 
t-test. An automated Kruskal-Wallis test was used to identify significant differences between 
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three or more subject groups. P values less than 0.05 were considered significant. 
Unsupervised cluster analysis was performed using the hierarchical clustering (HCL) 
algorithm.  
 
We also used Graph Pad Prism 6 for analysis. Group means were compared using the Mann-
Whitney t-test or the Kruskal-Wallis test. Correlations were determined using the Spearman 
correlation test. P values less than 0.05 were considered significant. 
 
5.3  Results 
 
5.3.1  Trafficking receptor expression by conventional and regulatory T cells in the 
peripheral blood of patients with psoriasis and healthy controls. 
 
We analysed integrin and chemokine receptor (CR) expression by conventional T cells 
(Tconvs) and regulatory T cells (Tregs) in the peripheral blood (PB) of 44 psoriasis patients 
and 44 age and sex matched controls. Demographic and clinical information for the patients 
are provided in Table 5.1.  
 
We have previously shown that the expression of CD127, the α-chain of the interleukin-7 
receptor, along with CD25 allows for the identification of CD25+CD127lo Tregs within CD4+ 
T cells in human PB [61]. In this study, we developed 11 and 13-colour flow cytometry 
panels to investigate the proportion of cells expressing nine chemokine receptors and 
integrins (β7, CD49d, CLA, CCR4, CCR10, CCR5, CD62L, CXCR3 and CCR6) within 
circulating Tconvs and Tregs with the aim of providing an indication of their likelihood of 
entering tissues. 
 
Representative histograms showing expression of these chemokine receptors on Tregs and 
Tconvs can be seen in Figure 5.1. Tregs were defined as CD25+CD127lo (Figure 5.1A) and 
Tconvs as CD4+ T cells outside this gate. Figure 5.1C shows the correlation between the 
Table 5.1 Clinical characteristics of psoriasis patients included in study 
 
Characteristic Patients (n=44) 
Age, median (range), years 46.5 (22-78) 
% Male 77 
Disease duration, median (range), years 20 (3-45) 
% Psoriasis + psoriatic arthritis 27 
Disease activity (PASI), mean ± SD 7.8 ± 7.8 
% Methotrexate users 25 
% TNFi (Infliximab) users 36 
% Untreated (includes topical only)  45 
PASI = Psoriasis Area Severity Index; TNFi = Tumour necrosis factor 
inhibitor 	  	  	  
	  
  
Figure 5.1: Expression of chemokine receptors and integrins by conventional T cells 
(Tconvs) and regulatory T cells (Tregs) in the peripheral blood of patients and 
controls. Mononuclear cells were isolated as described and examined by flow cytometry 
for the expression of markers that allowed for the identification of Tregs, defined as 
CD4+CD127loCD25+ (A), and Tconvs, defined as everything outside the indicated Treg 
gate. (B) Tregs and Tconvs were next subdivided on the basis of CD45RO expression in 
order to identify CD45RO+ (effector/memory) and CD45RO- (naïve) subsets, and analysed 
for the various chemokine receptors and integrins examined (β7, CD49d, CLA, CCR4, 
CCR10, CCR5, CD62L, CXCR3 and CCR6). Numbers indicate cells within the gate as a 
percentage of the parent population.	   (C) Correlation between the frequencies of CD4+ 
Tregs identified by gating for CD127loCD25+ versus CD127loFOXP3+ in 44 psoriasis 
patients. The correlation was statistically evaluated using a non-parametric Spearman test 
(****). 	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percentage of Tregs identified as CD25+CD127lo and FOXP3+CD127lo in the 44 psoriasis 
patients studied. The frequency of Tregs within the two gates in each individual was very 
highly correlated.  
 
Because the ability to enter non-lymphoid tissues is closely correlated with post-thymic 
differentiation in response to antigen, expression of integrins and chemokine receptors was 
examined along with CD45RO, an effector/memory marker, on both Tconvs (Figure 5.1B, 
left panel) and Tregs (Figure 5.1B, right panel). Effector/memory (CD45RO+) Tconvs and 
Tregs expressing the integrin or chemokine receptor of interest, calculated as a percent total 
CD45RO+ Tconvs/Tregs, appear in the upper right gate of each panel and naïve (CD45RO-) 
Tconvs and Tregs expressing the integrin or chemokine receptor of interest, calculated as a 
percent total CD45RO- Tconvs/Tregs, in the upper left gate. These subsets were quantified 
for all 88 patients and controls and used for further analysis.  
 
5.3.2  Levels of conventional and regulatory T cell subsets in the peripheral blood of 
psoriasis patients and healthy controls. 
 
We used a bioinformatic analysis software, MeV, to draw simultaneous, automated 
comparisons between multiple Tconv and Treg subset data obtained from flow cytometry. 
Data were uploaded into the software and a heat map was subsequently generated (Figure 
5.2A), providing a simple way to simultaneously visualize the data. Each column represents a 
psoriasis patient (left) or control (right) and each row a Tconv or Treg subset, gated as 
indicated in Figure 5.1.  
 
Once data is loaded into MeV and a heatmap is generated, various statistical and clustering 
tools can be applied to allow for the identification of significant similarities and differences 
between subject groups. We next performed an automated t-test to identify the significant 
differences in Tconv and Treg subset frequencies between psoriasis patients and controls. 
This identified ten subsets that were significantly different between patients and controls; all 
	  	  	  
	  
Figure 5.2. Decreased expression of trafficking receptors on Tregs in the peripheral blood of psoriasis (PSO) patients (n=44) 
when compared with healthy controls (n=44). Peripheral blood mononuclear cells from patients and controls were examined by flow 
cytometry for the expression of β7, CD49d, CLA, CD62L, CCR4, CCR5, CCR6, CCR10 and CXCR3 within their Tconv and Treg 
(CD4+CD127loCD25+) compartment. (A) Data obtained from flow cytometric experiments is visualised colorimetrically in a heat map. 
Each row represents a Tconv or Treg subset; each column a patient or control. Frequencies that are increased relative to the row’s 
mean are indicated in yellow, decreased in blue and frequencies that show no difference are indicated in black. (B) An automated 
Mann-Whitney t-test indicated that ten subsets displayed significantly different frequencies between patients and controls (p<0.05), 
shown here in a heat map. All ten of these subsets were found to be significantly decreased in PSO patients. The ten Tconv (C) and 
Treg (D) subsets displayed as bar graphs. Each point represents an individual subject and horizontal lines represent means. The 
Mann-Whitney t-test was used to compare differences between patients and controls. * = p < 0.05, ** = p < 0.01, **** = p < 0.0001. 	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were decreased in psoriasis, as shown in the heat map in Figure 5.2B. Four of these subsets 
were within the Tconv compartment and six were within Tregs.  
 
Figure 5.2C & D illustrates the ten subsets identified by MeV in a more traditional format. 
CXCR3+ and CLA+ effector/memory Tconvs were decreased in the PB of psoriasis patients 
when compared to controls (means 37% vs 47%, and 18% vs 22%). Furthermore, CD62L+ 
and β7+ naïve Tconvs were decreased in the PB of psoriasis patients when compared to 
controls (means 67% vs 78%, and 78% vs 82%) (Figure 5.2C). Within the effector/memory 
Treg compartment, frequencies of CXCR3+, CCR6+, CCR5+ and CCR4+ Tregs were 
significantly reduced in patients with psoriasis (Figure 5.2D) (CXCR3+; mean 24% vs 34%, 
CCR6+; mean 56% vs 64%, CCR5+; mean 27% vs 31%, CCR4+; mean 90% vs 93%). 
Additionally, CXCR3+ and β7+ naïve Tregs were significantly decreased in psoriasis patients 
(mean 9% vs 11%, and 33% vs 39%) (Figure 5.2D).  
 
None of the Tconv and Treg subset percentages analysed correlated with disease activity 
score (PASI) or disease duration for the psoriasis patients (data not shown).  
 
5.3.3  Levels of conventional and regulatory T cell subsets in the peripheral blood of 
untreated psoriasis patients, treated psoriasis patients and healthy controls. 
 
In order to determine whether treatment contributed to differences between psoriasis patients 
and controls, patients were divided into untreated (n=20, includes patients using topical 
therapy) and treated (n=24) groups. There were no significant differences between untreated 
and treated patients in age (mean 45 vs 50 years) and disease duration (18 vs 23 years). 
However the treated patients had a significantly lower disease activity score as measured by 
PASI (mean 4 vs 12). An automated Kruskal-Wallis test was subsequently performed in 
MeV in order to identify the significant differences in Tconv and Treg subset frequencies 
between untreated psoriasis patients, treated psoriasis patients and controls. This identified 
nine subsets that were significantly different between the three groups (Figure 5.3A).  
	  
 
 
 
 
Figure 5.3: Frequencies of nine Tconv and Treg subsets were significantly different between untreated PSO patients, 
treated PSO patients and controls. Peripheral blood mononuclear cells from patients and controls were examined by flow 
cytometry for the expression of β7, CD49d, CLA, CD62L, CCR4, CCR5, CCR6, CCR10 and CXCR3 within their Tconv and Treg 
(CD4+CD127loCD25+) compartment. (A) An automated Kruskal-Wallis test indicated that nine subsets displayed significantly 
different frequencies between untreated PSO patients (n=20), treated PSO patients (n=24) and controls (n=44) (p<0.05). Data is 
visualised here in a heat map where each row represents a Tconv or Treg subset; each column a patient or control. Frequencies 
that are increased relative to the row’s mean are indicated in yellow, decreased in blue and frequencies that show no difference are 
indicated in black. The nine Tconv (B) and Treg (C) subsets selected by statistical analysis to be significantly different between the 
three groups displayed as bar graphs. Each point represents an individual subject and horizontal lines represent means. The 
Kruskal-Wallis test was used to compare differences between groups. * = p < 0.05, ** = p < 0.01, *** = p < 0.001. 
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Data for the nine subsets identified by MeV are presented in Figure 5.3, B&C. In regards to 
the Tconv compartment, all four subsets that were decreased in the psoriasis group as a 
whole were found to be significantly different amongst the three groups (Figure 5.3B). 
Interestingly, the decrease in two of these subsets, the CXCR3+ and CLA+ effector/memory 
Tconvs, was entirely due to a decrease in the treated psoriasis patient group. CXCR3+ 
effector/memory Tconvs were significantly reduced in the treated psoriasis group when 
compared to controls (means 34% vs 47%) while no difference was seen in the untreated 
group. CLA+ effector/memory Tconvs were also significantly reduced only in the treated 
psoriasis group when compared to controls (mean 16% vs 22%). On the other hand, CD62L+ 
naïve Tconvs were significantly decreased in the PB of both untreated and treated psoriasis 
patients. β7+ naïve Tconvs were also slightly decreased in both untreated and treated patients. 
 
Interestingly, we found that the number of total Tregs is significantly increased in the PB of 
untreated psoriasis patients when compared to treated psoriasis patients (mean 11.4% vs 
7.7% of CD4+ cells) (Figure 5.3C). In Figure 5.2, we showed that the levels of CXCR3+ and 
CCR6+ effector/memory Tregs were significantly reduced in the PB of patients. This 
decrease was evident in both treated and untreated patients. On the other hand, β7+ and 
CD49d+ naïve Tregs are significantly decreased only in untreated psoriasis patients (means 
30% vs 39% and 14% vs 20%) (Figure 5.3C).  
 
5.3.4  Unsupervised hierarchical cluster analysis of patients based on frequencies of 
Tconv and Treg subsets and clinical parameters. 
 
We next wished to determine whether incorporating clinical parameters into analysis of flow-
based data from psoriasis patients would give us further insights into whether any of these 
clinical parameters significantly affected the frequency of Tconv and Treg subsets (Figure 
5.4). We performed an unsupervised hierarchical clustering of the 44 patients based on the 
frequencies of their Tconv and Treg subsets and five clinical parameters; PASI, presence of 
	  
	  
Figure 5.4: Unsupervised hierarchical cluster analysis of PSO patients based on 
frequencies of Tconv and Treg subsets and clinical parameters results in patients 
on TNF inhibitor therapy to cluster together. Data obtained from flow cytometric 
experiments and clinical information recorded at the time the peripheral blood sample was 
taken is visualised colorimetrically in a heat map. Each row represents a Tconv/Treg 
subset or a clinical parameter; each column represents a patient (n=44). Frequencies that 
are increased relative to the row’s mean are indicated in yellow, decreased in blue and 
frequencies that show no difference are indicated in black. Unsupervised hierarchical 
clustering caused patients to fall into three groups; one consisting of 11 out of the 16 PSO 
patients on TNF inhibitor therapy (boxed in red).  
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arthritis, disease duration, TNF inhibitor (TNFi) use (n=16) and methotrexate (MTX) use 
(n=11). This resulted in patients clustering into three groups; one consisting of 11 out of the 
16 psoriasis patients on TNFi therapy (boxed in red). 
 
5.3.5  Levels of conventional and regulatory T cell subsets in the peripheral blood of 
psoriasis patients on TNF inhibitor therapy.  
 
To investigate the effect of TNFi use on the frequencies of the Tconv and Treg subsets 
examined, we categorized patients into two groups, TNFi users (n=16) and non-TNFi users 
(n=28). There were no significant differences between TNFi users and non-TNFi users in age 
(mean 47 vs 48 years), disease duration (24 vs 19 years) and methotrexate (MTX) use (25% 
MTX users in both groups). However the TNFi users had a significantly lower disease 
activity score as measured by PASI (mean 2 vs 11, p=0.0003). We performed an automated 
Kruskal-Wallis test in order to identify the significant differences in Tconv and Treg subset 
frequencies between psoriasis TNFi users, psoriasis non-TNFi users and controls. This 
identified ten subsets that were shown to be significantly different between these three 
groups, displayed in a heatmap in Figure 5.5A.  
 
Traditional graphs of the ten subsets identified by the automated Kruskal-Wallis test are 
presented in Figure 5.5, B&C. Although we previously showed that CXCR3+ 
effector/memory Tconvs were significantly reduced only in treated psoriasis patients (Figure 
5.3B), this decrease was not due to TNFi use (Figure 5.5B). Patients not on TNFi therapy 
displayed reduced levels of CXCR3+ effector/memory Tconvs when compared to controls 
(mean 35% vs 47%) while TNFi users were not significantly different from controls. 
Interestingly, TNFi therapy appears to have a significant effect on subsets in the naïve Tconv 
compartment.  CCR6+ naïve Tconvs were significantly increased in TNFi users when 
compared to non-TNFi users (mean 2.2% vs 1.7%). Furthermore, CD62L+ and β7+ naïve 
Tconvs are significantly reduced only in non-TNFi users when compared to controls.  
 
	  
 
 
 
 
 
Figure 5.5: Frequencies of ten Tconv and Treg subsets were significantly different between PSO patients on TNF inhibitors 
(PSO+TNFi), PSO patients not on TNF inhibitors (PSO) and controls. Peripheral blood mononuclear cells from patients and 
controls were examined by flow cytometry for the expression of β7, CD49d, CLA, CD62L, CCR4, CCR5, CCR6, CCR10 and CXCR3 
within their Tconv and Treg (CD4+CD127loCD25+) compartment. (A) An automated Kruskal-Wallis test indicated that ten subsets 
displayed significantly different frequencies between PSO+TNFi (n=16), PSO (n=28) and controls (n=44) (p<0.05). Data is 
visualised here in a heat map where each row represents a Tconv or Treg subset; each column a patient or control. Frequencies 
that are increased relative to the row’s mean are indicated in yellow, decreased in blue and frequencies that show no difference are 
indicated in black. The ten Tconv (B) and Treg (C) subsets selected by statistical analysis to be significantly different between the 
three groups displayed as bar graphs. Each point represents an individual subject and horizontal lines represent means. The 
Kruskal-Wallis test was used to compare differences between groups. * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001.  
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In Figure 5.2 we showed that levels of CXCR3+, CCR4+ and CCR6+ effector/memory Tregs 
and β7+ naïve Tregs were decreased in the PB of psoriasis patients. Here we showed that this 
decrease was not evident in TNFi users, whereas non-TNFi users had significantly reduced 
levels of all these subsets when compared to controls (Figure 5.5C). In addition, patients on 
TNFi therapy had significantly increased levels of CCR6+ effector/memory and naive Tregs 
when compared to patients not on TNFi therapy (mean 65% vs 51% and 11% vs 8%). 
Furthermore, patients on TNFi therapy had significantly increased levels of β7+ naïve Tregs 
when compared to patients not on TNFi therapy (mean 39% vs 29%). This suggests that 
TNFi use normalises the frequency of Treg subsets expressing CXCR3, CCR4, CCR6 and β7 
in the PB of psoriasis patients.  
 
5.3.5.1  Longitudinal analysis of Tconv and Treg subsets in the peripheral blood of 
psoriasis patients pre and post TNF inhibitor therapy. 
 
An analysis of TNFi treated patients provided only correlative data and cannot be used to 
conclude that the changes seen in the TNFi group are specifically due to treatment. TNF 
inhibitors are used to treat patients after they have failed other therapies, suggesting that this 
group of patients may be inherently different to other patients. In order to answer this 
question, it is important to monitor the effects of anti-TNF on Treg and Tconv subsets pre 
and post treatment. We were able to collect PB samples from seven patients pre and post 
therapy with Infliximab, a TNFi. An overview of the samples collected from these seven 
patients is outlined in Table 5.2. 
 
When examining Tconv subsets, no significant differences were found pre and post therapy 
with a TNFi (Figure 5.6). However it is important to note that it is difficult to achieve 
significance with a small number of patients, of which only four had a complete set of 
samples for each of the 5 time points (Table 5.2). In Figure 5.5 we showed that there was a 
significant increase in CCR6+ naïve Tconvs in TNFi users when compared to non-TNFi 
users. When patients were examined longitudinally, there was a slight increase in the 
Table 5.2 Longitudinal samples from patients pre and post TNFi (Infliximab) 
therapy (n=7) 
 
Week 0 
(pre) 
2 6 15 52+ 
P1      
Samples √ √   √ 
PASI 16.8    4 
P2      
Samples √ √ √ √ √ 
PASI 3    0 
P3      
Samples √ √ √ √ √ 
PASI 3  3  1.2 
P4      
Samples √ √ √ √ √ 
PASI 1.2    0 
P5      
Samples √  √   
PASI 18.6  2   
P6      
Samples √ √ √ √ √ 
PASI 0.3   3 2 
P7      
Samples √ √ √ √  
PASI 3   4.2  
 
PASI = Psoriasis Area Severity Index; TNFi = Tumour necrosis factor 
inhibitor 	  	  	  
	  
 
 
 
 
 
Figure 5.6: Longitudinal analysis of Tconv subsets pre and post TNFi therapy in 
seven PSO patients. Peripheral blood samples were collected from seven patients pre 
(week 0) and post treatment with TNFi Infliximab (Table 5.2) and examined by flow 
cytometry for the expression of trafficking receptors CXCR3, CCR4, CCR6, CLA, CCR5, 
CD62L, Beta-7 and CCR10 within their effector/memory (CD45RO+) and naïve 
(CD45RO-) Tconv compartment. Points represent the group means at each of the time-
points (weeks 0, 2, 6, 15 and 52+). The Kruskal Wallis test was used to identify 
differences between groups. No significant differences were found. Horizontal lines on 
the right hand side represent means (±SEM) from the three groups analysed in Figure 
5.5; PSO (black), PSO+TNFi (red) and Controls (blue).  
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frequency of this subset (mean 1.4% to 1.9%), but this did not reach statistical significance. 
CD62L+ naïve Tconvs were also slightly increased in TNFi treated patients (Figure 5.5). 
Interestingly, when TNFi patients were examined longitudinally, we saw a gradual increase 
in the frequency of CD62L+ cells within the naïve (mean 55% to 80%) and effector/memory 
(mean 30% to 51%) Tconv compartments pre and 52 weeks post treatment (Figure 5.6). 
Once again this change did not reach statistical significance. On the other hand, although we 
found that β7+ naïve Tconvs were significantly reduced only in non-TNFi users when 
compared to controls, TNFi use itself did not increase the frequency of this subset when 
comparing pre and 52 weeks post treatment.  
 
In terms of Tregs, in Figure 5.5 we showed that CXCR3+, CCR4+ and CCR6+ 
effector/memory Tregs and β7+ naïve Tregs were reduced only in patients not on TNFi 
therapy, suggesting that TNFi therapy may increase the frequency of these subsets. We also 
showed that patients on TNFi therapy had significantly increased levels of CCR6+ 
effector/memory and naive Tregs when compared to patients not on TNFi therapy. When 
examined longitudinally, TNFi therapy did not increase the frequency of CXCR3, CCR6 or 
β7 expressing Tregs (Figure 5.7). However, there was a trend towards increased frequency of 
CCR4+ effector/memory Tregs (mean 86% to 91%) following TNFi use, which did not reach 
statistical significance. Interestingly, there was a gradual increase in the percentage of 
CD62L+ effector/memory (mean 46% to 70%) and naïve (mean 29% to 65%) Tregs, similar 
to what we saw in Tconvs. This difference reached statistical significance in naïve Tregs 
when comparing pre TNFi therapy to 52 weeks of therapy, indicating that treatment with a 
TNFi results in increased levels of CD62L+ cells in the PB of psoriasis patients.  
 
5.3.6  Levels of conventional and regulatory T cell subsets in the peripheral blood of 
psoriasis patients treated with methotrexate. 
 
To investigate the effect of methotrexate (MTX) on the frequencies of the Tconv and Treg 
subsets examined, we categorized patients into two groups, MTX users (n=11) and non-MTX 
	  
 
 
Figure 5.7: Longitudinal analysis of Treg subsets pre and post TNFi therapy in 
seven PSO patients. Peripheral blood samples were collected from seven patients pre 
(week 0) and post treatment with TNFi Infliximab (Table 5.2) and examined by flow 
cytometry for the expression of trafficking receptors CXCR3, CCR4, CCR6, CLA, CCR5, 
CD62L, Beta-7 and CCR10 within their effector/memory (CD45RO+) and naïve 
(CD45RO-) Treg compartment. Points represent the group means at each of the time-
points (weeks 0, 2, 6, 15 and 52+). The Kruskal Wallis test was used to identify 
differences between groups. * = p < 0.05. Horizontal lines on the right hand side 
represent means (±SEM) from the three groups analysed in Figure 5.5; PSO (black), 
PSO+TNFi (red) and Controls (blue).  
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users (n=32). There were no major differences between MTX users and non-MTX users in 
age (mean 53 vs 46 years), disease duration (24 vs 19 years), PASI (mean 5.9 vs 8.4) and 
TNF inhibitor use (36% vs 38%). We performed an automated Kruskal-Wallis test in order to 
identify the significant differences in Tconv and Treg subset frequencies between psoriasis 
MTX users, psoriasis non-MTX users and controls. This identified 13 subsets that were 
significantly different between these three groups, displayed in a heatmap in Figure 5.8A.  
 
The data from the 13 subsets identified by the automated Kruskal-Wallis test are presented in 
Figure 5.8, B&C. Psoriasis patients on methotrexate had reduced levels of CXCR3+ and 
CLA+ effector memory Tconvs in their PB when compared to controls (CXCR3; means 27% 
vs 47%, CLA; means 14% vs 22%) (Figure 5.8B). The frequency of total Tregs was also 
significantly reduced in psoriasis patients taking methotrexate when compared to patients not 
taking methotrexate (mean 6.7% vs 10.4%) (Figure 5.8C). In terms of trafficking receptors, 
both groups of patients on methotrexate and not on methotrexate display decreased levels of 
CXCR3+ effector/memory Tregs when compared to controls. However methotrexate use also 
appeared to have a significant effect on the levels of other CRs and adhesion molecules on 
Tregs, with patients on this therapy displaying reduced levels of CCR4+, CCR6+, CLA+ and 
CCR10+ effector/memory Tregs and increased levels of β7+ effector/memory Tregs in their 
PB.   
 
5.3.7  Levels of skin-associated trafficking receptors correlate with total Tregs in the 
blood of psoriasis patients. 
 
We examined the relationship between the levels of skin and gut-associated trafficking 
receptors and total effector/memory Tregs in the PB of 44 psoriasis patients and 44 age and 
sex matched controls (Figure 5.9). In doing so, we found that levels of Tregs expressing the 
skin-associated trafficking receptors CLA, CCR4 and CCR10 positively correlated with total 
effector/memory Tregs in the PB of psoriasis patients but not controls (Figure 5.9A). This 
indicates that while the number of Tregs expressing skin-homing-molecules CLA, CCR4 and 
	  
 
 
 
 
 
Figure 5.8: Frequencies of thirteen Tconv and Treg subsets were significantly different between PSO patients on 
methotrexate therapy (PSO+MTX), PSO patients not on methotrexate (PSO) and controls. Peripheral blood mononuclear cells 
from patients and controls were examined by flow cytometry for the expression of β7, CD49d, CLA, CD62L, CCR4, CCR5, CCR6, 
CCR10 and CXCR3 within their Tconv and Treg (CD4+CD127loCD25+) compartment. (A) An automated Kruskal-Wallis test 
indicated that 13 subsets displayed significantly different frequencies between PSO+MTX (n=11), PSO (n=32) and controls (n=44) 
(p<0.05). Data is visualised here in a heat map where each row represents a Tconv or Treg subset; each column a patient or 
control. Frequencies that are increased relative to the row’s mean are indicated in yellow, decreased in blue and frequencies that 
show no difference are indicated in black. The 13 Tconv (B) and Treg (C) subsets selected by statistical analysis to be significantly 
different between the three groups displayed as bar graphs. Each point represents an individual subject and horizontal lines 
represent means. The Kruskal-Wallis test was used to compare differences between groups. * = p < 0.05, ** = p < 0.01 *** = p < 
0.001.  
 
 
 
	  	  	  	  
 
 
 
Figure 5.9: Levels of Tregs expressing the skin-associated trafficking 
receptors CLA, CCR4 and CCR10 correlate with total Tregs in psoriasis 
patients only. Peripheral blood mononuclear cells from patients and controls were 
examined by flow cytometry for the expression of skin-associated trafficking 
receptors CLA, CCR4 and CCR10 and gut-associated receptors β7 and CD49d on 
their Tregs. (A&B) Relationship between total CD45RO+ Tregs and Treg subsets 
expressing CLA, CCR4 and CCR10 (A) and β7 and CD49d (B). The correlation was 
evaluated using a non-parametric Spearman test.  
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CCR10 does not differ significantly between untreated psoriasis patients and controls 
(Figure 5.3), the proportion of Tregs expressing these molecules increases as total Treg 
frequency increases in patients, suggesting a selective increase in skin-homing and an effort 
to get Tregs into the skin. This relationship was not evident for gut-associated molecules β7 
and CD49d (Figure 5.9B). 
 
5.3.8  Levels of T-bet+ Th1 and RORγt+ Th17 type CD4 T cells in peripheral blood of 
psoriasis patients and controls. 
 
Psoriasis has been shown to involve both Th1 and Th17 type immune processes [251, 252]. 
We wished to examine the levels of T-bet+ Th1 and RORγt+ Th17 type cells in the PB of 
patients and controls. In order to do this, we developed a flow cytometry panel that allowed 
us to identify circulating CD4+ T cells that express T-bet and RORγt without the need for in 
vitro stimulation (Figure 5.10A). Furthermore, we examined CD4+ T cells for the co-
expression of RORγt and FoxP3 and identified a population of RORγt+FoxP3+ cells.  
 
The levels of T-bet+ Th1 type cells, RORγt+ Th17 type cells and RORγt+FoxP3+ cells did not 
differ between patients and controls (Figure 5.10B). Interestingly however, these subsets 
displayed different relationships with age in psoriasis patients and controls (Figure 5.10C). 
T-bet+ Th1 type cells positively correlated with age in controls but not in patients while 
RORγt+ Th17 type cells and RORγt+FoxP3+ cells negatively correlated with age in psoriasis 
patients only. Psoriasis patients had increased levels of RORγt+ Th17 type cells at a younger 
age when compared to controls. No correlations were found between T-bet+ Th1 type cells, 
RORγt+ Th17 type cells or RORγt+FoxP3+ cells and disease duration (data not shown).  
 
We also studied the relationship between the number of T-bet+ Th1 type cells, RORγt+ Th17 
type cells and RORγt+FoxP3+ cells and total effector/memory Tregs in the PB of patients and 
controls (Figure 5.10D). No significant correlations were seen between levels of T-bet+ Th1 
type cells and Tregs in patients or controls. However the level of RORγt+ Th17 type cells 
	  	  
 
 
 
 
 
  
Figure 5.10: Levels of T-bet+ Th1 and RORγt+ Th17 type CD4 T cells in 
peripheral blood of psoriasis patients and controls. Peripheral blood 
mononuclear cells from patients and controls were examined by flow cytometry for 
the expression of T-bet, RORγt and FoxP3. (A) CD4+ T cells are examined for the 
expression of the transcription factors T-bet, RORγt and FoxP3. Three cell 
populations were identified; T-bet+ Th1 cells, RORγt+ Th17 cells and RORγt+FoxP3+ 
cells. (B) Percentages of T-bet+ Th1 cells, RORγt+ Th17 cells and RORγt+FoxP3+ 
cells within CD4+ cells in psoriasis patients (n=44) and controls (n=44). Each point 
represents an individual donor and horizontal bars represent the group means. The 
Mann-Whitney t-test was used to compare differences between patients and 
controls, no significant differences were found. (C) Relationship between T-bet+ Th1 
cells, RORγt+ Th17 cells and RORγt+FoxP3+ cells and age. (D) Relationship 
between the frequency of T-bet+ Th1 cells, RORγt+ Th17 cells and RORγt+FoxP3+ 
cells and total effector/memory (CD45RO+) Tregs. Correlations were evaluated 
using a non-parametric Spearman test. 
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very significantly correlated with total effector/memory Tregs in controls (p<0.0001) but not 
in patients, indicating a possibly deregulated Th17/Treg balance.  
 
5.4  Discussion 
 
Tregs in human PB were originally defined as CD4+CD25high [60] making it difficult to 
determine the exact delineation between CD25high and CD25+/intermediate cells. This has partly 
contributed to the conflicting results regarding the level of Tregs in the PB of psoriasis 
patients [65, 238-242]. We have previously shown that human Tregs can be accurately 
identified as CD4+CD25+CD127lo [61]. We set out to use this definition to analyse the total 
frequency of Tregs, as well as various subsets of effector/memory and naïve Tregs that 
express the trafficking receptors β7, CD49d, CLA, CCR4, CCR10, CCR5, CD62L, CXCR3 
and CCR6 in the peripheral blood of patients with psoriasis (Figure 5.1).  
 
We report that the frequency of total CD4+CD25+CD127lo Tregs is unchanged when 
comparing the PB of our entire psoriasis patient cohort with controls (Figure 5.2). In two 
other studies that used FoxP3 to identify Tregs, it was also demonstrated that levels of Tregs 
were not different in the PB of psoriasis patients [240, 242]. However in one of these studies, 
Tregs were shown to be significantly increased in patients with high disease activity, defined 
as a PASI score > 25 [242]. When we examined Tregs in relation to disease activity, we did 
not find a correlation (data not shown). This may be because our cohort did not include 
patients with PASI scores > 25.  
 
Although we found Treg frequency to be unchanged in the PB of our entire patient cohort, it 
was increased in the PB of untreated patients when compared to treated patients (Figure 5.3). 
While the statistical significance of this increase was reliant on a couple of outliers in the 
untreated patients, there is still a trend towards increased Treg frequency in untreated patients 
when these outliers are removed. This is consistent with a report from another group that 
demonstrated an increase in CD4+FoxP3+ Tregs in the PB of untreated psoriasis [244]. This 
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indicates that there may be a disease specific increase in Treg frequency in psoriasis patients. 
It could be argued that if Tregs are increased in psoriasis, then a Treg deficiency is unlikely 
to be implicated in disease pathogenesis. However it is likely that the increase in Treg 
numbers is a result of ongoing inflammation and may indicate an attempt by Tregs to control 
the aberrant immune response. For this reason, it is important to examine Tregs that express 
various trafficking receptors in order to identify potential deficiencies in Treg subsets with 
the potential to migrate to diseased tissue. 
 
CD4+ T cells make up a large proportion of the inflammatory cells within psoriatic skin 
lesions [235-237]. The differential expression of trafficking receptors by CD4+ T cells 
determines their migration to specific tissue environments including psoriatic plaques. T cells 
infiltrating psoriatic skin lesions have been shown to express the adhesion molecules CLA 
[254-257], CCR4 [255, 256], CCR5 [258], CCR6 [255, 259], CCR10 [260] and CXCR3 
[256, 261]. Although numerous studies have also shown CD4+FoxP3+ Tregs to be enriched in 
psoriatic skin lesions [242-250], it has been demonstrated that the ratio of Tregs to Tconvs is 
higher in distant symptomless skin than in psoriatic plaques, where the ratio is skewed 
towards inflammatory effector T cells [250]. It is therefore plausible that an imbalance of 
Tregs and Tconvs at psoriatic sites could contribute to disease.  
 
The co-localisation of Tregs with Tconvs in tissues has been shown to be crucial for their 
capacity to in regulate immune responses [112, 113, 118]. Despite this, the expression of 
trafficking receptors by Tregs in the PB or skin of psoriasis patients has not previously been 
examined. We hypothesised that deficiencies in trafficking receptor expression by Tregs may 
result in less Treg entry into the skin, consequently leading to the initiation and progression 
of a chronically dysregulated immune response. We found a significantly reduced frequency 
of effector/memory Tregs, but not Tconvs, expressing CXCR3 and CCR6 in the PB of both 
treated and untreated psoriasis patients (Figure 5.2 & 5.3). CXCR3+ Tregs have been shown 
to accumulate at sites of Th1 mediated inflammation whereas CXCR3- deficient Tregs fail to 
localise and control this type of inflammation [112]. Furthermore, impaired CCR6 expression 
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on Tregs has been shown to result in dysregulated Th17 responses [118]. Psoriasis has been 
shown to involve both Th1 and Th17 type immune processes [251, 252] and therefore a 
reduction in CXCR3+ and CCR6+ Tregs could indicate a trafficking deficiency resulting in 
less Treg entry into psoriatic lesions and consequential disrupted control of inflammation.  
 
No differences in the proportion of skin homing CLA-, CCR4- or CCR10- expressing Tregs 
were seen between untreated psoriasis patients and controls, either in the naïve or 
effector/memory compartments (Figure 5.3). However, while the number of Tregs 
expressing skin-homing-molecules did not differ between psoriasis patients and controls, the 
proportion of Tregs expressing these molecules increased with total effector/memory Treg 
frequency in patients only, suggesting a selective increase in skin homing and perhaps an 
attempt by Tregs to control tissue-specific inflammation (Figure 5.9). Interestingly, naive 
Tregs expressing the gut homing phenotypes β7 and α4 (CD49d) were reduced in the blood 
of patients with psoriasis.  
 
We also found smaller proportions of β7+ and CD62L+ naïve Tconvs in the PB of psoriasis 
patients. Expression levels of CD62L have previously been shown to be reduced on CD4+ T 
cells in the PB of psoriasis patients, and it has been suggested that this was due to shedding 
of the molecule as a result of increased activation [262]. However we have shown that the 
reduction in CD62L+ Tconvs in psoriasis patients was due to a reduction in the naïve, not 
activated, compartment of Tconvs.  
 
TNF-α plays an important role in the inflammatory process of psoriasis, as indicated by 
increased levels of TNF-α in psoriatic lesions [263] as well as the effectiveness of treatment 
with TNF-α inhibitors [264]. Due to the high costs and risks associated with TNF-α 
inhibitors, such as increased risk of infection, sepsis and the reactivation of tuberculosis, 
guidelines suggest that TNF-α inhibitors should be reserved for patients unresponsive to 
topical therapy, phototherapy and disease-modifying anti-rheumatic drugs (DMARD) [265-
267]. Despite this, the mechanism underlying the effectiveness of TNF-α blockade is not 
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completely understood, hence hindering our ability to select patients that will fail other 
therapy but respond effectively to TNF-α inhibitors. 
 
It has been demonstrated that lesions from psoriasis patients treated with TNF-α inhibitors 
contain a higher Treg to Tconv ratio [268], suggesting that Tregs may have a role in the 
therapeutic effects of treatment. Very few studies have examined the effects of TNF-α 
blockade on Tregs in the PB of psoriasis patients. We found that the TNF-α inhibitor 
Infliximab had no significant effect on the frequency of Tregs in the PB of psoriasis patients 
(Figure 5.5 & 5.7). In support with our findings, CD4+CD25+FoxP3+ Treg frequency has 
been shown to increase from baseline to 24 weeks in patients following treatment with the 
TNF-α inhibitor Etanercept, but not Infliximab [269]. This suggests a drug class effect and 
outlines the importance of studying the immune effects of each individual TNF-α inhibitor. 
 
TNF-α inhibitors have been shown to reduce T cell numbers in psoriatic lesions, suggesting a 
possible decrease in cell infiltration [246, 270, 271]. Despite this, we are the first to examine 
the effects of TNF-α inhibition on trafficking receptor expression in psoriasis. Without 
longitudinal studies on a group of patients undergoing TNF-α inhibitor therapy, it is difficult 
to conclude that the changes seen in the TNF-α inhibitor users are specifically due treatment. 
TNF-α inhibitors are used to treat patients after they have failed other therapies, suggesting 
that it is possible that this group of patients may be inherently different to other patients. 
Therefore it is important to monitor the effects of TNF-α inhibitors on Treg and Tconv 
subsets pre and post treatment. We analysed PB samples from seven patients pre and post 
therapy with Infliximab.  
 
Although we saw an increase in the frequency of CCR6+, CD62L+ and β7+ naïve Tconvs in 
TNF-α inhibitor users (Figure 5.5), only the increase in CD62L appeared to be due to TNF-
α inhibitor use. When TNF-α inhibitor users were examined longitudinally, we saw a gradual 
increase in the frequency of CD62L+ and effector/memory Tconvs pre and 52 weeks post 
treatment (Figure 5.6). In terms of Tregs, although the levels of CXCR3+, CCR4+ and CCR6+ 
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effector/memory Tregs and CCR6+ and β7+ naïve Tregs were higher in TNF-α inhibitor users, 
suggesting that TNF-α inhibitor therapy may have increased the frequency of these subsets, 
when examined longitudinally TNF-α inhibitor therapy did not increase the frequency of 
CXCR3, CCR6 or β7 expressing Tregs (Figure 5.7). However, there was a trend towards 
increased frequency of CCR4+ effector/memory Tregs following TNF-α inhibitor use. 
Interestingly, there was a gradual increase in the percentage of CD62L expressing 
effector/memory and naïve Tregs, similar to what we saw in Tconvs. This difference reached 
statistical significance in naïve Tregs when comparing pre TNF-α inhibitor therapy to 52 
weeks of therapy, indicating that treatment with a TNF-α inhibitor results in increased levels 
of CD62L+ cells in the PB of psoriasis patients.  
 
CD62L and CCR7 are involved in the recruitment of T cells to lymphoid tissue. Interestingly, 
it has been demonstrated that in psoriatic lesions, lymphoid-like tissue exists in the dermis 
[272]. In a study that examined CCR7 and its ligand CCL19 in psoriatic lesions, it was 
demonstrated that disease resolution by anti-TNF-α agents is associated with the inhibition of 
the CCR7/CCL19 axis and the dissolution of lymphoid-aggregates [273]. Therefore, the 
increase in CD62L+ cells in the PB of psoriasis patients we observed following TNF-α 
inhibitor therapy could be due to reduced entry into the skin as a result of the dissolution of 
these lymphoid aggregates.  
 
In psoriasis, disease-modifying anti-rheumatic drugs (DMARD), such as methotrexate 
(MTX), are often the first line of treatment [266]. The mechanism of the anti-inflammatory 
effect of methotrexate is not fully understood, although it has been suggested that MTX alters 
T cell activation and adhesion molecule expression [274]. PBMCs cultured with MTX 
contain a significantly lower frequency of T cells expressing CLA and CD25 [274]. 
Furthermore, a reduced frequency of CLA+ T cells has been observed in the PB and lesions 
of patients on MTX therapy [275]. In this study, the frequency of CLA+ T cells was shown to 
correlate inversely with the dose of MTX, with patients on the highest doses having the 
lowest frequency of CLA+ T cells [275]. Our work has extended on previous studies by 
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showing that MTX significantly reduces the levels of CXCR3+ and CLA+ effector/memory 
Tconvs and CCR4+, CCR6+, CLA+ and CCR10+ effector/memory Tregs in the PB of psoriasis 
patients (Figure 5.8), suggesting an effect on a more diverse range of adhesion molecules 
than previously documented. It is possible that the reduction in CD25 previously observed 
[274] in turn reduces activation-induced expression of adhesion molecules. Interestingly, we 
also found significantly reduced levels of total Tregs in psoriasis patients taking MTX. This 
may also be due to the reduction in CD25 previously described.  
 
Psoriatic skin lesions have been shown to contain IFN-γ producing Th1 type cells and IL-17 
producing Th17 type cells [252, 276-278], thus prompting the analysis of these cell types in 
the PB of patients.  In vitro stimulated peripheral blood mononuclear cells from patients with 
severe psoriasis have consistently been shown to contain increased levels of CD4+ IL-17 
producing effector/memory T cells [277, 279-281]. These IL-17 producing cells have been 
demonstrated within both the CLA+ (skin-homing) and CLA- CD4 T cell compartments 
[279]. In terms of IFN-γ producing cells in the PB of psoriasis patients, one study found no 
difference in the levels of these cells in the PB when compared to controls [279], while others 
have reported a slight increase [280].  
 
It is uncertain whether these artificially stimulated IFN-γ and IL-17 producing cells 
correspond to true Th1 and Th17 phenotypes. We developed a flow cytometry panel that 
allowed us to identify circulating CD4+ T cells that express the Th1 transcription factor T-bet 
and the Th17 transcription factor RORγt without the need for in vitro stimulation (Figure 
5.10).  
 
We report that the levels of T-bet+ Th1 type cells and RORγt+ Th17 type cells did not differ 
between psoriasis patients and controls. Interestingly however, these subsets displayed 
different relationships with age in psoriasis patients and controls. T-bet+ Th1 type cells 
positively correlated with age in controls only while RORγt+ Th17 type cells negatively 
correlated with age in psoriasis patients only. Psoriasis patients have increased levels of 
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RORγt+ Th17 type cells at a younger age when compared to controls, perhaps indicating an 
early initial phase of the disease marked by increased levels of Th17 cells.  
 
Interestingly, the levels of RORγt+ Th17 type cells very significantly correlated with total 
effector/memory Tregs in controls but not in patients. This indicates that there is a direct 
relationship between Tregs and RORγt+ Th17 cells in healthy humans and that this balance is 
deregulated in psoriasis. The balance between Tregs and RORγt+ Th17 cells may be an 
important determinant of whether skin inflammation is initiated and whether it progresses. 
Future experiments should aim to design a flow cytometry panel that will allow for the 
analysis of RORγt+ Th17 cells within CLA+ skin-homing T cells. This would allow us to 
delineate whether the abnormalities observed in the relationship between RORγt+ Th17 cells 
and age and RORγt+ Th17 cells and Treg frequency are apparent within, or indeed restricted 
to, the CLA+ skin-homing compartment.  
 
Due to a high degree of heterogeneity in psoriasis, it is a suitable disease for the application 
of personalised medicine. The recognition of biomarkers that can guide diagnosis, prognosis 
and treatment selection will provide many benefits to disease management. Flow cytometry 
entails rapid quantification of multi-dimensional characteristics for millions of cells. For this 
reason, there is a need for more efficient data viewing and analysis methods. We used 
bioinformatic tools to analyse flow cytometry data obtained in our study.  
 
In order to find a signature that can predict clinical outcome, it is important to be able to 
combine experimental data with clinical measures, again highlighting the significant role 
bioinformatic analysis can play in the identification of relevant clinical correlations. When 
we combined clinical measures into our analysis, we found that patients on anti-TNF-α 
therapy clustered together (Figure 5.4).  
 
However, although these patients clustered together, our longitudinal analysis of patients on 
anti-TNF-α therapy indicated that although some changes in Tconv and Treg subsets were 
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due to treatment, most were not. For example, although levels of CCR6+ effector/memory 
Tregs were significantly increased in patients on TNF-α inhibitors (Figure 5.5), we did not 
observe an increase in this subset in patients following TNF-α inhibitor therapy (Figure 5.7). 
In fact, we observed a slight, non-significant decrease in this subset following therapy (mean 
65 to 59). Interestingly, the frequency of CCR6+ effector/memory Tregs in patients pre TNF-
α inhibitor therapy is equal to the frequency of this subset in patients on TNF-α inhibitor 
therapy and controls (mean 65.1 vs 64.6). This suggests that this group of patients has 
inherently increased levels of CCR6+ Tregs, and this could be intrinsic to patients selected for 
TNF-α inhibitor therapy.  
 
Therefore it is possible that the patients on anti-TNF-α therapy in our study clustered 
together because they had different subset frequencies to begin with, highlighting the 
possibility of identifying candidates for anti-TNF-α therapy before they are trialled on other 
non-effective treatment. This highlights the power of bioinformatic tools for identifying 
predictive signatures in data obtained from flow cytometry. These observations need to be 
confirmed in studies with larger well-defined patient cohorts including patients that are 
treatment naïve. Furthermore, longitudinal studies are needed for both MTX and anti-TNF-α 
therapy. 
 
In psoriasis, biomarkers that can be used to identify preclinical disease or select patients for 
future treatment will aid in disease management and improve clinical outcome. We hope our 
methods will facilitate the uptake of flow cytometry and bioinformatic analysis in the study 
of psoriasis. 
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CHAPTER 6:  GENERAL DISCUSSION 
 
6.1  Regulatory T cell expression of trafficking receptors in healthy 
humans 
 
Over recent years, our understanding of the importance of Treg trafficking in the control of 
inflammation has increased. Indeed, in the application of Treg-based cellular therapy, the 
ability of infused cells to migrate to the appropriate tissue may be a crucial factor in 
determining the success of therapy. Hence an understanding of the factors controlling Treg 
localisation could be used to optimise Treg-selection and to contribute to the development of 
such therapy. 
 
Previous studies on Treg migration in humans used CD25hi to define Tregs [90, 91, 109, 110, 
135]. In Chapter 3 (section 3.3.2.1) we demonstrated that using CD25hi to identify Tregs in 
humans leads to inaccurate findings regarding their expression of trafficking receptors. We 
are the first to use the CD127loCD25+ phenotype to accurately identify all Tregs in order to 
study their trafficking phenotype. To do this, we examined the expression of β7, α4 
(CD49d), CLA, CD62L, CCR4, CCR5, CCR6, CCR10 and CXCR3 on CD127loCD25+ Tregs 
and compared them to conventional T cells (Tconvs) in the peripheral blood of 44 healthy 
humans.  
 
We found that within effector/memory Tregs, CLA, CCR4, CD62L and CCR6 are expressed 
on the highest proportion of cells. In comparing effector/memory Tconvs and Tregs, we 
established that CLA, CCR4, CCR10, CCR5, CD62L and CCR6 are expressed on a higher 
proportion of Tregs than Tconvs. No differences were found between effector/memory 
Tconvs and Tregs in terms of α4 (CD49d), β7 and CXCR3 expression. These experiments 
described in Chapter 3 establish that Tregs are diverse in terms of trafficking receptor 
expression and that this heterogeneity is different to that seen in Tconvs. Indeed, in an 
unsupervised hierarchical cluster analysis, we found that Tconvs and Tregs clustered in two 
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separate groups, highlighting that Tregs have a unique trafficking receptor signature that 
differentiates them from Tconvs. 
 
A proportion of circulating CD4+ T cells exhibit a degree of tropism for certain tissues, 
particularly the gut and skin.  The expression of certain adhesion molecules influences the 
selective entry of lymphocytes into tissues. Of these tissue-associated homing phenotypes, 
the gut specific α4β7 [100, 101] and the skin specific CLA, CCR4 and CCR10 [103, 104, 
141] are the most defined. 
 
While no differences were found between effector/memory Tconvs and Tregs in terms of 
expression of the gut-associated β7, a significantly lower proportion of naïve Tregs express 
β7 when compared to naïve Tconvs. Furthermore, the skin homing receptors CLA, CCR4 
and CCR10, are expressed on a much higher proportion of Tregs than Tconvs. For this 
reason, adult human Tregs can be concluded to show a bias towards migration to the skin, 
indicating an important role for Treg immune regulation at this site. Interestingly, the reverse 
has been shown to be true in early life, when the majority of Tregs express α4β7 [110]. This 
suggests a role for the gut in early immune imprinting, whereby Treg cell exposure to 
exogenous antigens in early life could shape the Treg compartment and influence homing 
receptor expression patterns and phenotype in later life.  
 
We also found that effector/memory Tregs contain a significantly higher proportion of 
CD62L+ central memory cells when compared to Tconvs, suggesting a role for Tregs in 
regulating systemic immunity as central memory cells within lymphoid tissues. This supports 
the claim that Tregs are involved in both regulating the priming of cells in lymphoid tissue 
and limiting inflammation in non-lymphoid tissue. 
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6.1.1  Co-expression of tissue specific homing receptors on Tconvs and Tregs 
 
While a few studies have examined the co-expression of skin and gut associated adhesion 
molecules and receptors on total CD4+ T cells in humans [143, 144, 147, 148], none have 
focused on Tregs. In Chapter 3 (section 3.3.3) we analysed these chemokine receptors and 
integrins in combination with each other on both Tconvs and Tregs. 
 
Expression of CLA and β7 is generally believed to be mutually exclusive [150]. However we 
have shown that a proportion of cells co-express these markers. Interestingly, we found that 
an average of 37% of β7+ effector/memory Tregs express CLA while only 8% of β7+ 
effector/memory Tconvs express CLA. Additionally, an average of 67% of β7+ 
effector/memory Tconvs express CCR4 while almost all (93%) of β7+ effector/memory Tregs 
express CCR4. This demonstrates that CCR4 is expressed by both gut and skin homing cells, 
indicating a role for CCR4 in trafficking cells to non-cutaneous peripheral tissues, the gut 
included. This is consistent with its association with homing to Th2 type inflammation 
(discussed below). On the other hand, we found that CCR10 and β7 are generally mutually 
exclusive on Tconvs, with only 4% of β7+ Tconvs expressing CCR10. In a study that 
examined the co-expression of CCR10 and β7 on memory CD4+ T cells but not Tregs, it was 
concluded that “practically no” CCR10+ cells express detectable β7 [148]. We showed that, 
in contrast to Tconvs, 30% of β7+ Tregs express CCR10. 
 
When the co-expression of trafficking receptors is used to define cell subsets, they reveal a 
broad variety of combinations that can target cells into diverse microenvironmental niches. 
The in vivo significance of the proportions of cells expressing these various combinations is 
currently unknown. Nevertheless, studying these subsets on both Tconvs and Tregs can 
generate hypotheses for future study and potential application to therapy. 
 
It can be postulated that the expression of trafficking receptors that favour certain tissues may 
define the best subpopulation of Tregs for therapy. Certainly, it has been demonstrated that 
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CLA expressing Tregs are more efficient at preventing skin destruction in an animal model 
of graft versus host disease (GvHD) [151]. In humans, increased frequencies of CLA+ Tregs 
at the time of neutrophil engraftment in allogeneic stem cell transplant (ASCT) patients have 
been shown to be associated with a reduction in acute GvHD involving the skin [152]. 
Furthermore, increased frequencies of CLA+ or β7+ Tregs are associated with reduced 
incidence [153] or severity [152] of skin or gut aGvHD, respectively. 
 
6.1.2  Th1 and Th17 associated chemokine receptors and Tregs 
 
It is thought that the preferential expression of CRs can be used to identify Th1, Th2 and 
Th17 type Tconvs and Th1, Th2 and Th17 – “like” Tregs. Generally, Th1 cells are believed 
to be CXCR3+ [159-162] while Th2 cells are CCR4+ [159-164] and Th17 cells CCR6+ [165, 
166]. However, more recently these definitions have changed with Th1 cells being described 
as consisting of both CXCR3+CCR6- and CXCR3+CCR6+ subsets, while Th2 cells are 
CXCR3-CCR6-CCR4+ and Th17 cells CXCR3-CCR6+CCR4+ [167, 168]. Studies that defined 
these CR expression patterns either examined cells artificially polarised in vitro [159, 160, 
163] or isolated circulating CR expressing CD4+ T cells from human blood and examined 
their cytokine profiles following in vitro stimulation [161, 162, 167, 168].  
 
In order to study the CR expression patterns of Th1 and Th17 type T cells, we took a novel 
approach and designed an 11 colour antibody panel that allowed us to combine the 
transcription factors T-bet and RORγt with their commonly associated CRs; CXCR3, CCR4 
and CCR6. We identified circulating CD4+ T cells that express T-bet and RORγt without the 
need for in vitro stimulation (Chapter 3, section 3.3.4).  
 
T-bet+ CD4+ cells were found to only express CXCR3, the CR commonly associated with Th1 
T-bet+ cells. Numerous studies have described circulating CXCR3+ CD4 T cells as Th1 type 
cells [159-162, 167-169]. However, it is evident in our study that in human PB not all 
CXCR3+ cells express T-bet. In fact, in the 44 healthy donors examined, an average of 89% 
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of CXCR3+CD4+ T cells did not express T-bet. All RORγt+CD4+ cells expressed CCR6, the 
CR commonly associated with Th17 RORγt + cells. However, CCR6+ cells did not all express 
RORγt. Interestingly, we also showed that subsets of RORγt + cells express the CRs CCR4 
and CXCR3. This pattern of expression of trafficking receptors is consistent with a pro-
inflammatory role in an array of peripheral tissues [170-172]. 
 
In order to examine “Th1” and “Th17” cells, identified as described in the literature [167-
169], for the expression of T-bet and RORγt, we gated CXCR3+ (“Th1”) and CXCR3-
CCR6+CCR4+ (“Th17”) cells within CD45RO+CD4+ cells and examined them for expression 
of T-bet and RORγt (Chapter 3, section 3.3.4.1). We found that “Th1” cells, defined as 
CXCR3+ effector/memory T cells, make up, on average, 23% of PB CD4+ T cells whereas T-
bet+ cells makeup only an average of 5.3%. Importantly, an avergae of 89% of CXCR3+ 
effector/memory T cells do not express T-bet in human PB. However, the flow cytometry 
data revealed that in many individuals, T-bet+ cells would fall within the CXCR3- gate, 
because CXCR3 expression on T-bet+ cells is generally lower than on T-bet- cells. “Th17” 
cells, defined as CXCR3-CCR6+CCR4+ effector/memory T cells, make up an average of 
10.8% of PB CD4+ T cells whereas RORγt + cells makeup an average of 7% of PB CD4+ T 
cells. Significantly, 71.5% of CXCR3-CCR6+CCR4+ effector/memory T cells do not express 
RORγt in human PB.  
 
Based on our findings, it appears that CRs alone cannot be used to isolate pure Th1 and Th17 
type cells. The use of these surface markers to isolate Th1 and Th17 cells overestimates their 
frequency in comparison to defining Th1 and Th17 cells based on intracellular staining for T-
bet and RORγt.  
 
6.1.2.1  RORγ t+FoxP3+ cells 
 
In mice, it has recently been demonstrated that subsets of Tregs co-express the transcription 
factors T-bet and RORγt with FoxP3 [112, 173, 174]. We were the first to examine the co-
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expression of T-bet and RORγt with FoxP3 on unstimulated CD4 T cells in human PB 
(Chapter 3, section 3.3.4.2). No cells co-expressing T-bet and FoxP3 were identified in 
human PB. However we did identify a subset RORγt+FoxP3+ cells. These cells made up 1.1% 
of circulating CD4+ T cells, were of the effector/memory phenotype (CD45RO+) and the 
numbers were highly correlated with the frequency of total RORγt+ cells in each individual.  
 
We also examined the expression of CRs CXCR3, CCR4 and CCR6 on the identified 
RORγt+FoxP3+ cells and compared them to FoxP3+ Tregs and RORγt+ Th17 cells. CR 
expression by FoxP3+ Tregs and RORγt+ Th17 cells was similar. Both these subsets 
expressed higher levels of CCR4 and CCR6 than Tconvs. RORγt+ cells expressed the highest 
levels of CCR6 while FoxP3+ cells expressed the highest levels of CCR4, with 
RORγt+FoxP3+ co-expressing cells taking on both these features, expressing CCR6 at levels 
similar to RORγt+ cells and CCR4 at levels similar to FoxP3+ cells. 
 
It has been reported that 3-4% of human memory CD4+CD25hi “Tregs” secrete IL-17 
following in vitro stimulation [176, 177]. In one study, a large proportion (34%) of “Tregs”, 
isolated as CD25hi, were found to express RORγt following stimulation [176]. This indicates 
that in vitro stimulation in combination with the inaccurate identification of Tregs as CD25hi 
leads to the overestimation of the frequency of RORγt+ Tregs in human PB, highlighting the 
importance of our work in identifying RORγt expression within unstimulated FoxP3+CD4+ T 
cells. Our studies did not determine whether de novo expression of transcription factors and 
cytokines after in vitro stimulation reflects physiological processes that would occur in 
response to antigen recognition in vivo. In the absence of a method to detect transcription 
factor expression in viable cells before sorting, the answer to this question remains outside 
the limits of current technology. 
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6.2  Regulatory T cell expression of trafficking receptors in autoimmune 
disease 
 
The syndrome of multi-organ autoimmunity (immunodysregulation, polyendocrinopathy, 
enteropathy X-linked (IPEX) syndrome) that results from a dysfunctional FoxP3 gene [62] 
highlights the importance of Tregs in maintaining tolerance to self-antigen in humans. The 
IPEX phenotype is also evidence that gross defects in Tregs will lead to overwhelming 
autoimmunity to a whole range of self-antigens. This is not the case in sporadic human 
autoimmune disease. Thus human autoimmune disease is more likely to result from a partial 
dysregulation of peripheral tolerance through subtle abnormalities in Treg subset frequencies, 
function and development.  
 
Epidemiological studies have demonstrated that genetic factors are important in determining 
susceptibility to autoimmune disease. These observations include the evident clustering of 
autoimmune disease within families and the higher rate of concordance for autoimmune 
disease in monozygotic twins when compared to dizygotic twins [33]. The association of 
several autoimmune diseases within families suggests a level of shared genetic susceptibility 
amongst them. MHC molecules make the biggest contribution to disease susceptibility, with 
susceptibility to the majority of autoimmune diseases, including RA [282]  and psoriasis 
[283], being linked to MHC alleles. Other risk loci shared amongst several autoimmune 
diseases are associated with pathways relevant to Tregs, such as IL2RA [284, 285] and 
CTLA-4 [286]. However, these susceptibility polymorphisms also occur in normal, healthy 
people where they are compatible with normal immune function. Furthermore, migration 
studies provide evidence for differences in the incidence of autoimmune diseases in 
genetically similar populations living in different conditions [44]. This suggests that an 
environmental factor predisposes individuals to autoimmune disease development. 
Interestingly, birthplace has the strongest influence [287], hence signifying an environmental 
role in early life [288].  
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The “hygiene hypothesis” was originally proposed to explain the increasing incidence of hay 
fever and eczema in the UK and the very significant link to birth order, with decreasing 
susceptibility as birth order increased [289]. The hypothesis suggests that allergic diseases 
are prevented by infection in early childhood, and that improvements in household amenities, 
declining family size and higher standards of personal hygiene have reduced the chances of 
childhood infection. This hypothesis has since been extended to apply to other immuno-
inflammatory diseases, and is believed to be the cause of the rising incidence of autoimmune 
disease in parallel with improved hygiene and socio-economic living conditions [40]. It has 
been argued by Barbara Fazekas de St Groth that there is increasing evidence [290, 291] that 
the gut microbiome is the environmental factor most influential on predisposition to immuno-
inflammatory disease [288]. It has been demonstrated that commensal gut microbes are 
established in early life [292] and this could provide a mechanism underpinning the hygiene 
hypothesis by explaining how exposure to microbes early in life can have life-long impact on 
the immune system [288]. 
 
How infection protects against autoimmune disease is unknown. It has been suggested that 
infection stimulates the development of Tregs whose effects extend beyond the invading 
microbe. In a recent study carried out to assess the influence of heritable vs non-heritable 
factors on immune cell population frequencies in 210 healthy twins, it was found that most 
subsets were dominantly influenced by non-heritable factors [293]. Importantly, this study 
demonstrated that with age, the frequency of Tregs in monozygotic twins diverged, 
suggesting an environmental influence on Tregs that increases with time [293]. 
 
It has been suggested that the control of DC stimulatory capacity is the first point at which 
Tregs could work to prevent autoimmune disease [80]. Tregs downregulate the steady-state 
DC expression of co-stimulatory molecules in vivo, therefore preventing autoimmunity by 
fine-tuning costimulation to control the peripheral threshold for T cell activation [80]. This 
provides an explanation of how Treg deficiencies could result in susceptibility to 
autoimmune disease. If costimulation increases due to a Treg defect, auto-reactive T cells 
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could receive a signal sufficient for driving proliferation and differentiation, steps crucial for 
a pathogenic autoimmune response [288]. An individual’s genotype affects the specificity of 
their peripheral auto-reactive cells, the expression of self-antigens and their affinity for self-
MHC. Therefore, when an individual’s Treg network fails to perform at its full potential, they 
would become susceptible to the development of those diseases to which they had a genetic 
predisposition [288]. This explains how abnormalities in Tregs could result in a wide range 
of autoimmune responses. 
 
As exposure to infection changes with improved living standards, defects in the Treg 
compartment may become more frequent, thus explaining the increasing incidence of 
autoimmune disease, the decreasing age of on-set and why more disease predisposition 
genotypes become involved [288]. According to this model, the severe tissue damage that 
results from autoimmune disease is therefore not due an aggressive response, but rather the 
inability of the immune system to clear the self-antigen, hence leading to chronic 
inflammation [288].  Consequently, the Treg abnormalities that initiate such responses may 
in fact appear minor and insignificant.  
 
We aimed to search for abnormalities in migratory Treg subsets that may be implicated in the 
pathogenesis of diseases localised to different tissues. To do this, we measured the 
proportions of Tregs expressing a range of adhesion molecules in the PB of patients with 
rheumatoid arthritis (RA) (Chapter 4) and psoriasis (Chapter 5). A summary of the results 
for Tregs is presented in Table 6.1. 
 
We found a reduction in migratory subsets of Tregs in the PB of both RA and psoriasis 
patients. RA patients had a significantly reduced frequency of total effector/memory Tregs 
and effector/memory Tregs expressing CXCR3, CCR4, CCR5 and CCR6 in their PB. 
Psoriasis patients had a significantly reduced frequency of effector/memory Tregs expressing 
CXCR3 and CCR6 in their PB. These differences were independent of disease activity, 
suggesting that these findings could indicate a primary Treg deficiency resulting in less Tregs 
 
Table 6.1: Summary of significant differences in frequencies of effector/memory and naïve Tregs expressing trafficking receptors in the 
peripheral blood of rheumatoid arthritis and psoriasis patients when compared to controls. 
 
Treg subset (%) RA  
(n=34) 
RA+TNFi 
(n=10) 
Psoriasis 
(n=44) 
Psoriasis (untreated)* 
(n=20) 
Psoriasis+TNFi 
(n=16) 
CD45RO+ CXCR3+ ↓  ↓  ↓  ↓  = 
CD45RO- CXCR3+ = ↓  ↓  = = 
CD45RO+ CCR4+ ↓  = ↓  = = 
CD45RO- CCR4+ = = = = = 
CD45RO+ CCR5+ ↓  ↓  ↓  = = 
CD45RO- CCR5+ = = = = = 
CD45RO+ CCR6+ ↓  = ↓  ↓  = 
CD45RO- CCR6+ = = = = = 
CD45RO+ β7+   = = = 
CD45RO- β7+   ↓  ↓  = 
CD45RO+ α4+   = = = 
CD45RO- α4+   = ↓  = 
CD45RO+ CLA+   = = = 
CD45RO- CLA+   = = = 
CD45RO+ CCR10+   = = = 
CD45RO- CCR10+   = = = 
CD45RO+ CD62L+   = = = 
CD45RO- CD62L+   = = = 
 
Significant differences are in comparison to matched controls. 
TNFi = Tumour necrosis factor inhibitor 
*Untreated psoriasis includes patients using topical therapy only 
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entering the joints and skin, with consequential disrupted homeostasis. Interestingly, in 
psoriasis it has been demonstrated that the ratio of Tregs to Tconvs is higher in distant 
symptomless skin than in psoriatic plaques, where the ratio is skewed towards inflammatory 
effector T cells [250]. This supports the hypothesis that an imbalance of Tregs and Tconvs at 
the site could contribute to disease.  
 
When we compared TNF-α inhibitor users to non-users and controls in RA and psoriasis, we 
found significant differences in the TNF-α inhibitor users. However, it is difficult to 
conclude that these differences are specifically due to treatment without longitudinal studies 
on a group of patients undergoing TNF-α inhibitor therapy. Because TNF-α inhibitors are 
used to treat patients after they have failed other therapies, it is possible that this group of 
patients may be inherently different to other patients. Therefore it is important to monitor the 
effects of TNF-α inhibitors on Treg subsets pre and post treatment. In psoriasis, we analysed 
PB samples from seven patients pre and post therapy with Infliximab and found that although 
some changes in Tconv and Treg subsets could be attributed to treatment, most were not. For 
example, although levels of CCR6+ effector/memory Tregs were significantly increased in 
patients on TNF-α inhibitors, we did not observe an increase in this subset in patients 
following TNF-α inhibitor therapy. This suggests that this group of patients has inherently 
different levels of Treg subsets and this could be intrinsic to patients who receive TNF-α 
inhibitor therapy because of a failure to respond to other therapies. This further reinforces 
that differences in Treg subset frequencies may represent primary abnormalities in 
individuals that may not only predispose them to disease, but can also be indicators of 
disease severity and future response to treatment. 
 
Autoimmunity is a multifaceted disease with variations in response to therapy, clinical 
manifestations and age of on-set evident within a single disease. The elucidation of all the 
possible Treg phenotypes and how they vary from health to disease brings us one step closer 
to understanding the pathogenesis of autoimmunity and to the development of effective 
therapeutic intervention.  
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Our observations need to be confirmed in future studies with larger well-defined patient 
cohorts at different stages of disease and therapy regime. Furthermore, future longitudinal 
analysis and follow-up of response in patients undergoing therapy is crucial in establishing a 
definite relationship between pre-treatment Treg subsets and therapeutic response. 
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